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1 Samuel, chapter 17 
 
 Saul and the Israelites are facing the Philistines at the Valley of Elah. Twice a day for forty 
days, the giant Goliath, the champion of the Philistines, comes out between the lines and 
challenges the Israelites to send out a champion of their own to decide the outcome in 
single combat. However, Saul and all the other Israelites are afraid of him. David, who 
brought food for his elder brothers is also present at the front lines. Told that Saul has 
promised to reward any man who defeats Goliath, David accepts the challenge. Saul 
reluctantly agrees and offers his armor, which David declines, taking only his sling and five 
stones chosen in a brook. 
David and Goliath confront each other, Goliath with his armor and shield, David with his 
staff and sling. “The Philistine cursed David by his gods,” but David replies: “This day the 
Lord will deliver you into my hand, I will strike you down, cut off your head, and I will give 
the dead bodies of the host of the Philistines this day to the birds of the air and to the wild 
beasts of the earth; that all the earth may know that there is a God in Israel, and that all 
this assembly may know that God saves not with sword and spear; for the battle is God’s, 
and he will give you into our hand.”  
David hurls a stone from his sling with all his might, and hits Goliath in the center of his 
forehead. The Philistine falls on his face to the ground; David takes his sword and cuts off 
his head. The Philistines flee and are pursued by the Israelites “as far as Gath and the 
gates of Ekron.” David puts the armor of Goliath in his own tent and takes the head to 
Jerusalem, and Saul sends Abner to bring David to him. The king asks whose son he is, and 
David answers, ‘I am the son of your servant Jesse the Bethlehemite.” 
 
 
 
 
 
 
 
 1 Samuel, hoofdstuk 17 
 
Saul en de Israëlieten zijn in gevecht met de filistijnen in de Vallei van Elah. Tweemaal per 
dag, voor veertig dagen staat de reus Goliath, de sterkste man van de filistijnen tussen de 
linies en daagt de Israëlieten uit voor een man tegen man gevecht tegen hun sterkste 
man.  Saul en alle Israëlieten zijn bang voor Goliath. David, die zijn oudere broers van 
voedsel voorziet is ook aanwezig bij de front linies. Zijn broers vertellen hem dat degene 
die Goliath verslaat door Saul rijkelijk beloond zal worden. David wil deze strijd aan gaan 
en weet Saul ervan te overtuigen dat hij de Goliath kan verslaan. Saul stemt uiteindelijk in 
en biedt David zijn zwaard aan. David slaat dit aanbod echter af. 
 
David en Gotliath komen tegenover elkaar te staan. Gotliath met schild en zwaard en 
David alleen met zijn herdersstaf en zijn slinger.  De filistijnen vervloeken David en zijn 
god, maar David antwoordt: “Vandaag zal God jou aan mij uitleveren, ik zal je verslaan, je 
hoofd eraf hakken en ik zal de dode lichamen van de filistijnen aan de vogels van de lucht 
en de beesten van de aarden geven; zodat de wereld zal weten dat er een God bestaat, en 
dat iedereen zal weten dat God niet redt met zwaard en speer, voor dit is Gods strijd.”  
 
David neemt een steen en werpt deze met zijn slinger uit al zijn kracht richting Goliath. De 
steen raakt Goliath in het voorhoofd. Goliath valt voorover met zijn gezicht op de grond. 
David neemt zijn zwaard en hakt zijn hoofd eraf. De filistijnen vluchten, achterna gezeten 
door de Israëlieten verder dan Gath en de poorten van Ekron. David neemt het hoofd van 
Goliath naar Jeruzalem en Saul stuurt Abner om David te halen.  Saul vraagt wiens zoon hij 
is en David antwoordt: “Ik ben David de zoon van Jesse uit Bethlehem.”    
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 Abbreviations 
 
Ab  Antibody 
ADC   Antibody-dependent complement activation  
ADCC  Antibody-dependent cellular cytotoxicity 
AML  Acute myeloid leukemia 
APC  Antigen presenting cell 
BCG  Bacilli Calmette-Guérin  
cAMP  Cyclic Adenosine monophosphate 
CB  Cord blood 
CD  Cluster of differentiation 
CEA  Carcinoembryonic antigen   
CHO  Chinese hamster ovary   
CML  Chronic myeloid leukemia 
COX  Cyclooxygenase 
CTL  Cytotoxic T lymphocyte  
CTLA-4  Cytotoxic T lymphocyte antigen-4 
DC  Dentritic cell 
DNA  Desoxyribonucleic acid  
DNAM-1 DNAX accessory molecule-1 
FDA  Food and drug administration 
FI-DC  FMKp/IFN-γ DC, differentiated with IL-13 
FMKP  Membrane fraction of Klebsiella pneumoniae 
Gal  Galactose 
GalNAC  N-acetylgalactosamine 
G-CSF  Granulocyte colony-stimulating factor  
GM-CSF  Granulocyte macrophage colony-stimulating factor 
GvHD  Graft-versus-Host disease 
GVT  Graft-versus-tumor 
H  Hour 
hDLL  Human Delta-like ligand 
HLA  Human leukocyte antigen 
iDC  immature Dendritic cell 
IFN  Interferon 
IL  Interleukin 
KIR  Killer immunoglobulin-like receptor 
LPS  Lipopolysaccharide 
mAb  Monoclonal antibody 
MDSC  Myeloid-derived supressor cell 
MFI  Mean fluorescence intensities 
MICA/B  MHC class I-related chain A/B 
MUC1  Mucin 1 
NCR  Natural cytotoxicity receptor 
NK cell  Natural killer cell 
NK-22 cell Natural killer-22 cell  
NKT cell  Natural killer T cell 
PAMP  Pathogen-associated molecular pattern 
PGE  Prostglandin 
Poly (I:C) Polyribocytidylic acid  
PRR  Pattern recognition receptor 
SCT  Stem cell transplantation 
SEB  Staphylococcal Enterotoxin B 
SEM  Standard error of the mean 
Ser  Serine 
TAA  Tumor-associated antigen 
TCM cell  Central memory T cells 
TCR  T cell receptor 
TEM cell  Effector memory T cells 
TH cell  Helper T cell 
Thr  Threonine 
TIL  Tumor infiltrating lymphocytes 
TLR  Toll-like receptor 
 TNF  Tumor necrosis factor 
TP-DC  TNF-α/PGE2 Dc, differentiated with IL-13 
Treg  Regulatory T cell 
WT-1  Wilms’ tumor 1 
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Cancer and immunotherapy 
 
In the story of David and Goliath, which was written centuries ago, we were taught that a 
battle can only be won by intelligence and not by pure strength. Only when targeting the 
enemy´s weak spot David was able to conquer Goliath. In analogy to this story, also in the 
battle against cancer pure strength is not enough. Where several destructive anticancer 
therapies have failed to cure all cancer patients, immunotherapy might be a more clever 
strategy, since it specifically targets cancer cells aiming at their weakness.    
With approximately 25% of all deaths, cancer is the leading cause of mortality in Western 
countries. Since the early nineties the mortality rates of cancer have decreased, which is 
due to early detection and treatment of pre-malignant and malignant lesions. However, 
the lifetime probability to develop cancer is with 44% for men and 38% for women, still 
high (1). Most cancer patients are treated with a combination of surgery, chemotherapy 
and radiation and advances in these therapies have improved cancer survival. At this 
moment approximately 50% of all cancer patients survive (2), which is not only due to 
improvements of conventional therapies, but also by the use of new treatment options, 
including immunotherapy. Favorable results of immunotherapy that were reported over 
de last decades, hold promise for the future. 
 
The immune system 
In steady state conditions, when invading pathogens or malignant cell transformation 
perturbs normal tissue homeostasis, tissue responses result in innate immune cell 
infiltration and initiate an acute inflammatory response (Figure 1). Inflammatory 
mediators produced by early infiltrating macrophages, neutrophils and mast cells recruit 
other innate and adaptive immune cells into the damaged tissue. Additionally, these 
immuno-active mediators induce tissue and vascular responses that increase tissue 
perfusion and repair. Tissue resident antigen presenting cells (APCs), like dendritic cells 
(DCs), engulf foreign or altered-self antigens and migrate into the lymph nodes to present 
these antigens to cells of the adaptive immune system (3, 4). Recently, it has been 
demonstrated that natural killer (NK) cells bidirectionally interact with DCs at the interface 
of innate and adaptive immunity (5-7). Additionally, NK cells are efficient innate effector 
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cells that can rapidly eradicate infected or malignantly transformed cells by a specialized 
machinery of activating and inhibitory receptors on the NK cell surface. NK cells can do 
this without the need of memory or antigen specificity (8).  
The innate immune system orchestrates the induction of adaptive immune responses. 
Efficient activation of adaptive immune cells, T and B cells, is only established upon 
encounter with APCs. T and B cells are committed to recognize specific antigens by 
generation of antigen receptors by somatic recombination. Upon antigen recognition 
clonal expansion of T and B cells is needed to induce an effective immune response (9, 
10). Therefore, compared to the innate system, the adaptive immune system is more 
specialized, but also slower (days compared to hours) in mounting immune responses. 
However, due to induction of memory cells, the adaptive immune response is initiated 
more rapidly upon a second encounter with the same antigen (11) (Figure 1).  
Eventually, the activation of both the innate and adaptive immune system is needed to 
conquer infection and cancer. After elimination of pathogens or pathological cells, the 
immune response is suppressed to reconstitute normal tissue homeostasis. However, if 
normal tissue homeostasis is not reached a state of chronic inflammation is induced. 
During this state interactions between immune cells are disturbed, which attributes to 
cancer formation (12, 13).   
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Figure 1. The immune response. 
The mammalian immune system has two overarching divisions, the innate and the adaptive. The innate immune 
system includes, among other components, various phagocytes that can ingest and destroy pathogens or 
apoptotic cell particles. These cells also activate the inflammatory response by secretion of chemokines and 
cytokines, thereby recruiting and activating other innate immune cells. One of these immune cells migrating 
from the blood into the inflamed tissue is the NK cell, which is an efficient killer of both infected as well as 
malignantly transformed cells. For activation of the adaptive immune system, DCs have to migrate into the lymph 
node, where they can present their antigen to T cells, thereby activating these cells. This T cell activation is 
enhanced by NK-DC crosstalk, cells which are both at the interface of the innate and adaptive immune system. 
After antigen recognition, antigen-specific T cells start to proliferate and both effector and memory T cells are 
formed. The effector T cells migrate into the inflamed tissue to eliminate pathological cells. Memory T cells are of 
importance to promptly eliminate invaders upon a second inflammatory response. B cells differentiate by the 
same pattern into effector and memory B cells. Effector B cells are plasma cells that secrete antibodies, which 
can bind pathological cells and induce antibody-dependent complement activation or antibody-dependent 
cellular cytotoxicity (ADCC). 
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The paradox of the immune system and cancer 
The first observation of the involvement of the immune system in cancer was described in 
1863 by Rudolph Virchow, who identified immune cells residing in tumor tissue (14). Later, 
it was shown that clinical prognosis is associated with the type of immune cells that 
infiltrate this malignant tissue (15, 16).  
A medium and high cytotoxic activity of peripheral blood lymphocytes 
17
is associated with 
reduced cancer risk, whereas low activity is associated with an increased risk suggesting a 
role for natural immunological host defense mechanisms against cancer ( ). This is 
supported by the observation that immuno-deficient mice as well as organ transplant 
patients treated with immune-suppressive therapy are more prone to develop cancer (18-
22). 
Not all activities of the immune system are protective for cancer development. Cancer 
patients often harbor T cells that are functionally impaired (23), contain NK cells that 
express lower numbers of activating receptors (24) and accumulate chronically activated 
myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Treg) (25, 26). Increasing 
evidence suggests that chronic inflammation is associated with tumor development or 
tumor growth and about 15% of all malignancies can be attributed to infections (27, 28). 
Examples of infection and inflammation that lead to an increased risk in cancer 
development are: Helicobacter pylori infection, causing stomach cancer (29); human 
papillomavirus infection, which is associated with cervical cancer development (30); 
chronic pancreatitis leading to pancreatic cancer (29); and inflammatory bowel disease, 
which predisposes for the development of colon cancer (31, 32). This can be explained by 
the inflammation-induced production of high concentrations of reactive oxygen and 
nitrogen species that have potential DNA-damaging effects. In an inflammatory 
environment, characterized by cell renewal and proliferation, these effects on the DNA 
can be detrimental and result in cancer formation (33). However, not every infected 
individual develops cancer, indicating that cancer development is a multifactorial process. 
Possible factors responsible for cancer development are genetic predisposition (mutations 
or polymorphisms), toxic environmental factors, and the immune status of the individual 
(22, 34). 
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In apparent paradox to the data on predisposition of cancer development in immuno- 
compromised individuals, long-term treatment with aspirin or cyclooxygenase (COX) 
inhibitors, which also suppress the immune response, reduces the risk of tumor 
development (35-37). Both anti-inflammatory drugs inhibit the production or function of 
prostaglandins (PGE) and vasoactive molecules that are involved in immune cell activation. 
Since inadequately high amounts of PGE are produced during chronic inflammation, these 
drugs suppress chronic inflammation and ultimately tumor formation (38).  
In conclusion, next to genetic predisposition and environmental factors, tumor 
development depends on a delicate equilibrium of inflammation-related tumor induction, 
tumor immune surveillance and tumor escape (39). On the one hand, chronic 
inflammation induces tumor formation and established tumors actively secrete immuno-
active molecules, that potentiate neoplastic progression (27). On the other hand, the 
immune system provides us with a well-orchestrated machinery of tumor surveillance, 
which is effective in recognition and rejection of malignant cells, also known as immuno-
editing (Figure 2) (40). This function of the immune system opens new opportunities for 
cancer immunotherapy.  
 
 
 
Figure 2. The paradox of cancer and the immune system. 
Immune surveillance is needed for tumor elimination, but is also responsible for the recruitment of immune cells. 
Immune cells produce pro-inflammatory mediators, creating a tumor-promoting environment that leads to 
tumor progression. Immunotherapy aims at enhancing immune surveillance and thereby tumor elimination.  
Chapter 1 
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Cancer immunotherapy 
The main goal of cancer immunotherapy is to augment antitumor immunity and inhibit 
immune regulatory responses that lead to tumor tolerance. Different immunotherapeutic 
strategies have been classified as either active- or passive therapy (Figure 3). Passive 
immunotherapy employs immune components created outside of the body that provide 
specific immunity after administration. In contrast, active immunotherapy stimulates the 
body’s own immune system to fight cancer. These cancer immunotherapeutic strategies 
can either be aspecific or specific, thereby enhancing general immune responses or 
antigen-specific responses, respectively. Its specificity is the major advantage of 
immunotherapy over conventional anticancer therapy (e.g. chemotherapy and 
radiotherapy), rendering only cancer cells to be targeted without harming normal tissue. 
As a consequence, treatment related morbidity and mortality are reduced. Though the 
subdivision between passive and active immunotherapy seems very strict, there is a 
substantial overlap between the two different therapeutic strategies.  
 
 
Figure 3. Cancer immunotherapy. 
Schematic representation of different immunotherapeutic approaches categorized in either passive- or active 
immunotherapy and further subdivided in specific or aspecific.  
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Passive immunotherapy 
The main effectors of passive immunotherapy are antibodies that recognize antigens 
expressed by tumor cells. Over the last decade also antibodies targeting immune cells 
have been developed. These strategies use passive immunotherapeutic components to 
induce active immune responses. Other forms of passive immunization are adoptive T cell 
transfer of either antigen-specific T cells or Pre- T cells, adoptive NK cell transfer and stem 
cell transplantation (SCT).   
 
Antibody therapy 
Antibodies (Ab) produced by B cells have the capacity to bind immunogenic tumor cell 
surface molecules and mediate tumor cell lysis by complement activation (ADC) or 
induction of antibody-dependent cell-mediated cytotoxicity (ADCC) (Figure 4). 
Additionally, these Abs can bind receptors inducing steric inhibition or neutralization of 
cytokines, thereby interfering with the tumor cell cycle or providing pro-apoptotic signals. 
Furthermore, Abs can complex with free antigens, augmenting engulfment, processing 
and presentation of these antigens by APCs.  
Transfer of monoclonal antibodies (mAbs) is the most successful form of immunotherapy 
and over the last years numerous mAb therapies have been developed (40-44). Favorably, 
these mAbs are directed to specific immunogenic epitopes overexpressed by tumor cells, 
since there is only a negligible chance of autoimmune reactions (45). Such tumor-
associated antigens (TAA) often display differences in their glycosylation pattern or 
represent alternative splice variants (46). To enhance the therapeutic effect of mAbs, they 
can be linked to radionuclides or toxins (47). The most well-known mAb used in clinical 
practice is the CD20-binding antibody Rituximab. Though successful in anticancer therapy, 
CD20 is not a TAA since it is not only expressed in many B cell lymphoma but also by 
healthy B cells. Therefore, Rituximab induces ADCC of malignant as well as non-malignant 
B cells (48). It is added to the standard chemotherapy protocol of non-Hodgkin’s 
lymphoma (cyclophosphamide, doxorubicin, vincristine and prednisone), because the 
percentage of patients reaching complete remission increased significantly (48, 49). 
Another mAb widely applied in cancer treatment is Trastuzumab, which binds the Her-
2/Neu receptor often expressed by breast cancer cells (50).  
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Figure 4. Induction of antibody-mediated immune responses.  
Humoral immune responses can be established by passive antibody transfer, which can induce antitumor 
responses by ADC and ADCC. Bispecific antibodies are used to link tumor and effector cells inducing tumor cell 
lysis. Antibody transfer can also induce active immunization by enhancing antigen presentation by antigen-
coupled antibodies that bind to DCs or by activation of macrophages and DCs due to ligation of the CD40 
costimulatory receptor. TCR = T cell receptor, NCR = natural cytotoxicity receptor, KIR = Killer immunoglobulin-
like receptor. 
 
Move advanced immunotherapeutic approaches use passive antibody therapy to induce 
active immune responses. An example is the use of bispecific antibodies that target tumor 
antigens as well as immune effector cells (51). This in vivo targeting strategy is also used to 
couple tumor-specific antigens to antibodies that specifically bind APCs, thereby inducing 
phagocytosis and antigen presentation (52, 53) (Figure 4). More advanced are the new-
generation mAbs that have immune-modulating effects, like antibodies blocking cytotoxic 
T lymphocyte antigen-4 (CTLA-4), which leads to decreased activation of Tregs, thereby 
enhancing antitumor immunity (54).  
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In vivo data have shown that the use of mAbs as monotherapy has only a minimal effect 
on survival, however, in combination with conventional therapies or as a preventive 
adjuvant-treatment after tumor remission mAb treatment has proven to be much more 
effective (55).  
 
Adoptive T cell transfer 
Adoptive T cell transfer is based on the ex vivo identification of autologous or allogeneic T 
cells that display antitumor activity. These cells are then ex vivo expanded and activated 
before being reinfused. Before reinfusion, the patient’s immune system can be effectively 
manipulated by chemotherapy, radiotherapy or surgery to exert optimal T cell responses 
(56, 57). T cells, used in adoptive T cell transfer can be obtained from the peripheral blood, 
the tumor draining lymph nodes or from the tumor itself (tumor infiltrating lymphocytes 
(TIL)) (Figure 5). 
  
 
 
Figure 5. Adoptive T cell therapy. 
TILs are isolated, cultured and selected for their specific T cell receptor expression. T cells expressing high avidity 
T cell receptors recognizing tumor cells are selected and proliferation/activation of these cells is induced. 
Eventually they are reinjected into the cancer patient to induce antitumor responses.  
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The effectiveness of adoptive T cell transfer was first reported in the context of 
melanoma, where TILs showed antitumor reactivity. These TILs were expanded ex vivo and 
then re-injected into melanoma patients where they showed effective in vivo antitumor 
activity (58). Although initial clinical response rates were high, antitumor responses were 
not long lasting, since the median survival of injected TILs was shorter than one week (59).  
To improve clinical responses, only very pure T cell fractions were used with effective 
depletion of Tregs (60). Even more important to prevent immune responses against the 
newly infused T cells, cancer patients were actively lymphodepleted before re-infusion 
(61). Not only CD8+ T cells have been identified to display potent anticancer reactivity (62) 
but also CD4+ T cells have been implicated in this reactivity (63). Adoptive T cell transfer 
has been proven to induce tumor regression in gastric cancer (64), renal cell cancer (65-
67), melanoma (68) and lung cancer, however the effects on overall survival are 
disappointing and vary the different cancer subtypes.   
The induction of tumor regression by T cell transfer in anticancer therapy, has led to the 
development of genetically altered T cells. Using retroviral vectors, genes encoding T cell 
receptors (TCRs) can be effectively transduced into lymphocytes to redirect their 
specificity (69-71).  
Another new approach in T cell transfer is the development of ex vivo generated T cells 
from stem cells. In animal models these techniques have been shown feasible and T cell 
progenitors have been isolated (72). In mice, important signaling pathways for in vitro T 
cell development have been identified, and amongst others Notch and Flt3 signaling are 
essential signals (73, 74). In humans it has been proven to be more complicated to 
generate T cells in vitro (75, 76). The only successful approaches rely on the use of stromal 
cell lines (77) or the injection of precursor T cells into humanized mice (78, 79), indicating 
that a thymic microenvironment is needed for human T cells to develop. It is not certain if 
fully mature T cells are needed for effective adoptive T cell transfer. For T cell 
repopulation after immuno-ablative anticancer therapy (like in stem cell transplantation) T 
cell precursors might also form an attractive option. Many obstacles, however, have to be 
overcome before such therapies can be applied in cancer patients. For instance, the 
functionality of stem cell-derived T cells remains to be determined. Additionally, in the 
context of reinfusion of mature T cells, it is not known whether the in vitro culture systems 
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induce positive and negative selection and thereby potentially generating auto-reactive T 
cells (80). With the use of T cell progenitors this could be prevented, since the selection 
process is completed in the patient’s own thymus. Nevertheless, it is still unclear whether 
in vitro generated T cell precursors will migrate into the human thymus.    
Both, autologous as well as allogeneic T cells can be used for adoptive T cell transfer for 
cancer. Allogeneic T cells are able to kill tumor cells not only by the recognition of specific 
tumor antigens but also by other non-self antigens. However, these therapies are often 
complicated by aggressive graft-versus-host disease (GvHD). Since allogeneic T cells do not 
distinguish tumor cells from normal tissue cells, new protocols have been developed to 
deplete alloreactive T cells recognizing healthy tissue (81). 
In summary, T cells can be adoptively transferred in cancer patients. Adoptive transfer of 
antigen-specific T cells is a form of specific, passive immunotherapy, whereas transfer of 
pre-T cells and allogeneic T cells are considered a form of aspecific, active  
immunotherapy. Even though antitumor responses have been reported for both forms of 
adoptive T cell transfer, improvement of these therapeutic strategies is needed to further 
enhance the clinical effectiveness.  
 
NK cell therapy 
NK cells are the most efficient effector cells of the innate immune system and were first 
described in 1975, when it was shown that natural cytotoxic cells were able to kill tumor 
cells without being previously sensitized (24, 82). The function of NK cells was eventually 
described by Kärre et al, who postulated the missing-self hypotheses and proved in mice 
that MHC class-I deficient lymphoma cells were rejected (83). Later this mechanism was 
extended with the addition of the induced-self hypothesis (Figure 6) (84). Both hypotheses 
describe the ability of NK cells to kill target cells. This cytotoxic activity is based on a 
delicate balance of inhibitory and activating signals. The balance depends on the 
expression of MHC class I and activating ligands on the target cell as well as on expression 
of the respective receptors recognizing these ligands by NK cells. The missing-self 
hypothesis describes the capacity of NK cells to kill target cells due to their altered 
expression of MHC class I. When a cell becomes virally infected or malignantly 
transformed, MHC class I expression is downregulated to overcome T cell-mediated tumor 
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cell lysis, however decreased class I expression makes tumor cells more vulnerable for NK 
cell kill. Activation of NK cell cytotoxicity is mediated by killer immunoglobulin like 
receptors (KIRs) expressed on the NK cell surface. Upon engagement of these inhibitory 
KIRs with MHC class I molecules of a target cell, inhibitory signals are transmitted, 
prohibiting NK cells to kill the target cell. However, if the inhibitory KIRs cannot bind their 
MHC class I ligand, they become licensed to kill the target cell (85). Killing of these MHC 
class I missing target cells can only be initiated after simultaneous detection of activating 
signals, mostly stress signals, on the surface of tumor cells or ligation of activating KIRs. 
Expression of numerous activating receptors can also induce NK cell killing even in the 
presence of MHC class I surface expression, this mechanism is described in the induced- 
self hypothesis (Figure 6).  
 
 
Figure 6. NK cell function. 
NK cells are activated by a delicate balance of activating and inhibiting signals. Upper: by interacting with normal 
tissue cells that express MHC class I and stress ligands, NK cells do not become activated because the inhibitory 
signal is stronger than the activating signal. Middle: by interacting with tumor cells that upregulated the amount 
of stress molecules, NK cells become activated because the activating signals overrule in inhibitory signal 
(induced-self). Lower: Interaction with tumor cells that have downregulated their expression of MHC class I, will 
lead to NK cell activation (missing-self). 
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To make use of these NK cell characteristics, adoptive NK cell therapies have been 
introduced. Investigators reasoned that NK cell activity in cancer patients is altered. 
Therefore, NK cells from patients were harvested and activated ex vivo with IL-2 before 
being reinjected into the patient (86, 87). Although some clinical responses were reported, 
most autologous NK cell protocols did not induce significant effects. Other lines of 
research focused on the use of stem cell-derived NK cells in which KIR profiles can be 
altered or to make use of NK cell lines expressing all KIRs (88, 89), however these 
techniques have been proven to be difficult and are still under investigation. Additionally 
allogeneic NK cells are used in anticancer therapy, which will be discussed in more detail in 
the next paragraph in relation to stem cell transplantation (SCT).  
 
Stem cell transplantation  
Hematopoietic stem cell transplantation (SCT) has been suggested to be a form of passive 
immunotherapy, which has been proven effective in most hematological malignancies and 
some solid tumors. Since the classification of active and passive immunotherapy 
sometimes seems a bit arbitrary, SCT has also been classified as active immunotherapy. 
Both autologous and allogeneic SCT are currently utilized in clinical practice. Autologous 
transplantation replaces the patient’s own bone marrow after intense myeloablative 
chemotherapy and is therefore considered as a rescue treatment and not a form of 
immunotherapy.  
In allogeneic SCT, antitumor responses are induced by the graft-versus-tumor (GVT) effect 
exerted by the donor’s immune cells and not by the intensive chemo- and or radiotherapy 
prior to transplantation. Patient and donor are matched for major human leukocyte 
antigen (HLA) class I and II molecules, however minor mismatches still exist. Due to these 
minor mismatches and due to the inflammatory response after tumor cell damage 
induced by the conditioning therapy, alloreactive T cells can exert antitumor responses 
(90). Hematopoietic stem cells can be derived from bone marrow or cord blood, but the 
most convenient source is the isolation of granulocyte colony- stimulating factor (G-CSF) 
mobilized stem cells from the peripheral blood (91). Stem cells can either be obtained 
from HLA-matched siblings or from unrelated matched donors (volunteers that are 
registered in a worldwide database). To ablate the immune system, patients are pre-
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treated with intense chemo- and/or radiotherapy, thereby reducing the tumor load and 
more importantly enhancing engraftment due to suppression of the recipient’s immune 
system (91).  
Next to the antitumor effect, SCT also causes serious side effects. Alloreactive T cells are 
not only capable of inducing GVT effects, but can also destruct healthy cells. This process 
is known as graft-versus-host disease (GvHD) (92). Another side effect of SCT is related to 
the toxicity of the preconditioning, which makes allogeneic SCT only available for young 
patients. However, with the development of the new non-myeloablative SCT with reduced 
toxicity also older patients can be transplanted (93, 94). Additionally, the intense 
conditioning is responsible for immuno-ablation, which is associated with an increased risk 
of opportunistic and viral infections, due to neutropenia and slow T cell recovery (95). 
Currently new techniques are being developed to deplete the transplanted stem cell 
fraction only of alloreactive T cells that could induce GvHD and not T cells that can fight 
infection (96).   
 
Figure 7. Effects of alloreactive NK cells in haploidentical 
stem cell transplantation. 
If NK cells express one or more KIRs that cannot bind MHC 
class I (HLA-C1, C2, or Bw4), they become activated and kill 
the target cell (upper and middle). However if the tumor cell 
expresses al KIR ligands, NK cells are never able to exert 
allogeneic activity (lower). 
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Another form of alloreactive SCT is the mismatched haploidentical SCT, where the GVT 
effect is not only based on T cell alloreactivity, but also on the presence of alloreactive NK 
cells. Donors are selected on a HLA-KIR mismatch, which means that the recipient lacks 
one or more of the HLA class I ligands for donor inhibitory KIRs. Such a KIR mismatch will 
lead to alloreactive NK cell activation (Figure 7). In patients with acute myeloid leukemia 
(AML) treated with a SCT where donor and recipient displayed a KIR-HLA mismatch, it was 
shown that there was an increase in survival and reduced relapse rates (97). Notably, SCT 
that involved a KIR mismatch showed a reduced risk of GvHD development and increased 
percentage of engraftment. The capacity of alloreactive donor NK cells to kill recipient 
antigen presenting cells accounted for the decreased development of GvHD (97, 98). 
Despite the positive effects obtained by initial studies of mismatched haploidentical STC in 
AML patients, other studies failed to reproduce these results (99, 100). Discrepancies 
might be caused by differences in donor selection or by differences in the conditioning 
regimen (101).  
Because of the successes reported using haploidentical stem cells, many studies focus on 
using allogeneic NK cells in adoptive cell therapy for cancer (102). Adoptive transfer of 
these cells has been shown to be well tolerated and does not induce GvHD. Especially in 
patients with AML, haploidentical NK cell therapy has been proven successful (97). 
Allogeneic SCT is effective in cancer treatment and is therefore standard treatment in 
many hematological malignancies. However, toxicity of the conditioning regimen, graft 
failure, increased risk of infectious disease and development of GvHD form life threatening 
complications and indicate that optimization of SCT is needed.    
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Active immunotherapy 
Activation of the body’s own immune system can be aspecific, activating of overall 
immune responses or antigen specific. Antigen-specific immune responses can be 
achieved by administration of antigens or antigen loaded DCs. Aspecific activation is 
mediated by adjuvants, like cytokines and chemokines. 
  
 
DC vaccination 
Therapeutic DC vaccination strategies aim at activating the cancer patient’s immune 
system to overcome tolerance and to induce effective antitumor immune responses (4).  
In this strategy, DCs are obtained from the cancer patient, stimulated ex vivo, loaded with 
tumor antigens and then re-injected into the patient where they have to migrate into the 
draining lymph nodes. In these lymph nodes they bring about clonal expansion of T cells 
expressing a specific randomly arranged antigen-specific receptor (103, 104).   
For the ex vivo generation of DCs, several different DC subsets have been used including 
monocyte-derived DCs, stem cell-derived DCs, DC cell lines (105) and DCs obtained from 
dedifferentiated AML cells (106). In most clinical DC vaccination therapies, however, 
monocyte derived DCs are administered (107). In these vaccination therapies, monocytes 
are induced to differentiate into immature DCs (iDC) by cocktails containing GM-CSF in 
combination with either IL-4, IL-13 or IL-15 (107). The capacity of DCs to present antigen, 
express co-stimulatory molecules, home into the draining lymph nodes and to secrete 
cytokines, depends on their maturation status. DC maturation can be induced by T cells 
(CD40 ligand) (108), pro-inflammatory molecules (IL-1β, TNF-α, IFN-α, IFN-γ and PGE2) 
(109, 110) and DC-surface receptors involved in pathogen recognition (PRR) (110). The 
combination of different DC-maturation triggers determines which kind of TH cell response 
is initiated (Figure 8).  
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Figure 8. DC vaccination strategy.  
Monocytes derived from cancer patients (1) are differentiated into iDCs by different differentiation cocktails (2) 
followed by maturation, which is induced by cocktails containing proinflammatory cytokines, PGE2 or TLR-ligands 
(3). During maturation MHC class I and II membrane expression is upregulated and by different antigen loading 
techniques, DCs are induced to present antigens (4). These antigen-presenting DCs are reinjected into the patient 
(5), where they have to migrate into the draining lymph nodes (6). In these lymph nodes DCs interact with T cells 
and DC-cytokine secretion and expression of co-stimulatory molecules determines TH cell polarization and CTL 
induction (7). 
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Activation of T cells by DCs depends on four independent signals inducing their  
differentiation and potentiating either their helper, killer or suppressive activity. These 
four signals include antigen presentation, which determines the specificity of the 
response; co-stimulation, determining the magnitude of the response; cytokine secretion, 
which is responsible for the type of immune response; and homing instructions that 
instructs effector T cells to migrate to the tumor site (111-113). For the induction of a 
specific T cell response, DCs should first be capable to efficiently present antigen. To this 
end, many ex vivo antigen-loading strategies have been developed, resulting in antigen 
presentation in MHC class I and/or II. These strategies include loading DCs with proteins 
(114), peptides, exosomes (115), viral vectors (116), plasmid DNA and RNA transfection 
(116-118), immune complexes (119) and tumor cell lysates (120, 121) (Figure 8). Fine-
tuning of DC-maturation triggers, thereby influencing their cytokine profile, is of utmost 
importance for the efficacy of antitumor DC vaccination protocols. To induce an effective 
antitumor response TH1 and TH17 activation should be initiated whereas Treg induction 
should be avoided. Classical maturation cocktails often contain a combination of both 
TNF-α en PGE2. These DCs are most often used in clinical vaccination trials. However, over 
the past years increasing in vitro evidence suggests that TLR-ligand matured DCs might 
have a superior effect on TH1 polarization and subsequent CTL induction which is based on 
their enhanced IL-12 producing capacity (110, 122, 123). Finally, DC-mediated T cell 
homing to the tumor site is a very poorly understood mechanism and manipulation of this 
mechanism is still under intensive investigation.  
A large number of clinical phase I studies and smaller numbers of phase II and III studies 
with therapeutic DC vaccination protocols have been performed in human cancer 
patients. DCs have been successfully used to treat melanoma, lymphoma and renal cell 
carcinoma (124-128). They have proven to be safe and to induce tumor-specific T cells 
(129, 130). In 2010, the U.S. Food and Drug Administration (FDA) approved the first clinical 
vaccine preparation, which is used to treat prostate cancer (131). Additionally, in 
Switzerland the national public health organization has authorized a DC vaccination 
strategy for glyoblastoma (132). Despite these encouraging developments, overall clinical 
response rates to DC vaccination strategies do not exceed 10-40% (133, 134). A few 
potential problems for the lack of improvement in survival have been proposed and are 
listed in Table I (4, 135).  
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In conclusion, DC vaccination strategies have been proven effective, however to improve 
response rates in clinical trials, new DC vaccination techniques should be analyzed and 
their effects must be studied in defined cancer patients with a low tumor load.   
 
Table 1.  
 Obstacles in DC vaccination therapy 
 
1 
 
Patients used in trials are heavily immunosuppressed by chemo- and radiation therapy and often 
have a large tumor burden (134). 
2 Most injected DCs remain at the site of injection and do not migrate into the draining lymph nodes 
(136). 
3 T cell stimulation by DCs needs to be directed towards induction of TH1 polarization and CTL 
activation instead of activation of Treg cells (137, 138).  
4 Tumor suppressive effects may lead to T cell anergy, which is not easily overcome by DC 
vaccination (139). 
5 Most DC vaccination strategies only target one single tumor antigen, whereas tumors are able to 
edit expression of immunogenic antigens.  
 
 
 
Antigen therapy 
T cells, B cells and plasma cells can be stimulated in vivo to produce antibodies or induce 
CTLs, by administration of antigens to cancer patients. These antigens are phagocytized 
and presented in MHC class I and II molecules by APCs (including DCs) to B and T cells (55) 
(Figure 9). Antigens can be administered as whole tumor cells, gene-modified tumor cells 
and long or short peptides (114). Important antigens used in clinical trials are MAGE, 
which is expressed by many tumors but mainly melanoma, WT-1 that is highly expressed 
in leukemia and various types of solid tumors, MUC1, which is expressed by almost all 
adenocarcinomas and NY-ESO-1, mainly expressed in melanoma, ovarian and lung cancer 
(140-142). Immune cell activating adjuvants are often additionally used to enhance the 
effect of antigen vaccination strategies (Figure 9). 
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Figure 9. Induction of active immune responses.  
Induction of humoral and cellular immune responses can be induced by antigen administration. These and other 
immune responses can be enhanced by the simultaneous administration of TLR-ligands or cytokines. NK and T 
cells can additionally be activated by IL-2 and IL-12 stimulation. 
 
Immune adjuvants, chemokines and cytokines 
Adjuvants that stimulate molecular pathways in innate immune cells, enhancing tumor-
associated inflammation and recruitment of immune cells, have been utilized in clinical 
trials (143, 144). The most common cells targeted in active immunotherapy are APCs (40). 
Among these cells, DCs are the most potent antigen presenting cells that can be targeted 
by adjuvant therapy. The function of DCs can be enhanced by different adjuvants, both 
organic and inorganic (145). In clinical vaccination strategies the most utilized inorganic 
adjuvant is alum (146, 147). Over the last decade however, organic adjuvants are also 
frequently used. The majority of these organic adjuvants contain Toll-like receptor (TLR) 
ligands that induce activation of DCs to engulf tumor-associated antigens and present 
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them to cells of the adaptive immune system (148, 149). This activation of DCs by TLR-
ligands can be enhanced by cytokines. 
TLRs are the best characterized pattern-recognition receptors that bind highly conserved 
pathogen-associated molecular patterns (PAMPs) (150), which are expressed either 
extracellularly (TLR1, TLR2, TLR4, TLR5 and TLR6) or intracellularly (TLR3, TLR7, TLR8 and 
TLR9) and are capable of binding different pathogens. The location of the TLRs (intra- or 
extracellular) is organized according to the infectious route by which different pathogens 
enter the cell.  
The effect of TLR-ligands in cancer therapy was already demonstrated in the 19th century 
by William Coley, who showed that patients who developed bacterial infections after 
sarcoma surgery had visible regression of their tumors (151). Administration of TLR-
ligands, both locally or systemically, has been shown to have potent anticancer effects (46, 
152-155), which is evidenced by the effects of intravesicular injection of live bacilli 
Calmette-Guérin (BCG) in patients with bladder cancer (156). TLR-agonists can be used as 
monotherapy but also as adjuvants in immunotherapy and have been thought to 
overcome tolerance to tumor-self antigens (150, 152, 157). The antitumor responses are 
based on TLR-mediated DC activation, which leads to the production of chemokines and 
cytokines involved in recruitment of leukocytes and activation of NK cells and cyctotoxic T 
cells (CTLs) (5, 7, 39). Additionally, TLR-ligands can directly induce apoptosis of tumor and 
stromal cells, by binding to these cells (158, 159).  
DCs can not only be activated by the beforementioned TLR-ligands, also cytokines can be 
used to induce DC maturation, differentiation and activation. Attractive cytokines used for 
this purpose include Flt3L, GM-CSF and IFN-α. Administration of IFN-α in patients with 
chronic myeloid leukemia (CML) or renal cell cancer has been shown to induce effective 
antitumor immune responses mediated by both T and NK cells (5, 39).  
Immune effector cells can also be targeted to induce antitumor responses. Important 
effector cells are NK, NKT and T cells (160). In addition to their cytolytic capacity these 
cells are efficient producers of IFN-γ, a cytokine that has tumoricidal effects and activates 
DCs, macrophages and T cells. NK, NKT and T cells can become activated both in vitro and 
in vivo by IL-2 and IL-12 stimulation (161, 162). Therefore these cytokines are used in 
many different anticancer therapies. IL-2 has been used to treat melanoma and renal cell 
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carcinoma patients, with an overall response rate of 15-20% (161). IL-12 is the main 
cytokine responsible for the induction of TH1 responses and induces IFN-γ secretion by 
both T cells and NK cells (162). In turn, IFN-γ is a very potent DC-activating cytokine, 
thereby forming a positive feedback loop for enhancement of IL-12 production by DCs, 
which suggests that IL-12 might be a very potent adjuvant in cancer vaccines (162). Even 
though initial effects, characterized by substantial antitumor activity and complete 
remission in renal cell carcinoma (163, 164) and melanoma patients (165), were 
promising, administration of optimal doses of both cytokines proved to be toxic (18).  
IFN-α is another cytokine involved in NK cell activation since it induces NK cell 
proliferation and augmentation of NK cell-mediated tumor cell lysis (166, 167). 
Additionally, it increases T cell-mediated killing of neoplastic cells (163) and enhances the 
ability of DCs to present antigen (43). IFN-α is used in many different malignancies 
including hematological malignancies and solid tumors (168, 169). Especially in CML, IFN-α 
therapy has been proven effective (170, 171), since it induces hematological remission in 
60-80% of patients in early chronic phase CML. This clinical remission is correlated with 
upregulation of NK cell activity (164), presence of antibodies against CML-associated 
antigens (172) and presence of CML peptide-specific T cells (173).  
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Aim of the thesis 
 
Immunotherapy has been reported to be successful only in a minority of cancer patients 
and therefore optimization is needed to increase clinical success rates. Dendritic cell 
vaccines for solid tumors as well as hematological malignancies need to be optimized at 
different levels. First, tumor-specific antigens need to be identified. Second, monocyte–
derived DCs can be maturated and differentiated by many different strategies which have 
different effects on the induction of immune effector cells. Additionally, interaction of DCs 
with other innate or adaptive immune cells is important to induce effector responses. This 
can either be achieved by DCs migrating into lymph nodes or by DC-mediated recruitment 
of immune cells. Activation of different subsets of immune effector cells by DCs is of 
importance to predict possible clinical outcome. Therefore, it is of significance to 
understand more about the biology of immune responses and to know which immune 
cells should be preferentially targeted to induce antitumor responses. Equally important is 
the effect of immunosuppressive factors, like PGE2, produced by tumor cells and their 
microenvironment, on DC-mediated responses. This knowledge may lead to the 
administration of ex vivo developed effector cells, which can replenish the effector cell 
population, avoiding the negative effect of immunosuppressive factors. Finally, effective 
read-out systems of immune responses induced in patients need to be developed to 
assess therapy and predict possible clinical responses.  
In this thesis, all of these topics are investigated and optimized to develop a combination 
of improved immunotherapeutic strategies to effectively fight cancer (Figure 10). 
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Figure 10. Aim and outline of this thesis. 
To optimize DC vaccination protocols, tumor-specific antigens need to be identified. Monocytes can be isolated 
from blood, differentiated into immature DCs and matured by different stimuli to mature DCs. DCs are then 
loaded with tumor-associated antigens and injected into the patient. DCs, either have to migrate into the lymph 
nodes or can recruit immune effectors cells, thereby forming a tertiary lymphoid structure where they interact 
with effector cells. This interaction will either activate the patient’s own effector cells or T cells that were 
developed or activated ex vivo and injected into the patient. The effector cells are then involved in tumor cell 
lysis. Techniques to evaluate induction of immune responses are crucial to follow up treatment efficacy. 
Numbers in red represent the chapters of this thesis in which the topic is addressed.  
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Outline of the thesis 
 
In chapter 2 we investigated the expression of underglycosylated MUC1 (MUC1-Tn/STn) in 
ovarian cancer, which could serve as tumor-specific antigen to be targeted in 
immunotherapy. Additionally, the mAb recognizing this epitope could possibly be used in 
diagnostics as well as antibody treatment. To optimize DC vaccination strategies, we 
evaluated the in vitro effect of different DC-maturation protocols on the induction of T cell 
responses in chapter 3. Not only effects on induction of adaptive immune responses of 
these differently matured DCs were assessed, but also their capacity to recruit and 
activate NK cells was evaluated in chapter 4. PGE2 is a potent immune suppressor, which 
is secreted by many solid as well as hematological malignancies. Paradoxically, PGE2 is 
often used in DC maturation protocols. In chapter 5 we evaluated the effect of PGE2 on 
NK-DC interaction.   
To evaluate the induction of humoral immune responses by DC-mediated immunotherapy, 
we developed a flow cytometry-based assay to detect human serum antibodies to MUC1 
and underlycosylated MUC1, which is described in chapter 6. To enhance the 
effectiveness of DC vaccination and other forms of immunotherapy, ex vivo development 
of tumor-specific T cells that are not subjected to tolerance during development are of 
possible interest. Therefore we developed an ex vivo method to generate T cells, which is 
described in chapter 7. In chapter 8, a general discussion is presented, discussing the 
impact of our findings on improvement of cancer immunotherapy, with a special focus on 
the effect of NK-DC interaction in DC vaccination (Figure 10).  
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Abstract 
 
Aims: Mucin 1 (MUC1) is an important tumor-associated antigen (TAA), both over-
expressed and aberrantly glycosylated in adenocarcinomas. The objective of this study 
was to examine the MUC1-glycosylation status in primary ovarian adenocarcinomas and 
metastatic lesions. 
Methods and results: Paraffin-embedded tissue sections of 37 primary ovarian 
adenocarcinomas representing all histotypes (22 serous, 5 mucinous, 2 clear cell, 8 
endometrioid), 4 serous borderline tumors with intraepithelial carcinoma, 7 sections of 
ovarian endometriosis and 13 metastatic lesions were analyzed by immuno-
histochemistry. Non-neoplastic ovarian surface epithelium and serous cystadenomas were 
used as controls. All epithelia expressed the MUC1 protein. Of primary tumors, 76% 
expressed the differentiation-dependent glycoform and 84% the cancer-associated 
glycoform (Tn/Sialyl-Tn-epitopes). In metastatic lesions this was 77% and 85%, 
respectively. Notably, in 57% of ovarian endometriosis and 75% of intraepithelial lesions, 
the cancer-associated MUC1 epitopes were expressed, whereas normal ovarian surface 
epithelium and serous cystadenomas did not express these epitopes.   
Conclusions: The underglycosylated MUC1 epitopes are expressed by all histotypes of 
primary ovarian adenocarcinomas, by the vast majority of metastatic lesions and by 
possible ovarian cancer precursor lesions, whereas not by normal ovarian tissue. These 
results indicate that MUC1-associated Tn/STn-epitopes are important targets for 
immunotherapy and diagnostic imaging in ovarian cancer patients.  
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Introduction 
 
Ovarian cancer is the second most common gynecological malignancy in developed 
countries, and the most common cause of death among women developing gynecological 
cancer (1, 2). The high mortality rate is ascribed to the fact that more than 60% of ovarian 
cancer patients already have advanced disease at diagnosis. Therefore, ovarian cancer is 
also referred to as “silent killer”. Metastasis as well as intra-abdominal growth are 
frequent, because the malignantly transformed ovarian surface epithelium is continuous 
with the peritoneal mesothelium (3).  
The current treatment of ovarian cancer is surgical resection, followed by platinum-based 
chemotherapy. Despite advances in chemotherapy treatment, which have led to improved 
survival, relapse is still frequent in the majority of patients with advanced disease (4). To 
improve overall survival of ovarian cancer patients there is an urgent need for new 
treatment options. Immunotherapy has been demonstrated to be successful in the 
treatment of cancer (5). For antibody-mediated immunotherapy or cancer vaccines to be 
successful, identification of tumor-associated antigens (TAA), against which an immune 
response is induced, is of utmost importance. Up to this moment there have been few 
candidate-TAAs identified for ovarian cancer and clinical effects are limited (6).  
An interesting TAA is Mucin 1 (MUC1), because it is overexpressed in most 
adenocarcinomas (7-9). MUC1 is a protein expressed on the apical surface of most simple, 
secretory epithelia and on a variety of hematopoietic cells (10, 11). MUC1 is a 
transmembrane mucin with an extracellular domain made up largely of 20 amino acid 
tandem repeats. After translation, the MUC1 protein becomes modified by extensive O-
glycosylation. Within each tandem repeat, two serines and three threonines represent five 
potential O-glycosylation sites. The extent of glycosylation mainly depends on the 
expression of tissue-specific glycosyltransferases (8). Importantly, it has been demonstrated 
that in most adenocarcinomas and some hematological malignancies MUC1 is aberrantly 
glycosylated, has lost its apical expression and is secreted into the circulation (12-16). Due 
to aberrant glycosylation of MUC1 on tumor cells, new glycosylation-specific peptides are 
revealed, including the MUC1-associated Tn/STn-epitopes. These epitopes are generated 
when O-glycosylation is terminated immediately after the first N-acetylgalactosamine 
Chapter 2 
 
56 
(GalNAc) addition (Figure 1) (17, 18). The mechanisms responsible for Tn- and STn 
formation are still ill understood. It has been shown that alterations in ST6GalNAc-I 
transferase induces premature termination of glycosylation and subsequently enhances 
STn formation (19). Another documented mechanism involves somatic mutation of the 
Cosmc gene, a molecular chaperone regulating the enzyme responsible for the addition of 
galactose (Gal) to the first GalNAC (20). MUC1-associated Tn- and STn-epitopes, both 
recognized by mAb 5E5 (18, 21, 22), are potential TAAs, which can be targeted in 
immunotherapy but are also of importance in diagnostic imaging (17, 23).  
Overexpression of MUC1 has been reported in ovarian cancer (24, 25). The expression of 
MUC1-associated Tn/STn-epitopes has been suggested (26), based on a similar expression 
pattern of MUC1 epitopes as well as Tn/STn-epitopes. However, the expression of MUC1-
associated Tn- and STn-epitopes has never been proved. 
In this study, we determined whether primary ovarian tumors and metastatic lesions 
express aberrantly glycosylated MUC1. Since the most widely accepted candidate for the 
origin of ovarian cancer is the ovarian surface epithelium (OSE) (27), we examined the 
MUC1 glycosylation status of OSE adjacent to the tumor in neoplasic ovaria and the 
epithelium of serous cystadenomas. Additionally, we analyzed MUC1 expression of 
ovarian endometriosis and serous borderline tumors with intraepithelial 
carcinoma/micropapillary growth, because both have been reported to be precursor 
lesions of invasive ovarian adenocarcinomas (28). We demonstrate that the MUC1-
associated Tn/STn-epitopes are expressed on all different ovarian cancer histotypes and 
their metastases, while they are absent in normal ovarian tissue, rendering these epitopes 
potential targets for immunotherapy and immunodiagnostic imaging.   
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Materials and methods 
 
Tissue samples 
Paraffin-embedded tissue samples were obtained from files of the Department of 
Pathology, (Maastricht University Medical Center+) from 1990 to 2006. The study 
population consisted of 43 patients diagnosed with epithelial ovarian cancer. For 37 
patients, primary tumors were analyzed. For 8 of these patients, matched metastases 
were analyzed. Of 5 other patients, only metastatic lesions could be analyzed. As a 
control, normal OSE adjacent to the tumor of 9 MUC1 positive tumors and 7 serous 
cystadenomas were analyzed.  
The 37 primary ovarian tumors originated from different histotypes and comprised of 22 
serous adenocarcinomas, 5 mucinous adenocarcinomas, 2 clear cell carcinomas, 8 
endometrioid carcinomas. Additionally, 4 serous borderline tumors with intraepithelial 
carcinoma and 7 endometriosis lesions were analyzed. The 8 matched metastatic lesions 
were all typed as serous adenocarcinomas and the 5 non-matched metastatic lesions 
consisted of 4 serous adenocarcinomas and 1 mucinous adenocarcinoma. 
 
Antibodies 
MUC1 antibody 214D4 (purified from the supernatant of the 214D4 cell line (29)) was 
kindly provided by Dr. J. Hilkens (the Netherlands Cancer Institute, Amsterdam, the 
Netherlands). The mAb SM3 (supernatant (30)) was contributed by Prof. Dr. J. Taylor-
Papadimitriou (Guy's Hospital, London, United Kingdom). MAb 5E5 (supernatant (21, 22)) 
was donated by Prof. Dr. H. Clausen (Department of Glycobiology, University of 
Copenhagen, Denmark). A detailed description of the specificities of the MUC1 antibodies 
used in this study has been published previously (18). Briefly, the mAb 214D4 recognizes 
human MUC1 irrespective of its glycosylation pattern, mAb SM3 recognizes the 
differentiation-dependent glycoforms and mAb 5E5 exclusively recognizes cancer-
associated glycoforms of MUC1 (MUC1-associated Tn and STn) (Figure 1) (21). Although 
the mAbs SM3 and 5E5 both display cancer-associated reactivity (30), mAb SM3 also stains 
healthy human tissue as has been shown previously in the kidney and thymus (31, 32).  
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Figure 1. Glycosylation of tumor-associated MUC1. 
Schematic representation of carbohydrate antigens, mAb and glycosyltransferases assayed in this  
paper. O-linked glycosylation is initiated by polypeptide N- acetylgalactosaminyltransferases (a), adding N-
acetylgalactosamine (GalNAc) to serine (Ser) or threonine (Thr) of the polypeptide backbone, resulting in the Tn 
antigen, recognized by mAb 5E5. The Tn antigen may be sialylated by sialyltransferase ST6GalNAc-I (b), adding 
sialic acid (NeuAc) to the GalNAc moiety of Tn, resulting in the sialyl-Tn (STn) antigen, also recognized by mAb 
5E5. If not sialylated, core 1 structures maybe synthesized by galactosyltransferase Core 1 ß3-GalT (c), adding 
galactose (Gal) to the GalNAcmoiety of Tn, resulting in the T antigen. Addition of further sugar moieties will 
result in the formation of Core 2 antigen formation, recognized by mAb SM3. 
Immunohistochemistry   
Paraffin-embedded tissue sections were deparaffinised by xylol (Merck, Darmstadt, 
Germany) treatment and rehydrated in decreasing concentrations of methanol (Merck). 
After rehydration, endogenous peroxidase was blocked (0.5% H2O2 in methanol) for 30 
minutes and the slides were washed in PBS (Sigma-Aldrich, St. Louis, USA) supplemented 
with 0.05% Tween 20 (Merck). Specific staining of MUC1 was determined by incubation 
with primary anti-MUC1 mAbs or matched isotype controls overnight at 4°C. Afterwards, 
sections were rinsed with PBS/Tween 20 and incubated with Envision-HRP (DAKO, 
Glostrup, Denmark) for 20 minutes at room temperature. The color was developed by 
incubation for 3 minutes at room temperature using a substrate buffer containing 3,3'-
diaminobenzidine (5 µg/mL; DAKO) and 0.5% H2O2 (Sigma,
 Zwijndrecht, the Netherlands)  
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in PBS/Tween 20. Cytospins of the breast carcinoma cell line ZR75-1 (Department of 
Pathology, Maastricht University Medical Center+) proven to stain positive for all anti-
MUC1 mAbs served as intra-experimental positive control for all antibodies (32). The 
histological images were analyzed by microscope (Carl Zeiss, Sliedrecht, the Netherlands) 
with an objective magnification of 10-20x. Digital pictures were taken by a Jenoptic 
camera (Carl Zeiss). The ovarian tumor slides were analyzed independently by five 
investigators (C.V.E.; F.B.; M.H.; W.G.; K.V.d.V.). Staining of cytoplasm and cell membranes 
was evaluated and cells were considered positive when at least one of these components 
showed positive staining.  
 
Results 
 
Expression of MUC1-associated Tn/STn-epitopes in ovarian cancer and adjacent healthy 
tissue   
To determine the MUC1 glycosylation status, normal and malignantly transformed ovarian 
epithelium were immunoreacted with different MUC1 glycosylation-specific antibodies. 
Figure 2 shows a tissue section, containing normal OSE and malignantly transformed 
epithelium. Clearly, the MUC1 protein was expressed on the apical surface of normal 
ovarian epithelium, whereas the differentiation-dependent and cancer-associated 
glycoforms were not detected (Figure 2). In all 9 neoplastic ovarian tissue samples 
containing OSE, MUC1 expression of the normal epithelium was limited to the apical 
surface.  
Strikingly, the malignantly transformed epithelium of the same ovary showed abundant 
expression of the MUC1 protein (Figure 2B), as well as the differentiation-dependent and 
cancer-associated glycoforms of MUC1, detected by mAb SM3 and 5E5, respectively 
(Figure 2C, D). Furthermore, in some malignant cells apical expression of MUC1 was lost, 
and MUC1 was detected on the entire cell surface (Figure 2D, arrows).  
As an additional control of benign ovarian epithelium, serous cystadenomas were 
analyzed for expression of MUC1. All of these cysts (7/7) expressed the MUC1 protein 
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(mAb 214D4) and also 29% (2/7) expressed the differentiation-dependent glycoform, 
(mAb SM3) but none of them (0/7) the cancer-associated MUC1 glycoform (mAb 5E5). 
 
 
 
Figure 2. MUC1 expression by healthy and malignant ovarian epithelium.  
Expression of different MUC1 glycoforms on human ovarian tissue sections containing normal and malignant 
ovarian epithelium (serous adenocarcinoma). Sections were stained with mAb specific for MUC1 glycoforms. (A) 
Isotype control. (B) The glycosylated MUC1 isoform (mAb 214D4) was strongly expressed on the apical side of the 
normal epithelium, and on malignant transformed epithelium. (C) No expression of the differentiation-
dependent glycoform of MUC1 (mAb SM3) in normal tissue while malignant transformed tissue stained positive. 
(D) The cancer-associated isoform of MUC1 (mAb 5E5) was not expressed on normal tissue, but was expressed 
on the malignant tissue. Loss of apical surface expression is indicated (arrows). * Normal ovarian epithelium, ** 
malignantly transformed epithelium. 
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Expression of MUC1 and cancer-associated MUC1 on different ovarian cancer histotypes  
Since there are four different epithelial ovarian cancer histotypes, all were examined using 
the panel of MUC1 glycosylation-specific antibodies. The prevalence differs for each 
histotype, with the serous adenocarcinoma being the most common type of epithelial 
ovarian cancer, and the clear cell and endometrioid adenocarcinoma being rare (3). This 
was reflected in the number of tumors that was available for examination for each 
different histotype (22 serous adenocarcinomas, 5 mucinous adenocarcinomas, 2 clear cell 
carcinomas and 8 endometrioid adenocarcinomas). All ovarian cancer histotypes 
expressed MUC1 (37/37) (Table 1). The differentiation-dependent glycoform (mAb SM3) 
was found on 82% (18/22) of the serous, 60% (3/5) of the mucinous, 63% (5/8) of the 
endometrioid and on all of the clear cell (2/2) adenocarcinomas. The cancer-associated 
glycoform (mAb 5E5) was expressed on 86% (19/22) of the serous (Figure 3A), 80% (4/5) 
of the mucinous (Figure 3B), all of the clear cell (2/2) (Figure 3C) and on 88% (7/8) of the 
endometrioid adenocarcinomas (Figure 3D). 
 
Table 1. Expression of the different MUC1 glycoforms on the different ovarian carcinoma histotypes. 
 
Histotypes / mAb                                    
 
214D4 
 
SM3 
 
5E5 
 
Serous adenocarcinoma                       
 
100% (22/22) 
 
82% (18/22) 
 
86% (19/22) 
Mucinous adenocarcinoma                 100% (5/5) 60% (3/5) 80% (4/5) 
Clear cell carcinoma                            100% (2/2) 100% (2/2) 100% (2/2) 
Endometrioid adenocarcinoma           100% (8/8) 63% (5/8) 88% (7/8) 
 
In contrast to serous cystadenomas, ovarian endometriosis can serve as a precursor lesion 
of ovarian cancer, especially of the endometrioid and clear cell subtypes (27). Since most 
of the endometrioid adenocarcinomas express the MUC1 cancer-associated glycoform, we 
investigated the MUC1 glycosylation pattern of ovarian endometriosis. All endometriosis 
lesions expressed MUC1 (7/7) (Figure 4A), the differentiation-dependent glycoform (mAb 
SM3) was expressed by 57 % (4/7) and the cancer-associated glycoform (mAb 5E5) by 71% 
(5/7) of the endometriosis lesions (Figure 4B, C).  
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Additionally, serous borderline tumors with intraepithelial ovarian carcinoma, another 
precursor lesion of invasive ovarian adenocarcinoma, was examined for its MUC1 
expression. All of these lesions expressed the MUC1 protein (4/4) (Figure 5A), 50% (2/4) 
the differentiation-dependent glycoform (Figure 5B) and 75% (3/4) the cancer-associated 
glycoform (Figure 5C). 
In summary, the MUC1-associated Tn/STn-epitopes could be detected in tissue sections of 
all different ovarian cancer histotypes. Importantly, these epitopes were expressed on 
86% of the serous adenocarcinomas, the most frequently diagnosed ovarian malignancy. 
For the other histotypes the number of tumor sections analyzed was too low to draw firm 
conclusions, but tumors as well as ovarian cancer precursor lesions expressed the cancer-
associated MUC1 epitopes.    
 
 
 
Figure 3. Expression of the cancer-associated glycoform of MUC1 on the different ovarian cancer histotypes. 
 (A) Serous adenocarcinoma. (B) Mucinous adenocarcinoma. (C) Clear cell carcinoma. (D) Endometrioid 
adenocarcinoma. Detected with mAb 5E5.  
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Figure 4. Expression of different MUC1 glycoforms in 
endometriosis of the ovary. (A) The glycosylated MUC1 isoform 
(mAb 214D4), (B) differentiation-dependent glycoform of MUC1 
(mAb SM3) (C) and cancer-associated glycoform of MUC1 (mAb 
5E5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Expression of different MUC1 glycoforms in a 
serous borderline tumor with intraepithelial carcinoma. (A) 
The glycosylated MUC1 isoform (mAb 214D4), (B) 
differentiation-dependent glycoform of MUC1 (mAb SM3) (C) 
and cancer-associated glycoform of MUC1 (mAb 5E5). 
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Expression of MUC1 and cancer-associated MUC1 in ovarian cancer metastases  
As already indicated, ovarian tumors are prone to metastasize, therefore metastatic 
lesions were examined for their MUC1 expression. In 8 cases, it was possible to analyze 
both the primary tumor as well as the metastases. In the metastatic lesions, expression of 
MUC1 was detected in all (13/13) of the samples (Figure 6B). The differentiation-
dependent MUC1 glycoform was detected in 77% (10/13) and the cancer-associated 
MUC1 glycoform in 85% (11/13) of metastatic lesions (Figure 6C, D). When the MUC1 
expression profile of the metastases was compared with the profile of the primary tumor, 
the expression of MUC1 (mAb 214D4) was similar (100%). Additionally, in 63% (5/8) there 
was a similar expression profile of the differentiation-dependent MUC1 glycoform (mAb 
SM3) and even better results were obtained for the expression of MUC1-associated 
Tn/STn-epitopes (mAb 5E5), which showed comparable expression in all cases.  
 
 
 
Figure 6. Expression of different MUC1 glycoforms in a metastatic ovarian cancer lesion in the omentum. 
(A) Staining with isotype control. (B) The glycosylated MUC1 isoform (mAb 214D4), (C) differentiation-dependent 
glycoform of MUC1 (mAb SM3) (D) and cancer-associated glycoform of MUC1 (mAb 5E5) were expressed in the 
metastatic lesion. 
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Discussion 
 
We demonstrate that aberrantly glycosylated, cancer-associated MUC1 is expressed in situ 
in most ovarian cancer tumors, but not in OSE and serous cystadenomas. Moreover, we 
show that the cancer-associated MUC1 epitopes are not only present in primary tumors, 
but also in ovarian cancer precursor lesions and in metastatic lesions. The expression of 
cancer-associated MUC1 epitopes in breast cancer has already been identified (21). Until 
now, the presence of cancer-associated MUC1 specific Tn- and STn-epitopes in ovarian 
cancer has been suggested, but not yet proven (26). Here we show that the cancer-
associated MUC1 Tn/STn-epitopes, recognized by mAb 5E5, are indeed expressed in 
ovarian cancer and not in healthy ovarian tissue. In accordance with previous reports, the 
mAb SM3 also reacts with ovarian cancer tissue (30). Even though the mAbs SM3 and 5E5 
both display this cancer-associated reactivity in ovarian cancer, mAb SM3 also reacts with 
healthy tissue as has been shown previously in thymus, salivary glands, sebaceous glands 
and the distal tubulus of the kidney (31, 32). This indicates that antibodies recognizing 
MUC1-associated Tn/STn-epitopes might have more potential to be used in ovarian cancer 
diagnostics and especially in immunotherapy.  
Several studies have reported on the monoclonality of most epithelial cells in 
endometriotic cysts (33, 34) and therefore endometriosis is classified as a tumor-like 
lesion (28). The fact that the epithelium of ovarian endometriosis also expresses the 
MUC1-associated Tn/STn-epitopes, further supports the theory that endometriosis is 
actually a precursor lesion of ovarian cancer (27). Molecular events involved in the 
transformation of endometriosis have been studied extensively (27, 35) and decreased 
glycosylation of MUC1 may be a marker of this process. This is supported by the 
expression of MUC1-associated Tn/STn-epitopes by serous borderline tumors with 
intraepithelial carcinoma, which is confirmed to be a precursor of invasive serous 
adenocarcinomas. If antibodies recognizing the MUC1-associated Tn/STn-epitopes are 
suitable for discrimination between high and low risk endometriosis lesions, this will 
improve risk assessment and possibly therapy of younger women who want to preserve 
fertility. However, before being used in routine diagnostics, larger series of endometriosis 
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lesions and ovarian tumors have to be analyzed and related to clinical outcome in a 
comparative study.  
MUC1 is immunogenic, both humoral and cellular immune responses against normal and 
underglycosylated MUC1 have been identified (15). Humoral immune responses have 
been confirmed by the detection of anti-MUC1 antibodies in the serum of healthy women 
and in women with ovarian cancer (16, 36). Anti-MUC1 antibody levels tend to be lower in 
cancer patients, which is possibly caused by the formation of immune-complexes with 
serum-MUC1 (37). These anti-MUC1 antibodies have been shown to mediate antibody-
dependent cellular cytotoxicity (ADCC) of MUC1 positive cancer cells and to be protective 
in cancer development (38, 39). 
Despite its immunogenicity (23, 29, 40), MUC1 also contributes to escape from tumor 
immuno-surveillance and metastasis formation. In tumor cells, MUC1 has an anti-adhesive 
function, which is not only of importance in cancer development (40), but might be 
responsible for a diminished adherence of immune effector cells to the malignant cells 
(41).  
Immunotherapy will be essential to enhance immune responses to MUC1. MUC1 peptide 
vaccination or peptide-pulsed DC vaccination have shown to increase the amount of anti-
MUC1 antibodies and induce proliferation of MUC1-specific cytotoxic T cells (15, 42-44). 
However, induction of a clinical effective cellular or humoral immune response to MUC1 
has not yet been achieved. One of the reasons might be central tolerance to the mature 
MUC1 protein (21). Thymic medullary epithelial cells express the MUC1 protein, thereby 
most likely inducing negative selection of MUC1-specific T cells. However, the 
underglycosylated MUC1 isoforms are not present in the thymus, and therefore it was 
suggested by our group, that tolerance is induced only to the mature MUC1 and not the 
MUC1-associated Tn/STn-epitopes (32).  
In this study, the underglycosylated MUC1-associated Tn/STn-epitopes were identified as 
potential TAAs, which could be used as targets for immunotherapy and 
immunodiagnostics in ovarian cancer patients and patients who are diagnosed with 
ovarian cancer precursor lesions. The expression of these epitopes by ovarian cancer and 
precursor lesions indicates that there are alterations in MUC1 processing and elucidation 
of the mechanism behind these alterations might increase our knowledge on ovarian 
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tumor biology. Cancer-specific MUC1 is expressed in 86% of all different ovarian cancer 
histotypes and in 85% of metastatic lesions, but not in normal ovarian tissue. Moreover, in 
the most frequent histotype, the serous adenocarcinoma, the percentage of tumors  
expressing the cancer-associated MUC1 is high (86%). Additionally, antibodies recognizing 
MUC1-associated Tn/STn-epitopes represent an effective diagnostic tool for the detection 
of ovarian cancer cells in tissue and fluids. Finally, since the MUC1-associated Tn/STn 
antibodies exclusively detect tumor cells, these antibodies could be effectively used for 
antibody-mediated immunotherapy and radio-labeling could be very useful for in vivo 
imaging and therapy.  
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Abstract 
 
The limited response rate of cancer patients treated with dendritic cell (DC)-based 
vaccines indicates that vast improvements remain necessary. In many murine tumor 
models it has been demonstrated that the use of innate triggers (e.g. TLR triggers) in the 
maturation of DCs results in higher efficacy. However, as few of these innate triggers are 
generated clinical grade, there remains a great necessity to fill the gap between 
fundamental mouse studies and a clinical trial in humans. In the present study we used a 
TLR2/4-agonist (FMKp which is available clinical grade) in combination with IFN-γ (FI-
cocktail) in the maturation of elutriated monocyte-derived DCs and compared it with the 
most used DCs in current clinical trials (TNF-α/PGE2, i.e. TP-cocktail). In addition to the 
assessment of CD4+ T cell polarizing capacity, we compared the quantity and intrinsic 
quality of induced CD8+ T cells of two different DC maturation protocols with cells from 
the same donor. Besides differences in the cytokine profile, which could be coupled to 
increased TH1 and TH17 polarization, we demonstrate in this study that FMKp/IFN-γ 
matured DCs are twice as effective in inducing cytotoxic T cells against known tumor 
antigens. Both DCs induced phenotypically equivalent effector memory CD8+ T cells that 
did not show a significant difference in their intrinsic capacity to kill tumor cells. These 
findings point to the therapeutic applicability of FI-DCs as superior inducers of functional 
antigen-specific T cells. Their increased chemokine secretion is suggestive of a mechanism 
by which these DCs may compensate for the limited migration observed for all ex vivo 
cultured DCs when applied in patients. 
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Introduction 
 
Dendritic cells (DC) are very efficient initiators of potent immune responses in vivo. These 
cells are therefore attractive tools for cellular immunotherapy in the treatment of cancer 
and viral infections that evade regular immune surveillance (1-3). As a consequence, a 
range of methods to generate large amounts of DCs ex vivo has become available. They 
can be generated from a variety of sources, but DC differentiation from monocytes with a 
growth factor cocktail containing IL-4 and GM-CSF is the current gold standard (4, 5). 
Translating these culture methods into good manufacturing practice guidelines has 
allowed the introduction of DC-based immunotherapy into clinical practice. Early DC 
vaccination trials have proven to be feasible, non-toxic (6) and the principle studies proved 
that DCs loaded with tumor antigens can induce immune responses (7, 8). However, the 
limited rate of tumor regression in clinical trials has indicated that mounting clinically 
effective immune responses using ex vivo-generated DCs is difficult (9). Among the 
causative factors for this limited response is definitely our limited understanding of the 
molecular signals driving effective T cell responses without simultaneous induction of 
suppressive T cells. Since DCs can easily be manipulated in vitro, most effort has been 
invested in finding a relation between DC maturation and T cell stimulation (10). The 
multitude of maturation cocktails used for superior vaccination design illustrates that the 
optimal stimulatory signal remains to be established. The most often used DC maturation 
cocktail in current applications includes TNF-α and PGE2 with or without IL-1β and IL-6 
(11). Although this cocktail generated fully mature DCs that are able to induce antigen-
specific T cells and show migratory behavior in vitro, it has become clear that this cocktail 
is far from optimal (12). One of the most important disadvantages is the limited ability to 
mount potent TH1 responses illustrated by the lack of IL-12 production, which presumably 
results from the effect of PGE2 that is added to stimulate DC migration (13-16). Many 
maturation cocktails have been proposed as alternative. One attractive option involves 
the use of microbial ligands and Toll-like receptor (TLR) agonists in particular (17). The 
TLR2/4 agonist FMKp in combination with IFN-γ has been shown to exert powerful DC-
activation signals leading to high IL-12 secretion, TH1 skewing and cytotoxic T cell 
induction (18, 19).  
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Numerous studies have pointed toward the necessity of PRR (Pattern of Recognition 
Receptors) triggering (TLR stimuli in particular) in DC maturation to obtain potent T cell 
responses, and this was correlated with potent antitumor responses in animal models (20-
23). However, in the field of DC vaccination there is a big necessity to fill the gap between 
fundamental studies and a clinically approved trial. One tool which is available to fill this 
gap is performing in vitro experiments with primary human cells. These human studies are 
of particular relevance for the study of TLR-ligands as discrepancies in TLR expression and 
function between species have been reported (24). To date, only few TLR-triggering 
agents have been generated according to good manufacturing practice (GMP) allowing 
their use in the clinical practice. In addition, it also remains to be established how the 
induction of antigen-specific T cells is influenced by these ligands. 
Few studies comparing differential DC maturation focus on CD8+ T cell heterogeneity (25, 
26). In analogy with CD4+ T cell subsets, also functionally different CD8+ T cell subsets exist 
which exert opposite effects on T cell polarization in vivo (27, 28). These CD8+ subsets 
were designated TC1 secreting IFN-γ and TC2 secreting IL-4 (29, 30). In addition, CD8
+ T 
cells can differentiate upon antigen recognition into either central (TCM) or effector 
memory (TEM) T cells. The factors that drive CD8
+ T cells into these different phenotypes 
remain to be determined but the quantity and quality of stimulation by DCs and cytokines 
have been suggested as contributors (31). At present it remains unclear whether 
differential DC maturation can be exploited to generate different subsets of CD8+ T cells. 
To this end, we made a direct comparison of two clinically relevant DC maturation 
cocktails from the same DC preparations. The first cocktail consisted of a clinical grade 
preparation of membrane fractions of Klebsiella pneumoniae (FMKp) in combination with 
IFN-γ (FI-cocktail), whereas the second cocktail was composed of TNF-α and PGE2 (TNF-
α/PGE2, i.e. TP-cocktail) which is most often used in current DC vaccination trials. These 
DCs were compared according to their phenotype, migratory behavior and cytokine 
secretion which was correlated to their T helper cell polarization and their differential 
ability to induce cytotoxic T cells. The data provide insight into DC-regulated control of 
TH1/TH17 versus TH2 polarization, CTL phenotype and functionality, and establish FI-DCs as 
powerful inducers of antigen specific T cells. 
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Materials and methods 
 
Dendritic cells 
Immature DCs (immDC) were generated by ImmunoDesignedMolecules (Paris, France) 
from 5 HLA-A2+ leucopheresis products as previously described (17, 32) and frozen at 20 x 
106 cells per vial in 1.5 ml Iscove’s Modified Dulbecco’s Medium (Invitrogen Ltd., Paisley, 
UK) + 50% human serum (HS, Sanquin blood bank, Maastricht, The Netherlands) + 10% 
dimethyl sulfoxide (DMSO, Sigma-Aldrich Co., St. Louis, MO, USA). As partners in a joint EU 
project, we obtained immDCs from IDM. Upon thawing, cells were left to recover in serum 
free AIM-V® containing differentiation cytokines. The following two days immDCs were 
matured using one of two maturation cocktails. The TP-maturation cocktail consisted of 
AIM-V® with IL-4 (500 U/ml; Strathmann Biotech AG, Hannover, Germany), GM-CSF (400 
U/ml; Berlex, Richmond, CA, USA), TNF-α (1000 U/ml; Biosource, Camarillo, CA, USA) and 
PGE2 (18 μg/ml Sigma) (33). The FI-cocktail contained IL-13 (50ng/ml; Biosource, 
Camarillo, CA, USA), GM-CSF (500 U/ml), IFN-γ (500 U/ml; Strathmann Biotech AG) and a 
TLR2/4 agonist (1 μg/ml) (17). As TLR agonist, a GMP-grade lysate of Klebsiella 
pneumoniae was used (Pierre Fabre institute, Boulogne, France). This preparation contains 
membrane fractions (including the TLR2 ligand outer membrane protein A OmpA (34)) and 
proteoglycans (including the TLR4 ligand LPS) from Klebsiella pneumoniae. 
 
Scanning electron microscopy 
Glass coverslips (Miles Scientific, Naperville, IL, USA) were cut, transferred to a 24-well 
Plate and coated for 1 h with 50 μg/ml fibronectin (Roche Diagnostics GmbH, Mannhein, 
Germany). After washing the coverslips, ImmDCs were allowed to adhere and mature in 
cocktail-containing medium for 3 h, followed by two PBS washes. Coverslips were fixed in 
2.5% glutaraldehyde/PO4 for 10 minutes, washed twice with PBS and analyzed with a 
XL30TMP microscope (FEI Company, Eindhoven, the Netherlands).  
 
Flow cytometry 
All antibodies for flow cytometry were obtained from BD Pharmingen (BD Biosciences, 
Erembodegem, Belgium) except anti-CCR7 (R&D Systems, Minneapolis, MN, USA) and 
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anti-Foxp3 (eBioscience, San Diego, CA, USA). MUC113-21 and MART-126-35 specific HLA-
A*0201+ dextramers were purchased from Dako Cytomation (Glostrup, Denmark). 
Antibodies were used as either Fluorescein isothiocyanate (FITC), Pycoerytherin (PE), PE-
Cy7, Peridinin chlorophyll protein (PER-CP) or allophycocyanin (APC). All antibodies were 
incubated at the proper dilution for 30 minutes at RT. Cells were fixed in 1% 
paraformaldehyde/PBS (PFA, Merck, Darmstadt, Germany). 7AAD was used to exclude 
dead cells from analyses that were all performed on a FACSCalibur (BD Biosciences). 
 
Cytokine array 
After 48 h maturation, cell-free supernatants of differentially matured DCs (106 cells/ml) 
were harvested. Undiluted supernatants were analyzed on human cytokine antibody 
arrays VI-VIII (RayBiotech, Norcross, GA, USA) according to the manufacturer’s 
instructions. After development, blots were photographed with a LAS-3000 imaging 
system (Fujifilm, Sint-Niklaas, Belgium). The spots were quantitated using AIDA Array 
Analysis Software (ImaGenes, Berlin, Germany). Quantitated chemiluminescence values of 
individual spots were normalized to the mean of 6 positive control spots after background 
(mean of 4 negative control spots) subtraction using the RayBio Human Cytokine Antibody 
Array C Series 2000 Analysis Tool (RayBiotech). 
 
Cytokine secretion 
Quantification of IL-5, IL-6, IL-10, IL-12, IL-17, TNF-α, IFN-γ TGF-β1 and CCL19 in culture 
supernatants was performed using the respective ELISA kits obtained from Pierce Endogen 
(Rockford, IL, USA), R&D Systems, and Sanquin (Amsterdam, The Netherlands), and 
conducted according to the manufacturer’s instructions. Absorbance was measured at 450 
nm using a microtiterplate reader (BioRad, Hercules, CA, USA). Intracellular IFN-γ and IL-4 
production of antigen-specific T cells was determined after coculture with peptide pulsed 
T2 cells for 4 h at 37°C in the presence of 1 μg/ml Brefeldin A (BD Biosciences). After 
staining the extracellular antigens CD3 and CD8, cells were fixed and permeabilized using 
the Fix&Perm kit from Caltag Laboratories (Burlingame, CA, USA) followed by addition of 
anti-human IFN-γ and IL-4 (BD Biosciences) antibodies and incubation for 15 minutes at 
RT. Cells were fixed in 1% PFA/PBS and analyzed by flow cytometry. 
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Migration assay 
Migration of mature DCs towards chemoattractants was measured using Transwell® plates 
(Corning Costar, New York, NY, USA). The lower cabinet was filled with 600 μl AIM-V® 
containing 250 ng/ml CCL19 or CCL21 (R&D Systems, Minneapolis, MN, USA). Triplicate 
inserts were filled with 100 μl 106 DC/ml, and migration proceeded for 4 h at 37°C / 5% 
CO2. The migrated cells were collected from the lower compartment and counted using 
the Z1™ Coulter Counter (Beckman Coulter, Fullerton, CA, USA). To calculate the 
percentage of migrated cells, the total number of migrated DCs was divided by the total 
number of DCs in the upper well after subtraction of the mean number of spontaneously 
migrated DCs. 
 
Priming culture 
T cells were isolated from 9 x108 PBMCs of the same leukapheresis product by binding 
them to fixed sheep red blood cells (SRBC). After density centrifugation, SRBC were 
removed from the T cell fraction by lysis in NH4Cl and KHCO3. DCs were pulsed in AIM-V® 
for 2 h with 40 μg/ml MUC113-21 peptide (LLLTVLTVV; NeoMPS, Strassbourg, France) or 
40 μg/ml MART-126-35 peptide (ELAGIGILTV; NeoMPS) together with 5 μg/ml β2-
microglobulin and 50 μg/ml PADRE (AGVAAWTLKAAA). Subsequently, 24x106 T cells were 
stimulated with 2x106 peptide pulsed DCs in AIM-V® containing 10 ng/ml IL-7 (Biosource, 
Camarillo, CA, USA). After 7 days, T cells were harvested, counted and restimulated with 
2x106 pulsed DCs (20 μg/ ml MUC113-21 or 20 μg/ml MART-126-35 with 1 μg/ml β2-
microglobulin) in 24 ml AIM-V® supplemented with 20 U/ml IL-2 (Proleukin, Chiron 
Benelux BV, Amsterdam, The Netherlands). Medium with cytokines was refreshed every 
other day. On day 12 of the priming culture, T cells were collected and stained with CD8-
PE and APC-labeled MUC113-21 or MART-126-35 dextramers (Dako Cytomation) for 1 h at RT. 
Cell suspensions were filtered through MACS pre-separation filters (Miltenyi, Utrecht, the 
Netherlands) and CD8+/dextramer+ cells were sorted with the FACSAria (BD Biosciences). 
Sorted cells were cultured for 7 days in presence of phytohaemagglutinin (0.2 μg/ml) and 
IL-2 (40 U/ml) on feeder mix consisting of irradiated (80 Gy) PBMCs and JY cells. Viability 
was determined by trypan blue exclusion.  
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51Cr-Release assay 
The ability of sorted T cells to kill target cells was assayed using a standard chromium 
release assay. In short, antigen-specific T cells were incubated for 4 h at 37°C / 5% CO2 
with 104 target cells, at an E:T ratio of 20:1. As target cells we used T2 (Tap1/2-deficient) 
and MUC1 positive tumor cell lines (MCF7, breast cancer; OVCAR-3, ovarian cancer and 
RPMI8226, multiple myeloma) were labeled with 75 μCi 51Cr-sodiumchromate/106 cells 
(Amersham Life Sciences, Buckinghamshire, England). Target cells alone were used as 
negative control (spontaneous release) and target cells in the presence of 10% SDS (Bio-
Rad Laboratories, Hercules, USA) as positive control (maximal release). Supernatants were 
collected and analyzed with a gamma counter. Specific kill was calculated as: 
(CPMsample - CPMblanco) / (CPMSDS - CPMblanco) x 100% 
 
Statistical analysis 
To compare the percentages of antigen-specific T cells by both DCs (T+TP-DC and T+FI-DC, 
respectively), we normalized values to the percentages observed with TP-DCs (100%). The 
normalized percentage of T+FI-DCs was compared with this 100% value using the non-
parametric Wilcoxon signed rank test. Cytokine secretion between cell populations was 
compared with paired T-tests. P values are given. 
 
 
Results 
 
Dendritic cell phenotype and cytokine production after 48-hour maturation 
For all experiments aliquots of immDCs were thawed and matured with either the TP-
cocktail or the FI-cocktail (see M&M). Figure 1A shows representative scanning electron 
micrographs of both types of mature DCs (mDC) (n>20). TP-DCs exhibit a satellite 
morphology with long, unbranched dendrites whereas FI-DCs display a more elongated 
appearance with fewer but more branched processes. 
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Figure 1. Phenotypic characterization of TP- and FI-cocktail matured DCs. 
(A) Scanning electron micrographs of differentially matured DCs after 48 h of maturation on fibronectin coated 
glass coverslips. Bars represent 10 μm. (B) Flow cytometric comparison of surface expression of HLA-molecules 
and maturation markers. Filled areas represent surface expression of TP-DC whereas bold lines show FI-DC. 
Representative data of 5 donors from 3 experiments are shown. All markers were upregulated compared to 
immDCs (data not shown). (C) Human cytokine protein arrays were performed using undiluted culture 
supernatant of TP- and FI-DC 48 h after maturation in a density of 106 cells/ml. Quantitated chemiluminescence 
values of individual protein spots were normalized to the intensity of control spots after background subtraction. 
This normalized protein expression is plotted for differentially matured DC in an X/Y graph. The solid diagonal 
line represents proteins found in equal amounts in both samples. Proteins are not annotated when they are less 
than 1.5 fold upregulated in either sample, meaning they are located between both dotted lines (Y=1.5X and 
Y=0.66X) nor when their absolute expression is below 10x background (within grey box). (D) Quantitative 
comparison of production of CD4+ polarizing cytokines by TP-and FI-DC (48 h of maturation in a density of 106 
cells/ml) as measured by ELISA. For IL-12 and IL-10, 3 leukapheresis products were tested twice in independent 
experiments. For TNF-α, values are given for both 0-48 h production and 6-48 h production (after wash). Paired 
T- test significance: IL-12 (p<0.0001), IL-10 (p=0.03), IL-6 (p=0.002) and TNF-α (p=0.04) (when DCs were washed 
at 6 h) and TGF-β (p=0.18). 
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To evaluate the phenotype of both differently matured DCs, we assessed by means of flow 
cytometry the expression of MHC class I and class II molecules (HLA-A2 and HLA-DR, 
respectively), costimulatory molecules (CD80, CD83, CD86 and CD40), CD1a, which is 
involved in presentation of non-peptide antigens, and DC characteristic integrin CD11c. 
Both mature DCs populations showed an upregulation of HLA-DR, CD80, CD83, CD86, and 
CD11c as compared to immDCs (data not shown). When comparing the expression levels 
of maturation markers between TP-DCs and FI-DCs (Figure 1B), we reproducibly noted a 
higher expression level of CD80 by FI-DC. Furthermore, we reproducibly (n=5) observed a 
slight upregulation of CD83 upon maturation, which was more pronounced in TP-DCs 
(Figure 1B). No differences were seen in the expression levels of HLA-A2, HLA-DR, CD86, 
CD40, CD11c and CD1a between the two DC populations, which was also reproducible. 
Because DC-derived cytokines are considered key regulators in directing immune 
responses, we decided to screen whether both DCs differ in their production of different 
cytokines, therefore, a semi-quantitive antibody array analyzing 174 cytokines 
simultaneously was performed (Figure 1C). Quantitated chemiluminescence values of 
individual protein spots were normalized to the intensity of control spots (100% value) 
after background (0% value) subtraction. This normalized protein expression is plotted for 
differently matured DCs in an X/Y graph. The threshold for upregulation was set on 1.5. 
Eighty-six cytokines have spot intensities below the threshold (grey box in Figure 1C) in 
both samples and 33 factors are found in comparable amounts. Forty-seven out of 174 
soluble factors have higher (>1.5 fold) spot intensities in the supernatant of FI-DCs, 
whereas only 8 are found at higher levels in the supernatant of TP-DCs. The identity of the 
differentially secreted protein factors and their fold increase in relative spot intensity are 
listed in Table 1. For 7 cytokines and chemokines we confirmed upregulation with ELISA (4 
of which are shown in Figure 1D (IL-6, IL-12, IL-10 and TNF-α) and CCL5, CXCL10 and IL-4 
(data not shown). In all cases the difference could be confirmed in more donors. 
Furthermore, the fold difference in spot intensity appeared to be an underestimation of 
the true fold difference in protein secretion when measured with ELISA in all cases (n=7).  
Among the factors found to be upregulated, several cytokines used in the maturation 
were identified. Indeed, IL-13, IL-4 and GM-CSF are among the brightest spots detectable 
since they are added in high concentrations to the supernatant. Importantly, TNF-α is not 
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exclusively found in the supernatant of TP-DCs (present in the maturation cocktail), but is 
actively produced by FI-DCs (Figure 1D). To assess whether TP-DCs are also able to 
produce TNF-α the maturation cocktail was washed away after 6 h and the potential 
production between 6 and 48 h was analyzed. In contrast to the supernatant of washed FI-
DCs, no TNF-α was found in the supernatant of washed TP-DCs. Besides TNF-α, FI-DCs 
produce several cytokines involved in DC maturation (IL-1β, TNF-α and IL-6), suggesting an 
autocrine maturation process. However, the most striking difference was a group of 15 
chemokines (bold in Table 1) that potentially attract other immune cells and a number of 
cytokines involved in T cell polarization (IL- 6, IL-10, and IL-12) and T cell support (IL-7 and 
IL-15) that were found in higher quantities in the supernatant of FI-DCs as compared to 
TP-DCs.  
 
Table 1. Comparison of differentially produced cytokines by TP-DC and FI-DC. 
 
Proteins overexpressed in TP-DC 
 
Proteins overexpressed in FI-DC 
IL-4 68.6 IL-1β 78.1 CCL15 4.7 
TIMP-2 2.7 IL-13 76.5 TNF-β 4.6 
TIMP-4 2.1 IL-15 60.4 Leptin 3.8 
CXCL16 2.0 CCL20 41.5 NT-3 3.4 
Angiogenin 1.9 IL-10 32.5 IL-6 3.4 
CD14 1.8 IL-1α 30.5 SCF 3.2 
SCF R 1.6 M-CSF 27.3 IL-1ra 2.9 
MMP9 1.5 CCL13 24.8 CXCL9 2.9 
  CCL5 22.8 PDGF-BB 2.6 
  Oncostatin M 18.8 IGFBP-1 2.5 
  CCL8 18.5 IL-12p40 2.4 
  CXCL11 17.2 IGFBP-4 2.2 
  IL-7 17.0 IGF-1 SR 2.0 
  CCL1 16.2 PDGF-AA 1.9 
  CCL2 14.5 TNF-α 1.8 
  CCL3 11.7 IL-16 1.8 
  IL-12p70 8.6 CXCL10 1.7 
  CXCL5 8.3 NAP-2 1.7 
  CCL7 7.9 TGF-β1 1.6 
  IFN-γ 7.8 IL-2RA 1.6 
  Activin A 7.0 TGF-β3 1.6 
  LIGHT 6.7 CCL11 1.6 
  IL-2 6.3 ALCAM 1.5 
  CXCL1 4.8   
Cytokines indicated in italics are those added to the maturation cocktail and their high levels of expression 
validate the assay. Factors indicated in bold are chemokines potentially involved in immune effector cell 
attraction. Numbers represent the fold increase in relative spot intensity. 
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To study T cell polarizing cytokines quantitatively, these cytokines were measured in DC 
supernatants by ELISA. As shown in Figure 1D, FI-DCs show higher IL-12, IL-10, IL-6 and 
TNF-α (when DCs were washed at 6 h) production as compared to TP-DCs. Both DCs 
secrete low levels of the Treg inducing cytokine, TGF-β. 
 
Effect of the maturation cocktail on the migratory program of DCs 
For DCs to migrate, they have to be equipped with the appropriate set of chemokine 
receptors, whose expression is reprogrammed during the maturation process. To 
investigate the influence of both maturation cocktails on the chemokine receptor 
expression, we analyzed CCR6 and CCR7 expression. Both TP- and FI-DCs express low but 
reproducible levels of CCR7 (Figure 2A), but no CCR6 (data not shown) after 48 h of 
maturation.  
 
 
Figure 2. Effect of the maturation cocktail 
on the migratory program of DCs. 
(A) Flow cytometric evaluation of CCR7 
surface expression of TP- and FI-DCs. Dotted 
histograms represent isotype staining, 
whereas the filled histograms represent 
CCR7 staining of the DCs. (B) At different 
time points after the induction of DC 
maturation (0, 16, 44 and 68 h) DCs were 
harvested to assess their migratory capacity. 
105 DCs were transferred to the upper 
compartment of a transwell and allowed to 
migrate to a CCL19/21 gradient for 4 h. After 
4 h, migration was stopped and cells were 
counted. For every donor the percentage of 
DCs that migrated is plotted (n=3 or 4 for all 
time points except 68 h (n=1)). 
 
Because CCR7 is the key chemokine receptor that regulates trafficking of DCs to the lymph 
node, we compared their migratory behavior towards the CCR7 ligands; CCL19 and CCL21 
in transwell assays. To exclude the possibility that both maturation cocktails induce 
migration with different kinetics, we followed their migration at different time points after 
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maturation. ImmDCs were CCR7 negative, and did not migrate towards the chemokine 
gradient (data not shown). TP-DCs showed an increased migration through the transwell 
upon maturation while FI-DC did not migrate at any time-point (Figure 2B). 
 
TH cell induction by DCs cultured with different maturation cocktails 
The combination of cytokines present during the priming of naive T cells by DCs influences 
their polarization. Since TP- and FI-DCs display different cytokine profiles including 
polarizing cytokines, both DCs were pulsed with class I-restricted peptides and a pan HLA-
DR binding peptide (PADRE) and were used to prime autologous T cells. To analyze 
whether both DCs differ in their CD4+ T cell polarizing capacity the cytokine profile of T cell 
cultures stimulated with both DCs after 7 days was compared. IL-5 secretion was only 
observed in coculture experiments with TP-DCs (in 4/5) and not in cocultures with FI-DCs. 
This suggests that at least some TH2 polarization was induced by the former DC (Figure 
3A), which is supported by our observation of a small but reproducible percentage of 
CRTH2+ CD4+ cells only identified when stimulated with TP-DCs (Figure 3B). CRTH2 is the 
prostaglandin D2 receptor and is considered the best surface marker for the selective 
staining of TH2 cells (35). T cells stimulated with FI-DCs, on the other hand, produce more 
IFN-γ (in 4 out of 5 experiments), suggesting stronger TH1 polarization induced by these 
DCs. This is supported by the observation of a higher percentage of CD4+ T cells with a 
high expression of CXCR3, which is characteristic for TH1 polarized cells but is not as 
specific as CRTH2 for TH2 cells (data not shown).  
To determine if both DCs induce TH17 cells, we examined whether IL-17 was produced. In 
the supernatant of T cells stimulated with FI-DCs, higher quantities of IL-17 were found 
(Figure 3A), indicating that these DCs are more capable of inducing TH17 cells. Suppressive 
cytokines such as TGF-β and IL-10 were found in comparable amounts in both T cell 
cultures (Figure 3A).  
As DCs can induce Tregs in vitro, we compared a possible Treg induction by both DC 
populations by FACS analysis. CD4+ Tregs are characterized by a high expression of CD25 
and they express the transcription factor Foxp3, which is required for their regulatory 
function (36). On day 0, very low numbers of Tregs (CD25 and Foxp3 double positive cells) 
(<0.05%) were observed. Both DCs are capable of inducing Tregs, as approximately 1% of 
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CD4+ T cells were also Foxp3+ 7 days after the first stimulation with peptide-pulsed DCs 
(Figure 3C). No consistent difference in Treg induction could be found between TP- and FI-
DCs. 
 
 
Figure 3. Differential CD4+ T cell polarizing capacity of TP- and FI-DCs.  
24x106 T cells were stimulated for 7 days with 2x106 TAA-peptide- and PADRE-pulsed DCs in presence of IL-7. (A) 
Cytokine profile of the induced T cells after DC-T cell coculture as measured in the supernatant taken after 7 days 
of coculture (n>4). At this time point presence of DCs could be no longer detected. Paired T-test significance: IFN-
γ (p=0.12), IL-5 (p=0.08), IL-17 (p=0.06), IL-10 (p=0.76) and TGF-β (p=0.82). (B) Surface expression of CRTH2 as 
surface marker of TH2 polarized cells on CD4+ T cells (gated on CD3+) 7 days after stimulation of naive T cells with 
TAA-peptide- and PADRE-pulsed DCs. (C) Induction of Foxp3+CD25+CD4+ and CD3+ T cells at day 7 after 
stimulation. Gated on CD3+CD4+ cells. These data are representative for 3 individual experiments with different 
donors.  
 
FI-DCs induce more antigen-specific T cells as compared to TP-DCs 
To compare the induction of tumor antigen-specific T cells, both mDCs were pulsed with 
HLA-A2-restricted immunodominant epitopes of the tumor-associated antigens (TAA) 
Mucin-1 (MUC113-21) or Mart-1 / Melan-A (MART-126-35) and the pan HLA-DR binding 
peptide (PADRE). Figure 4A shows the average cell numbers during T cell stimulation 
assays and no increase in total T cell number was observed during the initial priming with 
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either mDC. Upon restimulation, a strong proliferative response was observed in both 
conditions, but no significant difference in the absolute T cell numbers was measured. 
 
 
Figure 4. Induction of antigen-specific CD8+ T cells by TP- and FI-DCs.  
24x106 T cells were stimulated with 2x106 TAA peptide- and PADRE-pulsed DCs in presence of IL-7. After 7 days, 
cells were counted and restimulated with autologous DCs in the presence of IL-2. On alternate days medium was 
refreshed and fresh IL-2 was added. (A) Average cell counts (± SD) at day 0, 7, 9 and 12 during T cell stimulation 
assay (n=7). (B) Quantitation of the percentage of MUC113-21- and/or MART-126-35-reactive T cells at day 12 
measured by dextramer staining on CD3+ cells (representative for n=7). (C) Comparison of the percentage of 
MUC113-21- and MART-126-35-specific T cells generated with TP- and FI-DCs at day 7 (left panel) and day 12 (right 
panel). The upper 2 lines in both figures represent 2 stimulation assays with MART-126-35-pulsed DCs, whereas the 
other 5 were performed with MUC113-21-pulsed DCs. Paired samples are connected with a dotted line (*P<0.05). 
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To assess whether both mDCs differed in their capacity to induce antigen-specific T cells, 
we quantified the number of antigen-specific CD8+ cells by dextramer staining on various 
days. In all individuals tested, we observed a higher starting frequency of MART-126-35-
specific T cells compared to MUC113-21-specific T cells. Possibly, for this reason, higher 
numbers of MART-126-35-specific T cells were obtained throughout the stimulation assays. 
Figure 4B shows dextramer staining of T cells after two stimulations. Although there was 
no difference in the overall proliferative response with either DC, there was a difference in 
the percentage, and the absolute numbers, of antigen-specific T cells generated. After the 
first stimulation (day 7), significantly more antigen-specific T cells were observed when 
stimulation was performed with FI-DCs than with TP-DCs (Figure 4C). In 6 out of 7 
experiments, more than double the absolute number of antigen-specific T cells after one 
stimulation was seen. After the second stimulation there was still a significant difference, 
and a two-fold increase was found in 5 out of 7 experiments (Figure 4C). 
 
Both DCs induce effector memory antigen-specific T cells with IFN-γ but no IL-4 
production 
As quantity and density of stimulation and the cytokine microenvironment may influence 
the fate of memory T cell differentiation, we analyzed whether the different DCs 
influenced CD8+ T cell specialization. CD8+, antigen-specific T cells generated with both 
DCs stained positive for CD45RO and CXCR3 (Figure 5A), and negative for CD45RA (data 
not shown) and CCR7 (Figure 5A). This indicates that the generated antigen-specific T cells 
were of the TEM and not the TCM phenotype.  
In addition to the TEM and TCM phenotype, antigen-experienced CD8
+ T cells can be 
classified as TC1, TC2 and TC0 based on their cytokine secretion. To determine the subtype, 
CD8 and dextramer double positive T cells were sorted from DC-T cell coculture 
experiments, incubated with peptide loaded T2 target cells and analyzed for cytokine 
expression. Upon antigen recognition, MUC113-21-specific T cells accumulated intracellular 
IFN-γ and no IL-4 accumulating T cells were found in any condition (Figure 5B). When 
MUC113-21 reactive T cells were stimulated with T2 cells loaded with an irrelevant (MART-
126-35) or no peptide, only a very small percentage of IFN-γ accumulating cells was 
identified. This intracellular staining was confirmed by IL-4 and IFN-γ ELISA (3 donors; data 
Dendritic cell maturation with a clinical grade TLR-agonist 
 
87 
 
 
not shown). Similar data were observed when evaluating MART-126-35 reactive T cells (data 
not shown). These data indicate that, despite the difference in cytokine secretion and in 
the induction of antigen-specific T cells, both DCs induce antigen-specific TC1 cells rather 
than TC2 cells.  
 
 
Figure 5. Phenotypic characterization of antigen-specific CD8+ T cells. 
(A) CD45RO, CCR7 and CXCR3 staining of T cells on day 11. CD45RO and CCR7 are plotted against dextramers for 
antigen-specific T cells and were gated on CD8+ cells. CXCR3 was double stained with CD8, and gated on the 
living, low FSC/SSC cells. Left panels represent T cells stimulated with TP-DCs and right panels represent T cells 
stimulated with FI-DCs. (B) Antigen-specific T cells were sorted at day 12 from T cell stimulation assays. After 7 
days of recovery on feeder cells in presence of IL-2, cells were stained or intracellular IL-4 (left panel) and IFN-γ 
(right panel) after stimulation (5 h) with peptide-pulsed (grey histograms) or non-pulsed (open histograms) T2 
cells. Cells were gated on CD3+ and CD8+. Isotype controls overlap with non-pulsed T2 cells (not shown). (C) Fas 
and FasL expression of antigen-specific T cells on day 12 of the T cell stimulation assay. Cells were gated on CD3+ 
and CD8+. Stainings are representative of at least 3 independent observations. 
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One of the cytolytic mechanisms by which antigen-specific T cells can induce cell death in 
target cells involves the induction of FasL on the surface of cytotoxic T cells (37). This 
bystander mechanism may account for high background killing in in vitro cytotoxicity 
assays. Therefore, FasL-expression was routinely checked on antigen-specific T cells. Prior 
to cell sorting and cytotoxicity assays, all specific T cells stained negative for FasL (Figure 
5C). In some experiments when a third stimulation was performed, expression of FasL was 
observed on the majority of antigen-specific T cells (data not shown). This was associated 
with reduced viability of T cell cultures and high background killing of target cells (data not 
shown). In contrast to the regulation of FasL, all T cells retained a constitutive expression 
of Fas throughout the stimulation assay (Figure 5C). 
 
The intrinsic capacity of MUC113-21 reactive T cells to kill target cells is not influenced 
by differential DC maturation  
To test whether differentially matured DCs influence the functionality of antigen-specific T 
cells, we compared their capacity to kill target cells. To exclude possible regulation by the 
CD4+ and the CD8+ compartment, antigen-specific T cells were sorted based on 7AAD-/FSC 
and gated on CD8+/MUC113-21
+ cells. The second sorting gate and post-sort purity is shown 
in Figure 6A. The minimal post sort purity was >90%. After a recovery and expansion 
period, T cells were evaluated for their capacity to kill various target cell lines. As shown in 
Figure 6B, MUC113-21 pulsed T2 cells are killed by MUC113-21- specific T cells while unpulsed 
T2 cells or MART-126-35 pulsed are not (data not shown). No differences in the amount of 
killing by T cells generated with either DC were seen. In addition, we showed, by studying 
lysis of MUC1 expressing HLA-A2+ tumor cell lines, that these T cells are also able to 
recognize naturally presented MUC1. Consistent with previous reports, we did not see 
lysis of the ZR-75.1 cell line (38). All other cell lines displayed varying levels of lysis when 
incubated with MUC113-21 reactive T cells, indicating that the MUC1-specific T cells can 
recognize the MUC1-peptide presented by tumor cell lines in the context of HLA-A2 
(Figure 6C). Although there was considerable interexperimental variability regarding the 
percentage of lysis of these cell lines, we did not observe (within one experiment) 
consistent differences between T cells generated with differentially matured DCs. 
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Figure 6. Sorting of antigen-specific T cells and comparison of their killing capacity of various target cells.  
(A) Day 12 T cell cultures were collected and stained with dextramers and with antibodies recognizing CD3 and 
CD8. Left and middle panels show representative examples of the sorting gate and the post sort purity. The right 
panel shows an example of the purity of the T cell cultures after 7 days of recovery on feeder cells. The minimal 
purity of these cultures to perform killing assays was set at 80% but as generally > 90%. (B) Chromium release 
assays of MUC113-21-pulsed and non-pulsed T2 cells with sorted MUC113-21 reactive T cells generated with TP-DC 
(black squares) and FI-DC (open squares). Data are calculated as % of maximal release when cells are exposed to 
10% SDS (n=3). (C) Chromium release assays of MUC1+ HLA-A2+ tumor cell lines by MUC113-21 reactive T cells 
generated with TP-DC (black squares) and FI-DC (open squares). Due to the limited amount of sorted T cells, not 
all the cell lines could be included in one experiment. Consequently, results of 3 independent experiments are 
combined.  
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Discussion 
 
The successful clinical application of DCs as anticancer therapies requires detailed 
understanding of the molecular events associated with DC maturation and their 
manipulation to optimize immune responses. Although many murine studies have shown 
that the concept of DC vaccination works, it cannot be directly translated into clinical 
practice (1). Therefore, it is of the utmost importance to translate the experimental work 
into clinically approved protocols in humans. To date human studies have shown only 
limited success (10). To investigate how the use of toll-like receptor agonists influences 
the quality and quantity of antigen-specific CD8+ T cells in humans, clinical grade 
monocyte-derived DCs were matured with IFN-γ in combination with a membrane fraction  
of Klebsiella pneumoniae containing TLR2/4 agonists (FMKp, which is available clinical 
grade) (39). Phenotypic characterization combined with intracellular cytokine staining 
showed no difference in the specific subset of cytotoxic T cells that was induced with 
these different DCs. All antigen-specific CD8+ T cells are characterized as CCR7-, CD45RO+ 
and CXCR3+ TEM cells. Both DCs induce predominantly antigen-specific CD8
+ T cells with 
IFN-γ but no IL-4 secretion, which is consistent with a TC1 phenotype. This characterization 
is further supported by the observation of activation-induced cell death in these cultures 
after a third stimulation, which was often associated with the induction of FasL on these T 
cells. Human TC1 clones have been shown to display a higher susceptibility to activation 
induced cell death as compared to TC2 clones (29). In addition, we observed no obvious 
difference in the killing capacity of sorted TAA-specific CD8+ T cells on the basis of equal 
cell numbers. This is supported by the observation that differentially matured DCs induce 
TAA-specific T cells with similar avidity (40). Taken together, these data indicate that the 
profound difference in cytokine profile of TP- and FI-DCs does not influence the intrinsic 
quality of generated T cells as both DCs induce phenotypically and functionally equivalent 
antigen-specific T cells. However, FI-DCs usually induced twice as many TAA-specific CD8+ 
T cells as compared to TP-DCs. Since this suggests that FI-DCs will also induce a larger CTL 
response in patients, it is relevant to elucidate the causative mechanism.  
The first mechanism why more antigen-specific T cells were observed with FI-DCs may be 
due to the cytokine profile. It has been demonstrated that IL-12 not only affects the 
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differentiation of TC1 cells (30) but also stimulates their expansion. In addition to IL-12, 
also other factors implicated in homeostatic proliferation such as IL-7 and IL-15 (41) are 
produced in higher quantities by FI-DCs. This indicates that in contrast to TP-DCs, FI-DCs 
are equipped with a cytokine profile which favors the rapid proliferation of CD8+ memory 
T cells.  
A second possible contributing factor to the observed difference in T cell induction may be 
differential TH polarization by both DCs. In the T cell stimulation assay CD4
+ T cell 
activation was increased by the addition of a panHLA-DR binding peptide (PADRE), which 
is also proposed as adjuvant for vaccination trials (42). We observed that PADRE facilitates 
mounting CD8+ T cell responses. However, by comparing surface markers differentially 
expressed by TH1 and TH2 cells [CRTH2 and CXCR3; reviewed in (43, 44)] and the cytokine 
profile of T cell cultures we show that PADRE does not replace the need of T cell 
polarization. Our observations of IL-5 secretion and CRTH2 positive CD4+ cells only in 
stimulation assays with TP-DCs suggest that with these DCs at least some TH2 polarization 
occurs. In contrast, the higher percentage of CXCR3+ CD4+ T cells upon stimulation with FI-
DCs together with a high IFN-γ production is indicative of a more potent TH1 skewing and 
the increased amount of IL-17 in these cultures indicates that there is also TH17 
polarization. These differences in T cell polarization are consistent with the cytokine 
profile of both DCs. FI-DCs produce more IL-12, favoring TH1 polarization, and the high 
production of IL-6 and IL-1β in combination with small amounts of TGF-β1 (in contrast to 
TP-DC) has been shown to favor TH17 differentiation (45, 46). Increased TH1 polarization 
has already been coupled with increased CD8+ T cell responses, but with regard to TH17 
induction it remains to be determined how they influence cytotoxic T cell induction. It also 
remains debatable whether the induction of TH17 cells is beneficial in cancer. TH17 cells 
can contribute to tumor growth by stimulating tumor-associated inflammation, but are 
also suggested to induce antitumor responses via an IFN-γ dependent mechanism (47, 48).  
DCs have been shown to expand functional Tregs in vivo and the nature of the DC 
maturation stimulus has been shown to determine the efficacy of Treg induction in vitro 
(13). Because PADRE has been proven to reverse chemotherapeutic-induced immune 
suppression in vaccinated mice, it is relevant to study whether PADRE prevents Treg 
induction in humans. However, with both DCs, a small but significant population of 
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CD4+CD25+Foxp3+ T cells was observed 7 days after the first stimulation as compared to 
the starting population. Although Foxp3 was recently shown also to be transiently 
expressed by newly activated T cells (49), it is unlikely that such cells are present 7 days 
after stimulation. At present, we are performing functional assays to study the 
consequences of Treg induction. 
To mount an effective antitumor response DCs are required to interact with the 
appropriate lymphocytes in the draining lymph node. CCR7-dependent trafficking to this 
anatomic location is considered essential for successful DC vaccines. Despite the 
difference in migratory potential of both DCs in transwell studies, recent in vivo trafficking 
studies have shown that only 2-3% of subcutaneously injected TP-DCs traffic towards 
draining lymph nodes in melanoma patients (50), which is comparable to nodal trafficking 
of FI-DCs in multiple myeloma patients using a similar vaccination regimen (51). Therefore, 
it still remains to be determined whether differentially matured DCs from one patient 
differ in their migration to lymph nodes and whether in vitro assays predict this migratory 
behavior. Besides trafficking to lymph nodes, DCs have to interact with appropriate 
lymphocytes, which are also chemokine driven. We show that differential maturation of 
DCs results in large differences in chemokine secretion. FI-DCs produce at least 15 
chemokines in higher quantities as compared to TP-DCs, including important T cell 
attracting chemokines such as CCL19, CCL5 and CXCL10, which may ultimately lead to 
preferential attraction of different immune effector cells. 
Taken together, we demonstrated that maturating DCs with a combination of TLR2/4 
agonists (which is available clinical grade) plus IFN-γ induces stronger TH1/TH17 skewing 
and a two-fold higher number of antigen-specific TEM killer cells than TNF-α plus PGE2 
matured DCs. In addition, we show that FI-DCs have a higher production of 15 
chemokines, suggesting that these cells are more potent attractors of other immune cells 
when administered in vivo. Importantly, injection of peptide-loaded FI-DCs alone has not 
been very successful in metastatic melanoma patients (52). This does not preclude the use 
of FI-DCs in the clinic but illustrates that for clinical success, other requirements than only 
DC quality such as tumor type, antigen selection and loading strategy, overriding 
immunosuppression, angiogenesis inhibition, among others, need to be manipulated. The 
present study demonstrates that TLR2/4 ligand plus IFN-γ matured DCs are superior 
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inducers of functional antigen-specific CD8+ T cells in comparison to the most often used 
DC in clinical trials. It can therefore be speculated that the induction of twice the number 
of antigen-specific T cells by the same number of injected DCs in vivo will result in a 
stronger antitumor response. Partly based on these results, a clinical trial is planned in 
multiple myeloma patients in which TLR2/4 plus IFN-γ matured DCs will be directly 
compared with DCs matured with the more conventional TNF-α plus PGE2 cocktail.   
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Abstract 
 
Besides their role in destruction of altered self-cells, NK cells have been shown to 
potentiate T cell responses by interacting with DCs. To take advantage of NK-DC crosstalk 
in therapeutic DC-based vaccination for infectious diseases and cancer, it is essential to 
understand the biology of this crosstalk. 
We aimed to elucidate the in vitro mechanisms responsible for NK cell recruitment and 
activation by DCs during infection. To mimic a bacterial infection, DCs were exposed to a 
membrane fraction of Klebsiella pneumoniae (FMKp), which triggers TLR2/4. DCs matured 
with these bacterial fragments can actively recruit NK cells in a CCR5-dependent manner. 
An additional mechanism of DC-induced NK cell recruitment is characterized by the 
induction of CCR7 expression on CD56dimCD16+ NK cells after physical contact with FMKp 
matured DCs, resulting in an enhanced migratory responsiveness to the lymph node-
associated chemokine CCL19. Bacterial fragment matured DCs do not only mediate NK cell 
migration but also meet the prerequisites needed for augmentation of NK cell cytotoxicity 
and IFN-γ production of which the latter contributes to TH1 polarization.  
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Introduction 
 
NK cells are important effector cells in the innate immune response against virally infected 
or malignantly transformed cells and their cytotoxicity is regulated by a delicate balance of 
inhibitory and activating signals (1). Recent studies suggest that the interplay between NK 
cells and DCs, the specialized antigen presenting cell of the innate immune system (2), is 
critical in shaping the adaptive immune response (3). This concept originates from several 
lines of evidence including: the discovery of NK cells colocalizing with DCs in the T cell 
areas of lymph nodes (4, 5), the coupling of NK cell recruitment to lymph nodes with the 
induction of more potent TH1 skewing (3), and the identification of NK cell subpopulations 
with helper properties (6). Although the exact mechanisms of NK-DC interaction remain to 
be elucidated, increasing evidence supports the importance of bidirectional NK-DC 
crosstalk (7, 8). 
On the one hand, NK-DC crosstalk is characterized by the capacity of activated NK cells to 
induce DC maturation with elevated IL-12p70 production and subsequently an increased 
capacity to induce TH1 and CTL responses (9). This NK-induced DC maturation depends at 
least in part on soluble factors such as TNF-α (10) and IFN-γ (11) as well as on engagement 
of the natural cytotoxicity triggering receptor 30 (NKp30) (12). Moreover, NK cells control 
the quality of the adaptive immune response by NKp30-mediated lysis of immature or 
inadequately matured DCs (13), enabling only fully mature DCs to migrate into lymph 
nodes and subsequently prime T cells. On the other hand, DCs are able to induce NK cell 
proliferation, augmentation of cytotoxicity and cytokine secretion (8). The DC-induced 
modulation of cytokine production by NK cells requires a strong immunological synapse 
between the two cell types and both DC-derived soluble factors (e.g.: IL-12 and IL-18) as 
well as contact-dependent factors (e.g.: IL-15 and NKG2D ligands) are implicated in this 
crosstalk (6, 14, 15). Mouse models have revealed a DC-dependent mechanism of NK cell 
recruitment into the lymph nodes. One of the functions of this recruitment is to provide 
IFN-γ, necessary for efficient TH1 skewing (3). In humans, the mechanism for DC-
dependent NK cell recruitment into inflamed lymph nodes remains to be unraveled and it 
is unclear whether chemokine profiles of activated DCs during infection match the 
prerequisites necessary for NK cell activation.  
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Klebsiella pneumomiae (K. pneumoniae) is an extracellular bacterium that induces 
activation of the innate immune system. In vivo mouse studies have revealed that 
endogenous IL-12, produced by alveolar macrophages, is a critical component of the 
antibacterial host defense against K. pneumoniae as blocking of IL-12 is associated with 
increased mortality (16). CXCL10 mediated NK as well as T cell recruitment and IFN-γ 
production has been reported to be essential to control K. pneumoniae infection (16, 17). 
This is supported by a study on CpG triggering during K. pneumoniae infection. CPG 
treated mice showed increased infiltration and activation of NK cells providing an early 
source of IFN-γ, which was associated with decreased mortality (18). NK cells are not only 
activated by other immune cells triggered by K. pneumoniae, but they are also equipped 
themselves with pattern recognition receptors (PRR) suitable for direct binding of the K. 
pneumoniae membrane protein OmpA, which triggers NK cells to produce IFN-γ and the 
antibactericidal peptide α-defensin (19).  
In this study, we addressed the question, whether DCs triggered with fragments of K. 
pneumoniae display the ability to recruit and activate NK cells, ultimately leading to TH1 
polarization. Additionally, we set out to elucidate which mechanisms are responsible for 
these processes. To mimic a bacterial infection, DCs were matured by a membrane 
fraction of K. pneumoniae (FMKp), which is a lysate of the outer membrane fraction of K. 
pneumoniae (K. pneumoniae) containing the DC-triggering agents LPS and outer 
membrane protein A (OmpA), which signal trough TLR 4 and TLR2, respectively (20). For its 
proven additional effect on upregulation of co-stimulatory molecules and modulation of 
cytokine secretion, IFN-γ was added to the FMKp maturation cocktail (21). This study led 
to the identification of chemokines and cytokines responsible for NK-DC crosstalk and we 
describe two possible mechanisms of NK cell recruitment into the inflamed lymph node. 
These in vitro observations are of relevance in unraveling the in vivo biology of NK-DC 
crosstalk.  
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Materials and methods 
 
Cell isolation 
Mononuclear cells from peripheral blood of healthy donors were isolated by density 
gradient separation using lymphoprep (Axis-Shield). NK cells were negatively selected by 
immunomagnetic cell separation (Miltenyi Biotec GMbH). CD4+ T cells were isolated using 
RosetteSep (StemCell Technologies). Naive CD4+ T cells were negatively selected by 
depleting CD45RO+ cells with immunomagnetic cell separation (Miltenyi Biotec GmbH). 
The purity of isolated populations exceeded 95% as determined by flow cytometry.  
 
Generation of DCs 
DCs were prepared from peripheral blood-derived monocytes, as previously described 
(22) and as control, highly pure monocyte fractions were obtained by elutriation from 
leukapheresis products of healthy volunteers, approved by the local medical, ethical 
committee of Maastricht University Medical Center+. Differentiation of monocytes was 
induced by 6 days of culture in AIM-V® medium (Gibco Life Technologies) containing 2000 
U/ml IL-4 (Strathmann Biotech) and 400 U/ml GM-CSF (Berlex) or 50 ng/ml IL-13 
(Biosource) and 500 U/mL GM-CSF. DCs were matured for 6-24 h in AIM-V® containing 
either 1000 U/ml TNF-α (Biosource) and 18 μg/ml PGE2 (Sigma-Aldrich) or 500 U/ml IFN-γ 
(Strathmann Biotech), and 1 μg/ml FMKp (Pierre Fabre). For maturation with single TLR2 
and TLR4 ligands, DCs were matured in the presence of the same amounts of IL-4, GM-CSF 
and IFN-γ as IFN-γ/FMKp matured DCs supplemented with 10 µg/ml Zymosan (InvivoGen) 
and/or 10 µg/ml LPS (InvivoGen). 
  
Flow cytometry 
All antibodies for flow cytometry, except anti-IL-15 and CCR7 (R&D Systems), were 
obtained from BD Biosciences. Antibodies were used in Fluorescein isothiocyanate, 
Pycoerytherin, Peridinin chlorophyll protein or allophycocyanin. Cells were incubated with 
antibodies at proper dilutions for 30 minutes at RT. Analyses were performed on a 
FACSCalibur (BD Biosciences) and analyzed with BD CellQuestTM Pro Software (BD 
Biosciences). 
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Migration assay 
Migration of NK cells was analyzed using 5,0 µm Transwell® plates (Corning Costar). The 
lower cabinet contained 600 μl cell free DC supernatant or AIM-V® containing 250 ng/ml 
CCL19 (R&D Systems). Triplicate inserts were filled with 100 μl containing 5x105 NK cells, 
migration preceded for 16 h at 37°C / 5% CO2. Migrated cells were counted using the Z1™ 
Coulter Counter (Beckman Coulter). To block migration, NK cells were incubated for 1 h 
with blocking antibodies for CCR5 (BD Biosciences), CCR7 or CXCR3 (R&D Systems) 
preceding migration. The contact-dependent increase in NK cell migration to 250 ng/ml 
CCL19 (R&D Systems) was determined after separating the NK cells from the NK-DC 
coculture by positive selection of DCs on HLA-DR (Miltenyi Biotec).  
 
Chemokine array 
Undiluted cell-free supernatants (24 h of maturation of 106 cells/ml) were analyzed on the 
human chemokine antibody array I (RayBiotech) according to manufacturer’s instructions. 
Chemokine blots were photographed with a LAS-3000 imaging system (Fujifilm) and spots 
were quantified using AIDA Array Analysis Software (ImaGenes). Quantitated 
chemiluminescence values of individual spots were calculated using the Chemokine 
Antibody Array C Series 2000 Analysis Tool (RayBiotech). 
 
Cytokine and chemokine secretion  
Quantification of IL-18, IL-12, CCL5, CXCL10 and CCL19 in 24 h DC maturation supernatants 
was performed using ELISA (MBL International Corporation and R&D Systems) according 
to manufacturer’s instructions. Absorbance was measured at 450 nm using a microtiter 
plate reader (BioRad). 
 
Cytokine production by NK cells 
Intracellular IFN-γ was determined after 16 h NK-DC coculture in the presence of 1 μg/ml 
Brefeldin A (BD Biosciences). After extracellular staining, cells were fixed, permeabilized 
using PermWash (BD Biosciences) and stained with anti-human IFN-γ (BD Biosciences). 
Cells were fixed in 1% PFA/PBS and analyzed by flow cytometry. Quantification of IFN-γ 
production was performed using IFN-γ ELISA kit (Sanquin) in 24 h cell free supernatant. NK 
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cell activation was blocked by preincubating cell-free DC supernatant for 1 h with 0,5 
μg/ml anti-IL-12 (R&D Systems) and 4 μg/ml anti-IL-18 (MBL International Corporation).  
For NK-DC contact-dependency, NK cells (105 cells/well) were separated from DCs (2 x 105 
cells/well) by culturing the cells in different compartments of a 0,4 µm Transwell® plate 
(Corning Costar).  
 
TH cell priming  
DCs (4 x 104 cells/well) were cocultured for 24 h in the presence or absence of NK cells (5 x 
104 cells/well), before they were coated with 1 ng/ml Staphylococcal Enterotoxin B (SEB, 
Sigma-Aldrich) for 1 h. SEB-coated DCs, were washed and placed in culture with 
CD45RA+/RO-CD4+ T cells (105 cells/well). On day 4, 20 U/ml rhIL-2 (Proleukin, Chiron 
Benelux BV) was added to the cultures. At day 10 the expanded TH cells were washed, 
plated in 96-well plates (105 cells/well), and stimulated with PMA/ionomycin (BD 
Biosciences) for 4 h in the presence of 1 μg/ml Brefeldin A (BD Biosciences). Intracellular 
IFN-γ staining was analyzed by flow cytometry. 
 
NK cell cytotoxicity assay 
NK cell cytotoxicity was analyzed by a flow cytometry-based kill assay as described (23). 
Briefly, NK cells were incubated for 24 h with either DC supernatant, medium alone or 
medium containing 1000 U/ml IL-2 (Proleukin). Target cells (Raji) were labeled with 3'-
dioctadecyloxacarbocyanine (DiO) according to the manufacturer’s instructions (Sigma). 
Target cells (104 cells) were incubated with effectors at various effector:target (E:T) ratios 
for 12 h, each ratio in triplicate. Percentages of killed target cells (PI+ DiO+) were 
determined by flow cytometry. Percentages of specific lysis were calculated: (% PI positive 
target cells - % spontaneous PI positive cells)/ % of vital cells) x 100. 
 
Statistics 
The statistical significance of differences between experimental samples was determined 
using Student’s t test for paired samples or ANOVA for multiple samples. Significance was 
accepted at the P < 0.05 (*) and P < 0.01 (**) levels. Data were analyzed using Prism 
software version 5.00 (GraphPad Software, Inc.). 
Chapter 4 
 
104 
Results 
 
DC-dependent NK cell recruitment is CCR5-mediated 
To investigate whether NK cells are involved in the immune response against bacteria, we 
tested the ability of DCs to induce NK cell migration. A bacterial infection was mimicked by 
triggering monocyte-derived DCs with FMKp. As a control, DCs were matured with the 
pro-inflammatory mediators TNF-α and PGE2 in the absence of bacterial triggers. In 
addition to FMKp, also purified, single TLR ligands were used to investigate whether these 
individual pathways dominate induction of NK-DC interaction. Therefore DCs were 
matured with either Zymosan (TLR2 ligand) or LPS (TLR4 ligand) in the presence of IFN-γ. 
Moreover, the combination of both single TLR-triggering agents was used to determine a 
possible synergism. 
IL-4/GM-CSF differentiated DCs were matured for 6 h in the presence of either TNF-
α/PGE2 or IFN-γ/FMKp after which the cells were extensively washed and transferred to 
serum-free medium without maturation stimuli. Washing was performed to avoid altered 
NK cell migration due to activation by the maturation cocktail. For the TNF-α/PGE2 and 
IFN-γ/FMKp matured DCs 6 h maturation irreversibly triggered maturation as evidenced by 
the upregulation of MHC class II and costimulatory molecules (Supporting Information 
Figure 1), which was comparable to expression of these markers detected after 48 h 
maturation (24). Filtered, cell-free, DC supernatant was harvested after 18 h of culture and 
transferred to the lower compartment of a Transwell®. Since NK cell migration is more 
reproducible at longer migration periods (Supporting Information Figure 2), recruitment 
assays were performed over a period of 16 h. NK cell migration to a CCL19 gradient was 
used as a positive control to normalize donor and interexperimental variability. After 16 h 
of NK cell migration, the supernatant of the IFN-γ/FMKp matured DCs contained 
significantly more NK cells as compared to the supernatant of the TNF-α/PGE2 matured 
DCs (Figure 1A). We did not observe a selective enrichment of CD56bright nor CD56dim NK 
cells in the lower well, suggesting that there was no preferential recruitment of either NK 
cell subset (data not shown). No significant difference in the number of migrated NK cells 
was detected when medium was present instead of the supernatant of TNF-α/PGE2 
matured DCs (data not shown), indicating that these DCs fail to attract NK cells. 
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To identify the chemokines responsible for the observed NK cell recruitment by IFN-
γ/FMKp matured DCs, chemokine arrays were performed on DC supernatants. The 
chemiluminescence values of the chemokine spots were quantified by densitometry, 
normalized to control spots and plotted in XY graphs (Figure 1B). DC maturation induced 
by IFN-γ/FMKp led to an enhanced (>1.5 fold increase in chemiluminescence) secretion of 
11 chemokines as compared to TNF-α/PGE2-induced maturation. These chemokines 
included CCL5, CXCL10 and CCL19 to which NK cells can respond (25-27). Quantification 
with ELISA confirmed that these chemokines were indeed produced by IFN-γ/FMKp 
matured DCs and not by TNF-α/PGE2 matured DCs (Figure 1C). To evaluate whether the 
chemokine production was induced by TLR-triggering or IFN-γ stimulation, DCs were 
matured by either FMKp or IFN-γ alone. Maturation with IFN-γ does neither induce DCs to 
produce CCL19 nor CCL5, however IFN-γ stimulates DCs to secrete CXCL10 (Figure 1D). 
FMKp is sufficient to trigger DCs to produce all three cytokines, albeit in lower 
concentrations as compared to maturation in the presence of both FMKp and IFN-γ, 
evidencing their additive effect.  
Additionally, other TLR ligands were used to induce DC maturation and induction of 
chemokine production was compared with the production by IFN-γ/FMKp matured DCs 
(Figure 1D). In the presence of IFN-γ, zymosan, LPS and the combination of both TLR-
ligands, triggered DCs to produce CCL19 and CXCL10, although at significantly lower 
amounts as compared to FMKp/IFN-γ matured DCs. Zymosan in contrast to LPS was not 
able to induce CCL5 production by DCs. No additive effect on chemokine secretion was 
observed when TRL2 and 4 were stimulated simultaneously. To evaluate if the differences 
in chemokine production between different TLR-triggered DCs influenced NK cell 
recruitment, supernatant of zymosan/IFN-γ and LPS/IFN-γ triggered DCs, matured by the 
same maturation and washing procedure as the IFN-γ/FMKp matured DCs were used in NK 
cell migration assays. Migration data revealed that IFN-γ/FMKp matured DCs recruited 
more NK cells than DCs matured with either FMKp or IFN-γ alone (Figure 1E). Moreover,  
FMKp/IFN-γ matured DCs also recruited significantly more NK cells than zymosan/IFN-γ 
matured DCs (Figure 1E). Furthermore, LPS/IFN-γ matured DCs, do not differ from IFN-
γ/FMKp matured DCs in their capacity to recruit NK cells even though they produce lower 
amounts of chemokines. 
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Figure 1. CCR5-dependent recruitment of NK cells by IFN-γ/FMKp matured DCs. 
Freshly isolated human NK cells and undiluted, filtered supernatants of IL-4/GM-CSF differentiated and TNF-
α/PGE2 or IFN-γ/FMKp matured DCs were used for analysis. (A) Percentage of NK cell migration towards 
supernatants of TNF-α/PGE2 and IFN-γ/FMKp matured DCs. Data were calculated as percentage of migrated NK 
cells, normalized to NK cell migration towards a CCL19 gradient (250 ng/ml). Data show mean + SEM of 7 
different donors; bars. *P<0.05, pared t-test. (B) Human chemokine protein arrays of DC supernatant. 
Quantitated chemiluminescence values of individual protein spots are represented. Normalized protein 
expression is plotted in an X/Y graph and only 1.5-fold upregulated proteins are annotated. Data are 
representative of results from 3 donors. (C) Quantitative comparison of CCL5, CCL19 and CXCL10 production by 
IFN-γ/FMKp and TNF-α/PGE2 matured DC as measured by ELISA in at least 5 different donors. *P<0.05, **P<0.01, 
paired t-test. 
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Figure 1. CCR5-dependent recruitment of NK cells by IFN-γ/FMKp matured DCs (continued).  
(D) Chemokine production of IFN-γ/FMKp, IFN-γ, FMKp, Zymosan/IFN-γ, LPS/IFN-γ and Zymosan/LPS/IFN-γ 
matured DCs, combined data of at least 5 different donors. Data show mean + SEM, *P<0.05, **P<0.01, ANOVA. 
(E) Percentage of NK cell migration induced by supernatants of IFN-γ/FMKp, IFN-γ, FMKp, Zymosan/IFN-γ, 
LPS/IFN-γ and Zymosan/LPS/IFN-γ matured DCs. Data show mean + SEM of 7 different donors. *P<0.05, 
**P<0.01, ANOVA. (F) Percentage of NK cell migration towards DC supernatant after blocking the chemokine 
receptors CCR5, CXCR3 or CCR7. Data are calculated as percentage of migrated NK cells normalized to NK cell 
migration towards medium (background). Data show mean + SEM of 4 different donors. **P<0.01, paired t-test. 
  
To establish which chemokines are involved in NK cell recruitment by IFN-γ/FMKp matured 
DCs, corresponding chemokine receptors on NK cells were blocked (CCR5 for CCL5, CXCR3 
for CXCL10 and CCR7 for CCL19). Only blocking of CCR5 reduced NK cell migration 
significantly (Figure 1F). No significant reduction was observed with a CCR7-blocking 
antibody, which is like anti-CCR5 an IgG2a antibody and therefore serves as an isotype 
control.  
In conclusion, DCs triggered with bacterial fragments of K. pneumoniae produce many 
chemokines in substantial amounts, including CXCL10, CCL19 and CCL5, and are able to 
recruit NK cells in a CCR5-dependent manner.  
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DC-dependent induction of CCR7 expression on NK cells increases NK cell migratory 
responsiveness to lymph node-related chemokines 
In steady state conditions the CD56brightCD16- NK cell subpopulation has been reported to 
express CCR7 (27), which allows them to migrate into lymph nodes (28). However, in 
response to IL-18-producing monocytes, induction of CCR7 has also been observed on 
CD56dimCD16+ NK cells (6). To investigate whether IFN-γ/FMKp matured DCs also induce 
CCR7 expression on NK cells, both cell types were cocultured. After 24 h NK cells were 
harvested, and CCR7 expression was evaluated using flow cytometry. Besides CCR7 
expression on CD56bright NK cells, CCR7 was also observed on the CD56dim NK cell 
subpopulation after coculture with IFN-γ/FMKp matured DCs (Figure 2A), which was 
significant in seven different donors (Figure 2B; P < 0.01). When NK cells were physically 
separated from DCs by a Transwell® (pore size 0,4 µm), CCR7 expression was still induced, 
albeit on a lower percentage of NK cells (Figure 2B). This indicated that the induction of 
CCR7 expression was predominantly contact-dependent. 
To test if this induction of CCR7 expression resulted in an increased migration towards 
lymph node-related chemokines, NK cells were isolated from NK-DC cocultures and tested 
for their capacity to migrate towards CCL19. Compared to freshly isolated NK cells, NK 
cells from NK-DC cocultures showed a significantly increased migratory responsiveness (P 
< 0.01; average migration index of 1.25) towards CCL19 (Figure 2C).  
These data indicate that, upon contact with DCs triggered with bacterial fragments, CCR7 
expression is induced on a subpopulation of NK cells, increasing their migratory 
responsiveness to CCL19, which is considered to be a lymph node-homing chemokine. 
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Figure 2. DC-dependent CCR7 induction on NK cells, inducing increased migratory responsiveness to CCL19. 
Freshly isolated human NK cells and undiluted, filtered supernatants of IL-4/GM-CSF differentiated and IFN-
γ/FMKp matured DCs were used for functional and phenotypic analysis. (A) Percentage of CCR7+ NK cells after 
culture for 24 h with AIM-V® medium, supernatant of IFN-γ/FMKp matured DCs or IFN-γ/FMKp matured DCs as 
detected by flow cytometry and gated on CD56+CD3− NK cells. Representative data out of 6 donors are shown. 
(B) Percentage of CCR7+ NK cells after 24 h coculture with IFN-γ/FMKp matured DCs. Data show mean + SEM of 7 
different donors. **P<0.01, paired t-test. (C) Migration index of NK cells, cocultured with IFN-γ/FMKp matured 
DCs and separated by magnetic bead separation, migrating for 16 h toward CCL19. Data show mean + SEM of 4 
different donors. **P<0.01, paired t-test. 
 
NK cell activation by IFN-γ/FMKp stimulated DCs enhances NK cell cytotoxicity and 
induces IL-12/IL-18-mediated IFN-γ production, resulting in TH1 polarization  
Recent data have shown that, lymph node-homing NK cells assist in TH1 polarization (3, 
29). Since IFN-γ/FMKp matured DCs were able to recruit NK cells, we investigated whether 
these DCs were also able to induce IFN-γ production by NK cells. To quantify the 
percentage of NK cells producing IFN-γ, intracellular IFN-γ staining was performed on NK 
cells cultured in DC supernatant (Figure 3A). A small subpopulation (about 2%) of NK cells 
accumulated IFN-γ when cultured for 16 h in the supernatant of IFN-γ/FMKp matured DCs 
(Figure 3B). Among the IFN-γ-accumulating NK cells we identified NK cells with both, high 
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and intermediate expression of CD56. Though small in number, the IFN-γ accumulating NK 
cell subpopulation was capable of producing detectable amounts of IFN-γ as measured by 
ELISA (Figure 3C). Induction of IFN-γ secretion of NK cells by DCs depends on the additive 
effect of IFN-γ and FMKp during DC maturation, since neither of these stimuli alone could 
induce as much IFN-γ production by NK cells as IFN-γ/FMKp matured DCs (Figure 3D). After 
activation by IFN-γ/FMKp DCs, the complete NK cell population showed upregulation of 
the NK cell activation markers CD69 and CD25 (Supporting Information Figure 3). Notably, 
NK cells cultured in the supernatant of the TNF-α/PGE2 matured DCs neither accumulated 
IFN-γ nor showed upregulation of activation markers.  
 To evaluate whether DCs triggered by single TLR-ligands, also induce NK cell activation, 
NK cells were incubated for 16 h in the supernatant of DCs matured with zymosan, LPS or 
the combination of both in the presence of IFN-γ. NK cells incubated with supernatant of 
these TLR-triggered DCs showed significantly lower production of IFN-γ than NK cells 
incubated with supernatant of IFN-γ/FMKp matured DCs (Figure 3D).    
Two crucial soluble cytokines responsible for NK cell activation are IL-12 and IL-18, which 
act interdependently in a two-signal mechanism (6). To examine if these cytokines are 
involved in the observed IFN-γ production, their presence in the supernatant of IFN-
γ/FMKp and TNF-α/PGE2 matured DCs was determined. IFN-γ/FMKp matured DCs 
produced IL-12p70 as well as IL-18, albeit with a large donor variation (Figure 3E). In 
contrast, TNF-α/PGE2 matured DCs did neither produce IL-12p70 nor IL-18. Since 
activation of NK cells by DCs depends on the additive effect of IFN-γ and FMKp, IL-12 
production after maturation with these triggers individually was examined. DCs produced 
IL-12 after FMKp triggering but not after IFN-γ triggering, however, the combination of 
FMKp and IFN-γ had a synergistic effect on IL-12p70 production (Figure 3F). When 
production of IL-12 by DCs matured with other TLR2 and TLR4 ligands was evaluated, it 
was found that LPS, in contrast to zymosan, induced IL-12 production and also the 
combination of LPS and zymosan did, however, the amount produced by these DCs was 
significantly lower than that of IFN-γ/FMKp matured DCs (Figure 3F).  
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Figure 3. IL-12p70 and IL-18 dependent activation of NK cells by IFN-γ/FMKp matured DCs.  
Freshly isolated human NK cells and undiluted, filtered supernatants of IL-4/GM-CSF differentiated and TNF-
α/PGE2 or IFN-γ/FMKp matured DCs were used for analysis. (A) Percentage of NK cells accumulating IFN-γ after 
activation for 16 h by supernatant of TNF-α/PGE2 and IFN-γ/FMKp matured DCs, as detected by flow cytometry 
and gated on CD56+CD3− NK cells. Representative data of 5 independent experiments are shown (B) and 
combined data of 5 different donors data show mean + SEM. **P<0.01, ANOVA. (C) Quantitative comparison of 
IFN-γ production by NK cells as measured by ELISA. Data show mean values of 10 donors. **P<0.01, ANOVA. (D) 
Quantitative comparison of IFN-γ production by NK cells activated for 16 h by supernatant of IFN-γ, FMKp, 
Zymosan/IFN-γ, LPS/IFN-γ and Zymosan/LPS/IFN-γ matured DCs. Data show mean + SEM of at least 5 different 
donors. **P<0.01, ANOVA. (E) Quantitative comparison of production of IL-12p70 and IL-18 by TNF-α/PGE2 and 
IFN-γ/FMKp matured DCs as measured by ELISA. Data show mean values of at least 8 donors. *P<0.05, **P<0.01, 
paired t-test. (F) Quantitative comparison of production of IL-12p70 by IFN-γ, FMKp, Zymosan/IFN-γ, LPS/IFN-γ 
and Zymosan/LPS/IFN-γ matured DC as measured by ELISA. Data show mean + SEM of 9 different donors. 
*P<0.05, ANOVA.  
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Figure 3. IL-12p70 and IL-18 dependent activation of NK cells by IFN-γ/FMKp matured DCs (continued). 
(G) Surface IL-15 presentation in trans by DCs matured by TNF-α/PGE2 or IFN-γ/FMKp as detected by flow 
cytometry. Representative data out of 3 different donors are shown. (H) Quantitative comparison of IFN-γ 
production by NK cells activated for 16 h by supernatant of IFN-γ/FMKp matured DCs, after neutralizing IL-12p70 
and/or IL-18, as measured by ELISA. Representative data of 3 independent experiments are shown. *, P<0.05; **, 
P<0.01. 
 
Upon physical contact with IFN-γ/FMKp matured DCs, NK cells produce slightly elevated 
amounts of IFN-γ as compared to NK cells cultured in DC supernatant (Supporting 
Information Figure 4), indicating that predominantly soluble factors, with minor 
contribution of contact-dependent factors, mediate IFN-γ secretion by NK cells. This 
phenomenon was observed in both autologous as well as Killer cell Immunoglobulin-like 
Receptor- (KIR) mismatched NK-DC co-cultures. A candidate cytokine responsible for this 
contact-dependent increase of IFN-γ production is IL-15, which can be presented in trans 
by DCs (15, 30). Therefore expression of IL-15 by IFN-γ/FMKp and TNF-α/PGE2 matured 
DCs was evaluated by flow cytometry. Notably, IFN-γ/FMKp DCs express more surface 
bound IL-15 (Figure 3G).   
The dependency of NK cell activation on DC-derived IL-12/IL-18 was examined by 
neutralizing both cytokines with the respective neutralizing antibodies. This resulted in a 
decreased IFN-γ production after neutralizing IL-18 and a complete block of IFN-γ 
secretion after neutralizing IL-12p70 (Figure 3H).  
To investigate whether the observed DC-induced NK cell activation by IFN-γ/FMKp 
matured DCs contributes to TH1 polarization, T cell stimulation assays were performed in 
the presence or absence of NK cells. Therefore, IFN-γ/FMKp matured DCs were coated 
with Staphylococcis Enterotoxin B (SEB) and cocultured for 10 days with naive CD4+ T cells 
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in either the presence or absence of NK cells. When NK cells were present, a significantly 
higher percentage of CD4+ T cells produced IFN-γ (Figure 4A; P < 0.01), which was 
reproducible in four donors (Figure 4B). 
 
 
Figure 4. DC-dependent NK cell activation induces TH1 responses. 
IFN-γ/FMKp matured DCs differentiated by IL-4/GM-CSF were cultured for 24 h in the presence or absence of 
freshly isolated NK cells, before they were pulsed with Staphylococcal Enterotoxin B (SEB) and cocultured with 
freshly isolated CD45RA+CD45RO−CD4+ TH cells. (A) Percentage of naive CD4+ T cells accumulating IFN-γ after 10 
days of coculture and stimulation with PMA/ionomycin for 4 h as analyzed by flow cytometry and gated on 
CD4+CD3+ T cells. Representative data of 5 independent experiments are shown. (B) Summary of 
CD45RA+CD45RO−CD4+ T cells accumulating intracellular IFN-γ of 5 different donors. 
 
Besides cytokine production, the other major NK cell function is cytotoxicity. To study the 
effect of NK-DC interaction on NK cell killing capacity, we investigated NK cell-mediated 
lysis of the Burkitt’s lymphoma cell line Raji after 24 h incubation with DC supernatant. 
Raji cells are insensitive for lysis by naïve NK cells, however if NK cells are preactivated 
they become susceptible for NK cell-mediated cytotoxicity. Therefore IL-2 activated NK 
cells were taken along as positive control in the cytotoxicity assay. Only NK cells incubated 
with the supernatant of IFN-γ/FMKp matured DCs showed an increased cytotoxic activity, 
whereas NK cells incubated with the supernatant of TNF-α/PGE2 matured DCs did not 
(Figure 5A). Notably, in neither DC supernatant IL-2 was detected (data not shown), ruling 
out IL-2 as causative factor for augmentation of cytotoxicity. Another possible candidate, 
which has been shown to induce NK cell cytotoxicity is IL-12 (31). Therefore IL-12p70 was 
neutralized, which dose-dependently reduced the specific lysis of Raji cells to the level 
observed after co-incubation with unstimulated NK cells (Figure 5B-C). IL-15, presented in 
trans by IFN-γ/FMKp matured DCs, is another candidate cytokine responsible for 
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augmentation of NK cell mediated lysis. However, blocking of this cytokine in the 
supernatant of DCs, did not result in decreased killing capacity of NK cells (data not 
shown). 
In conclusion, DCs triggered with bacterial fragments are able to induce IL-12/IL-18 
mediated NK cell activation, resulting in the production of IFN-γ and TH1 polarization. 
Additionally, the IL-12 produced by these DCs is also responsible for augmentation of NK 
cell cytotoxicity. 
 
 
Figure 5. NK-DC interaction augments NK cell cytotoxicity.  
Freshly isolated human NK cells and undiluted, filtered supernatants of TNF-α/PGE2 and IFN-γ/FMKp matured 
DCs were used for induction of NK cell cytotoxicity. NK cell cytotoxicity toward Raji cells was assessed by a flow 
cytometry-based kill assay. IL-2 activated NK cells represent a positive control and freshly isolated NK cells a 
negative control in inducing Raji cell lysis. (A) Data represent means ± SEM of triplicate wells. Data shown are 
representative of 6 independent experiments. (B) Cytotoxicity after neutralization of IL-12 in the supernatant of 
IFN-γ/FMKp matured DCs. Data represent means ± SEM of triplicate wells. Data shown are representative of 3 
independent experiments. (C) Dose-dependent decrease of cytotoxicity after neutralization of IL-12 in the 
supernatant of IFN-γ/FMKp matured DCs in a effector-to-target ratio of 20:1. Columns, Mean of 3 different 
donors. bars, SEM. *, P<0.05; **, P<0.01. 
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Discussion 
 
Under steady state conditions, NK cells do not home to tissues and lymph nodes. 
However, during inflammation it has been demonstrated that NK cells are able to migrate 
into inflamed tissue and draining lymph nodes (7, 25). At present it remains unclear what 
drives human NK cell migration in vivo. Primary immune responses to bacterial fragments 
(FMKP) induce DCs to produce high amounts of chemokines (Figure 1B) and we 
demonstrate that these DCs are able to recruit NK cells in a CCR5-dependent manner. It 
can be hypothesized that chemokines produced by DCs, triggered with bacterial 
fragments, are responsible for NK cell recruitment to inflamed tissue and into the 
inflammatory lymph node. The ability of human DCs to recruit NK cells is consistent with 
previous studies that report on CCL5 and CXCL10 production and NK cell recruitment by 
DCs either infected with Mycobacterium Tuberculosis (32), stimulated by oncolytic 
reovirus  (33) or matured with IFN-α/IFN-γ/TNF-α/IL-1β/poly-(I:C). Blocking of CXCR3 did 
not affect NK cell migration to IFN-γ/FMKp matured DCs, therefore our data suggest that 
CXCR3- and CCR5-dependent NK cell recruitment are two different mechanisms by which 
NK cells can be attracted by DCs. Both chemokine receptors CXCR3 and CCR5 are 
expressed by subpopulations of resting and activated NK cells and have been proven 
essential for NK cell migration to various tissues in response to pro-inflammatory stimuli 
(25, 28, 34). Which NK cell-recruitment mechanism is utilized seems to depend on the 
agents used in DC maturation and lack of NK cell recruitment by TNF-α/PGE2 matured DCs 
suggests that TLR-ligands or other PRR-triggering agents are necessary triggers for DCs to 
recruit NK cells. Triggering of different TLRs could explain the difference in chemokines 
dominant in NK cell recruitment and suggest that different infectious agents can induce 
different DC-chemokine profiles. This is supported by our data on differences in 
chemokine secretion between DCs triggered with TLR2 and TLR4 agonists, resulting in 
differential NK cell recruitment. Even though the current data indicate that TLR4 signaling 
induces DCs to secrete CCL5, it remains to be established whether this is the only pathway 
inducing production of this chemokine. IFN-γ/FMKp matured DCs produce 4-fold higher 
amounts of CCL5 than LPS/IFN-γ matured DCs which could be due to differences in the 
concentration of the TLR-triggering agents, since the exact concentrations of LPS and 
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OmpA in FMKp is unknown. Furthermore, at present it remains unclear whether FMKp 
also contains other PRR ligands responsible for higher chemokine secretion. A second line 
of evidence supporting the fact that different TLR triggers induce different DC chemokine 
profiles is illustrated in mouse studies on differential NK and T cell activation and 
recruitment by differently matured DCs (35, 36). Notably, the CXCR3- and CCR5-
dependent mechanisms by which DCs attract NK cells are not mutually exclusive, as it has 
been demonstrated that upon poly (I:C) triggering, intrasplenic NK cell trafficking depends 
on synergistic actions of CXCR3 and CCR5 (34).  
It can be envisioned that DCs, displaying a favorable chemokine profile, are able to recruit 
immune effector cells including NK cells, TH1 cells and CTLs and thereby creating a 
peripheral, tertiary lymph node (37). Next to this peripheral NK cell recruitment, DCs could 
facilitate NK cell migration into the lymph nodes. This has been demonstrated in a mouse 
model by LPS-matured DCs, which recruit NK cells into the draining lymph nodes (3). Since 
IFN-γ/FMKp matured DCs are active producers of CCR7, CXCR3 and CCR5 ligands, it can be 
anticipated that they attract NK cells during their arrival in draining lymph nodes by virtue 
of different mechanisms and our in vitro data demonstrate that CCR5-dependent 
recruitment is the most potent for these DCs. 
In addition to the CCR5-dependent NK cell recruitment, we show that DCs triggered by 
bacterial fragments have the ability to induce CCR7 expression on a subset of NK cells that 
increases their migratory responsiveness to CCL19. This represents a second mechanism 
of DC-induced NK cell homing into inflammatory lymph nodes. The factors inducing CCR7 
expression in our system have not been elucidated. Similar results have recently been 
obtained by Marcenaro et al., who showed an induction of CCR7 after co-incubating NK 
cells and DCs in an allogeneic setting (38). We, however, observed CCR7 induction in both 
allogeneic as well as in autologous settings, indicating that multiple mechanisms may 
account for CCR7 induction. In line with findings of Mailliard et al., who demonstrated (6), 
that IL-18 induces CCR7 expression on the same CD56dimCD16+ NK cell subset as the IL-18 
producing, IFN-γ/FMKp matured DCs (Supporting information Figure 5). Therefore IL-18 
could be one of the DC-dependent factors responsible for the CCR7 induction. In addition, 
the partial contact-dependency may also point to IL-18, because it has been shown that 
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DC-derived IL-18 is polarized and secreted in the immunologic synapse inducing local, high 
IL-18 concentrations (39). 
Besides their NK cell-attracting capacity, DCs matured with bacterial fragments also meet 
the prerequisites for NK cell activation. Using blocking antibodies, we demonstrated that 
both DC-derived IL-12 and IL-18 are necessary for IFN-γ secretion by a subpopulation of NK 
cells. Addition of rIL-12 to the supernatant of TNF-α/PGE2 matured DCs did not result in 
NK cell IFN-γ production (data not shown), which indicates that both IL-12 and IL-18 are 
required to induce IFN-γ secretion, supporting the two-signal requirement mechanism 
described by Mailliard et al. (6). Notably, the IFN-γ producing NK cell population contained 
both NK cells with an intermediate and with a high expression of CD56, which is 
remarkable since the CD56bright subpopulation has been described as the cytokine 
producing population after NK-DC interaction (40). Upon physical contact with DCs, NK 
cells produce even higher amounts of IFN-γ (Supporting Information Figure 4), indicating 
that predominantly soluble factors, with minor contribution of contact-dependent factors, 
mediated IFN-γ secretion by NK cells. This phenomenon was observed in both autologous, 
as well as Killer cell Immunoglobulin-like Receptor- (KIR) mismatched NK-DC co-cultures. 
Ligation of NK cell receptors could be responsible for this contact-dependency (15), 
however, the formation of an immunological synapse could also be an important factor 
(41). Next to IL-18, other possible candidates are MICA/B (15) and in trans presented IL-15 
(15, 30). The functional consequence of NK cell activation by IFN-γ/FMKp matured DCs 
appeared to be dual. On the one hand, NK cells produce sufficient cytokines to increase 
TH1 polarization that was shown previously to be completely dependent on NK cell-
derived IFN-γ (29). On the other hand, we demonstrated that IL-12 produced by IFN-
γ/FMKp matured DCs also augments NK cell cytotoxicity toward the Raji cell line. This 
augmentation has been documented after contact of NK cells with some bacteria or by 
NK-DC crosstalk during bacterial infection (11, 42).  
In conclusion, based on our in vitro data, it can be hypothesized that in vivo a K. 
pneumonia infection is responsible for induction of innate immune responses 
characterized by DC-dependent NK cell migration, facilitating NK-DC interactions both in 
the periphery as well as in lymphoid tissue. The molecular program triggered by FMKp and 
IFN-γ does not only permit DCs to recruit NK cells, but also induces the prerequisites 
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necessary to activate NK cell cytotoxicity and NK cell helper function for TH1 polarization 
and possibly subsequent CTL induction. DC vaccination studies for the treatment of cancer 
have revealed that NK cell activation is of importance for sustained antitumor responses 
(43). Since the examined DC maturation cocktails are clinically relevant DC-preparations 
used in DC-based vaccination studies, unraveling the in vitro mechanisms of NK-DC 
interaction is of importance for the development of therapeutic DC vaccination and DC-
targeting strategies for cancer and infectious diseases.  
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Supporting Information  
 
 
Figure 1. Surface phenotype of DCs maturated by TNF-α/PGE2 or IFN-γ/FMKp. 
DCs differentiated for 7 days in the presence of IL-4/GM-CSF and maturated for 24 h with TNF-α/PGE2 or IFN-
γ/FMKp (DCs were washed after 6 h maturation and were further matured for 18 h in AIM-V medium without 
maturation stimuli) were used for flow cytometric comparison of surface expression of HLA-molecules and 
costimulatory markers. Filled areas represent surface expression on immDCs, bold lines on TNF-α/PGE2 matured 
DCs and dotted lines on IFN-γ/FMKp matured DCs. Representative data out of 4 different donors are shown. 
 
 
Figure 2. NK cell migration towards a CCL19 gradient.  
Number of freshly isolated NK cells (105 cells) migrated towards different CCL19 (0 ng/ml, 62,5 ng/ml, 125 ng/ml 
and 250 ng/ml) gradients in a Transwell® assay in different time periods (4, 8 and 16 h). Columns, Mean values; 
bars, SEM. *, P < 0.05; **, P < 0.01. 
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Figure 3. NK cell activation phenotype.  
Phenotype after 24 h coculture with TNF-α/PGE2 or IFN-γ/FMKp matured DCs as detected by flow cytometry. (A) 
CD25 and (B) CD96 expression gated on CD56+NKp46+CD3- NK cells. Filled histogram NK cell coculture with TNF-
α/PGE2 and dotted line IFN-γ/FMKp matured DCs. Representative data of 3 different donors.  
 
 
Figure 4. Contact-dependent IFN-γ secretion.  
Quantitative comparison of IFN-γ production by NK cells (105 cells/well) cultured for 16 h NK in either the upper 
well of a 0,4 µm a Transwell® plate, separated from DCs (only soluble factors can induce NK cell activation) or in 
the lower well where they were cocultured with DCs (2 x 105 cells/well), as measured by ELISA. Columns, Mean 
values of 9 different donors, bars, SEM. *, P < 0.05; **, P < 0.01. 
 
 
Figure 5. IL-18 induced CCR7 expression by NK cells. 
 CCR7 expression after 24 h coculture with IFN-γ/FMKp matured DCs or IL-18 as detected by flow cytometry and 
gated on CD56+NKp46+CD3- NK cells. 
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Abstract 
 
Among prostaglandins (PG), PGE2 is abundantly expressed in various malignancies and is 
probably one of many factors promoting tumor growth by inhibiting tumor immune-
surveillance. In the current study, we report on a novel mechanism by which PGE2 inhibits 
in vitro NK-DC crosstalk and thereby innate and adaptive immune responses via its effect 
on NK-DC crosstalk. The presence of PGE2 during IFN-γ/FMKp dendritic cell (DC) 
maturation inhibits the production of chemokines (CCL5, CCL19 and CXCL10) and 
cytokines (IL-12 and IL-18), which is cAMP-dependent and imprinted during DC 
maturation. As a consequence, these DCs fail to attract natural killer (NK) cells and show a 
decreased capacity to trigger NK cell IFN-γ production, which in turn leads to reduced TH1 
polarization. In addition, the presence of PGE2 during DC maturation impairs DC-mediated 
augmentation of NK cell cytotoxicity. Opposed to their inhibitory effects on peripheral 
blood-derived NK cells, PGE2 matured DCs induce IL-22 secretion of inflammation 
constraining NKp44+ NK cells present in mucosa-associated lymphoid tissue. The inhibition 
of NK-DC interaction is a novel regulatory property of PGE2 that is of possible relevance in 
dampening immune responses in vivo.  
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Introduction 
 
Prostaglandins (PG) are potent immune modulators, which are produced during 
inflammation after the conversion of arachidonic acid by cyclooxygenase (COX)(1). 
Furthermore, PG are also abundantly produced by various types of tumors (2). COX2 
expression, which is correlated with a poor prognosis, is induced in a variety of human 
premalignant and malignant tumors, including solid tumors as well as hematological 
malignancies (3-6). Several lines of evidence demonstrate that COX2-derived PGs are 
involved in the promotion of tumor growth by regulation of cancer cell proliferation, 
apoptosis, migration and invasion (7-11). PGs are also produced by tumor-surrounding 
cells, creating a tumor-supporting environment by enhancing angiogenesis and inhibiting 
tumor immune surveillance (2, 11-14). 
Of all prostaglandins, PGE2 has a pivotal role in tumor immunosuppression. It has been 
hypothesized that this effect is caused by induction of a permanent state of inflammation 
(2), resulting in phenotypic and functional changes of T helper (TH) cells, cytotoxic T (CTL) 
cells, dendritic cells (DC), natural killer (NK) cells and myeloid-derived suppressor cells 
(MDSC) (12). PGE2 has been shown to deviate TH cell skewing from an antitumor TH1 
response toward a TH2/TH17 response by direct binding to these cells (15-17). Additionally, 
PGE2 is responsible for shifting the balance of IL-12/IL-23 production by DCs toward IL-23, 
which is a very potent cytokine responsible for TH17 expansion and survival (18, 19). As a 
consequence, less IL-12 and other pro-inflammatory cytokines are produced, thus 
inhibiting TH1 polarization (17, 20). PGE2 also decreases the cytotoxic capacity of CTLs 
directly by inducing the expression of inhibitory receptors on CTLs (21) and indirectly by 
inhibiting DC maturation and antigen presentation (22, 23). Moreover, tumor-associated 
PGE2 has been reported to be responsible for the preferential attraction and induction of 
regulatory T (Treg) cells, creating an immune-regulatory microenvironment (24, 25).  
Next to the modulating effects of PGE2 on the effector mechanisms of the adaptive 
immune response, PGE2 also has an effect on the innate immune response. NK cells, 
which are implicated in the innate defense against virally infected and malignantly 
transformed cells, have been reported to be affected by PGE2. It has been shown that 
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PGE2 suppresses proliferation, cytokine secretion, migration and NK cell-mediated 
cytotoxicity both in vivo and in vitro (26-30).  
Even though PGE2 has these direct effects on NK cells, it remains to be established 
whether PGE2 also has an effect on NK-DC crosstalk. We and others have previously 
reported on the importance of NK-DC crosstalk in modulating adaptive immune responses 
(29, 31, 32). This crosstalk is characterized by DC-dependent recruitment of NK cells and 
IFN-γ production by NK cells, of which the latter contributes to strong TH1 polarization 
(32). Additionally, DCs augment NK cell-mediated cytotoxicity of tumor cells. The DC-
derived cytokines IL-12, IL-18 and IL-15 have been implicated in NK cell activation and IL-
15 is also responsible for proliferation and survival of NK cells (32, 33).  
In the current study, we investigated how PGE2 influences NK-DC interactions. We 
identified the effects of PGE2 signaling on the production of key chemokines and cytokines 
responsible for NK cell interaction with DCs matured with IFN-γ and a membrane fraction 
of Klebsiella pneumoniae (FMKp). We show that PGE2 not only has a direct effect on NK 
cells, but also indirectly alters DC-mediated, NK cell effector functions.  
 
 
Materials and methods 
 
Cell isolation 
 Mononuclear cells from peripheral blood of healthy donors were isolated by density 
gradient separation using lymphoprep (Axis-Shield). NK cells and naïve CD4+ T cells were 
negatively selected by immunomagnetic cell separation (Miltenyi Biotec GMbH). The 
purity of isolated populations exceeded 95% as determined by flow cytometry.  
Human tonsils were obtained from the Department of Otorhinolaryngology-Head & Neck 
Surgery, Maastricht University Medical Center. NK cells were isolated to a purity of 70-
80% as described by Cella et al. (34).  
 
Generation of DCs 
DCs were prepared from peripheral blood-derived monocytes, isolated by density 
centrifugation and adherence as previously described (35). In addition, highly purified 
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monocyte fractions obtained by elutriation of leukapheresis products were used (purity 
>95%). Written informed consent was obtained from all leukapheresis donors in 
accordance with the Declaration of Helsinki. For every experiment, DCs from both 
isolation methods were used to avoid the effect of contaminating NK cells (<5% in density 
centrifugation isolated monocytes) on the results. Differentiation of monocytes was 
induced during 6 days of culture in AIM-V® medium (Gibco Life Technologies) containing 
2000 U/ml IL-4 (Strathmann Biotech) and 400 U/ml GM-CSF (Berlex). DCs were matured 
for 6 h in AIM-V® medium containing 500 U/ml IFN-γ (Strathmann Biotech), 1 μg/ml FMKp 
(Pierre Fabre) and different concentrations of PGE2 (Sigma-Aldrich). Where indicated, 10 μ 
M butaprost (EP2 agonist), 35 μM misoprostol (EP2/EP3/EP4 agonist), 10 μM sulprostone 
(EP1/EP3 agonist; Cayman Chemical), or 100 μ M of dibutyryl-cAMP (Alexis Biochemicals) 
were added. When selective EP-receptor agonists were compared, 10 μM PGE2 was used.  
 
Flow cytometry 
All antibodies for flow cytometry were obtained from BD Biosciences, except for CCR7, 
2B4, CXCR3, CCR5, NKp80, NKp44, IL-22 (R&D Systems), NKp30 (BioLegend) and NKG2A, 
NKG2D, CD158A, CD158B, CD158D, CD158E (Miltenyi Biotec GMbH). Cells were incubated 
with antibodies at proper dilutions for 30 minutes at RT. Analyses were performed on a 
FACSCanto (BD Biosciences) and analyzed with BD CellQuestTM Pro Software (BD 
Biosciences), WinMDI (Joe Trotter, http://facs.scripps.edu/) or FlowJo (Treestar, Ashland, 
OR) software. 
 
Migration assay 
Migration of NK cells was analyzed as described previously (32). To analyze the effect of 
CCL5 reconstitution on NK cell recruitment, supernatant of IFN-γ/FMKp DCs matured in 
the presence of PGE2 was supplemented with 50 ng/ml CCL5. Migration of DC was 
analyzed as described previously (35). 
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Cytokine and chemokine secretion by DCs 
Quantification of IL-18, IL-12, IL-23, CCL5, CXCL10 and CCL19 in 24 h maturation 
supernatants was performed using ELISA (MBL International Corporation and R&D 
Systems) according to manufacturer’s instructions.  
 
Cytokine production by NK cells 
NK cell cells were either cultured in the presence of PGE2 and stimulated with 2,5 µg/ml 
phorbol 12-myristate 13-acetate (PMA) and 2 µg/ml ionomycin or with supernatant of DCs 
matured with different concentrations of PGE2. To analyze the effect of CCL5 on NK cell 
recruitment, supernatant of IFN-γ/FMKp DCs matured in the presence of PGE2 were 
supplemented with 2 ng/ml IL-12 and/or 100 pg/ml IL-18. Quantification of IFN-γ 
production was performed after 16 h of stimulation using an IFN-γ ELISA kit (R&D 
systems). 
To evaluate IL-22 production by NK cells obtained from tonsils, NK cells were incubated 
with DCs in 1:2 ratio. Flow cytometric analysis of IL-22 secreting NK cells was performed as 
described by Cella et al. (34). 
 
TH cell priming 
In a 96-well plate, IFN-γ/FMKp matured DCs (4x104 cells/well) were coated with 1 ng/ml 
Staphylococcal Enterotoxin B (SEB, Sigma-Aldrich) for 1 h. SEB-coated DCs, were washed 
and placed in culture with CD45RA+/RO-CD4+ T cells (1x105cells/well). Every other day 
stimulation medium was replaced with supernatant of NK-DC cultures. In these NK-DC 
cultures, IFN-γ/FMKp matured DCs or IFN-γ/FMKp + 1000 ng/ml PGE2 matured DCs (2x105 
cells/well) were cultured with/without NK cells (1x105 cells/well). At day 10 the expanded 
TH cells were washed, plated in 96-well plates (10
5 cells/well), and stimulated with 
PMA/ionomycin (BD Biosciences). After 4 h, cells were harvested and surface and 
intracellular staining was performed as described (32). 
 
NK cell cytotoxicity assay 
For NK cell-mediated lysis of K562, unstimulated NK cells were cocultured with K562 cells 
for 4 h in the presence of different concentrations of PGE2. For NK cell-mediated lysis of 
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Raji, NK cells were preactivated for 18 h by either supernatant of IFN-γ/FMKp DCs matured 
in the presence of different concentrations of PGE2, medium alone or medium containing 
1000 U/ml IL-2 (Proleukin, Chiron Benelux BV). Target cells were labeled with 3′-
dioctadecyloxacarbocyanine (DiO) according to the manufacturer’s instructions (Sigma) 
and 2 × 104 target cells were incubated with pre-activated NK cells at various 
effector:target (E:T) ratios for 12 h, each ratio in triplicate. Percentages of killed target 
cells (PI+DiO+) were determined by flow cytometry. Percentages specific lysis were 
calculated as follows (36): 
 % total target cell death - % spontaneous target cell death (PI+)             x 100% 
     % vital cells (% PI- cells not incubated with effector cells) 
 
Statistics 
Statistical significance of differences between experimental samples was determined 
using Student’s t test for paired samples, ANOVA or Wilcoxon signed-rank test. 
Significance was accepted at the P < 0.05 (*), P < 0.01 (**) and P < 0,001 (***) levels. Data 
were analyzed using Prism software version 5.00 (GraphPad Software). 
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Results 
 
PGE2 directly inhibits NK cell cytokine production and NK cell-mediated cytotoxicity 
We investigated whether PGE2 affects the expression of inhibitory and activating 
receptors on the NK cell surface. To this end, freshly isolated NK cells were cultured for   
24 h in the presence or absence of PGE2. As shown in Figure 1A, only expression of NKG2D 
(NK cells: mean MFI 60,3 ± 16 and NK cells + PGE2: mean MFI 34,8 ± 9,7 ) and 2B4 (NK 
cells: mean MFI 103 ± 4,5 and NK cells + PGE2: mean MFI 70,8 ± 2,9) is significantly 
(P<0,05) reduced in six different donors (Wilcoxon signed rank test) due to PGE2 
treatment. The expression of the other activating and inhibitory NK cell surface markers, 
including specific Killer Immunoglobulin Receptors (KIRs), did not change. Additionally, 
expression of the chemokine receptors CCR5, CXCR3 and CCR7 was evaluated, since these 
chemokine receptors are implicated in NK cell migration (29, 31). PGE2, however had no 
effect on the expression of these receptors. As PGE2 has been shown to enhance IL-23 
receptor expression by TH17 cells (15), we evaluated if PGE2 had the same effect on NK 
cells. Flow cytometric analysis showed that IL-23 receptor expression on NK cells was not 
altered. The effect of PGE2 on surface expression of the activating receptors 2B4 and 
NKG2D suggests that PGE2 has an inhibitory impact on NK cell effector functions. To 
evaluate this impact, cytotoxicity assays were performed in either the presence or 
absence of PGE2. As target cells, K562 cells were used, since these cells fail to express HLA 
class I and are therefore efficiently killed by NK cells. A dose-dependent decrease in 
cytolytic activity was observed when PGE2 was present during the cytotoxicity assay 
(Figure 1B). Similar data have been reported previously (37). To evaluate the effect of 
PGE2 on IFN-γ production, a second NK cell effector function, NK cells were stimulated 
with PMA and ionomycin in the presence or absence of different concentrations of PGE2 
and 16 h supernatant was evaluated by ELISA for the presence of IFN-γ production. PGE2 
dose-dependently inhibited IFN-γ secretion (Figure 1C).   
Taken together these results show that PGE2 has a direct effect on NK cells, as it 
downregulates the expression of the NK cell-activating receptors 2B4 and NKG2A and it 
dose-dependently inhibits NK cell-mediated cytotoxicity and IFN-γ secretion.  
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Figure 1. Direct effect of PGE2 on NK cell phenotype, cytotoxicity and cytokine secretion.  
Freshly isolated NK cells were cultured for 24 h in the presence of PGE2. (A) Phenotypic analysis of NK surface 
receptor expression. Filled histograms, NK cells without PGE2, Bold lines, NK cells with 1000 ng/ml PGE2. 
Representative data of one out of 6 different donors. (B) Flow cytometry-based NK cell cytotoxicity assay against 
K562 by NK cells cultured with different concentrations of PGE2. Data shown are triplicates of one representative 
experiment out of 4 different experiments. (C) IFN-γ production by NK cells cultured with different 
concentrations of PGE2 and stimulated for 16 h with PMA and ionomycin, as evaluated by ELISA. Results are 
presented as mean plus SEM and are obtained from 3 different donors. * P<0.05. 
 
Effect of PGE2 on DC-derived chemokines is imprinted during maturation and inhibits NK 
cell recruitment  
NK cells can be recruited by mature DCs ultimately leading to NK cell activation (31, 32, 
38). This recruitment depends on DC-derived chemokines of which CCL5, CXCL10 and 
CCL19 are the most important. To study whether PGE2 treatment of DCs influences NK cell 
recruitment due to effects on the DC chemokine profile, we evaluated CCL19, CXCL10 and 
CCL5 secretion by DCs after maturation in the presence or absence of PGE2. To this end, 
monocyte–derived DCs were matured with a membrane fraction of Klebsiella pneumoniae 
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(FMKp) and IFN-γ as previously described (35). DCs were matured for 6 h with IFN-γ/FMKp 
and different concentrations of PGE2. After washing, to remove all maturation factors, 
DCs were incubated for another 18 h in medium only (total maturation of 24 h). 
Effectiveness of DC washing was evaluated by detection of PGE2 by ELISA. In none of the 
samples PGE2 was found (data not shown), indicating that IFN-γ/FMKp matured DCs do 
not produce PGE2. Addition of PGE2 during DC maturation did not affect upregulation of 
HLA-DR and co-stimulatory molecules (CD80, CD83, CD86 and CD40), suggesting that 
addition of PGE2 to the maturation cocktail did not hinder the development of mature 
DCs (Supporting information Figure 1A). However, PGE2 did induce a significant increase in 
surface expression of CCR7 (Supporting information Figure 1B).  
Increased CCR7 expression by TLR-triggered DCs cultured in the presence of PGE2 has 
been described previously (39). IFN-γ/FMKp matured DCs also showed a dose-dependent 
increase of CCR7 expression, which indeed resulted in functionally increased 
responsiveness to the lymph-node associated chemokine CCL19 (Supporting information 
Figure 1C).  
Chemokine (CXCL10, CCL19 and CCL5) production was evaluated by culturing DCs for 14 h 
in the presence of different PGE2 concentrations and quantified by ELISA (Figure 2A). 
Production of these chemokines significantly decreased with increasing concentration of 
PGE2. Since CCR5 has been indentified to be the most important chemokine receptor 
responsible for NK cell recruitment by IFN-γ/FMKp matured DCs (32), the negative effect 
of PGE2 on CCL5 production suggested a decrease in the capacity of PGE2 matured DCs to 
recruit NK cells. To test this hypothesis, migration assays were performed. Freshly isolated 
NK cells were allowed to migrate during 1,5 h to supernatant of DCs matured in the 
presence of different concentrations of PGE2. NK cell recruitment was significantly 
decreased when increasing doses of PGE2 were added during DC maturation (Figure 2B). 
Since DCs were extensively washed after 6 h of maturation, DC supernatant did not 
contain any PGE2 anymore, therefore NK cells were not directly exposed to PGE2. This 
indicates that the negative effect on NK cell migration does not depend on an effect of 
PGE2 on NK cell chemokine receptors, which has previously been described (29). After 
supplementing the supernatant of PGE2 matured DCs with CCL5, NK cell recruitment was 
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restored, indicating that indeed the effect of PGE2 on CCL5 production was responsible for 
decreased NK cell recruitment (Figure 2C). 
 
 
Figure 2. PGE2 inhibits DC-derived CXCL10, CCL5 and CCL19 secretion. 
Monocyte-derived DCs were matured with IFN-γ/FMKp in the presence of different concentrations of PGE2. After 
6 h maturation, DCs were washed to remove the stimulation medium, and matured for an additional 18 h in  
AIM-V® medium only. (A) Quantitative comparison of CXCL10, CCL5 and CCL19 production as measured by ELISA. 
Results shown are the mean plus SEM of combined data of at least 5 different donors. (B) Percentage of NK cells 
migrated in 1.5 h toward cell free supernatant of IFN-γ/FMKp DCs matured in the presence of different 
concentrations of PGE2. Data were calculated as percentage of migrated NK cells. Results presented are the 
mean plus SEM of combined data of 11 different donors. (C) Percentage of NK cells migrated in 1.5 h toward cell 
free supernatant of IFN-γ/FMKp DCs matured in the presence of PGE2 and supplemented with 50 ng/ml CCL5. 
Data were calculated as percentage of migrated NK cells, normalized to NK cell migration toward IFN-γ/FMKp 
DCs matured without PGE2. Results presented are the mean plus SEM of combined data of 4 different donors.  
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DCs have been shown to express all four different EP receptors (40). To evaluate which EP 
receptors mediate the effect of PGE2 on chemokine production by DCs, they were 
stimulated with specific agonists that preferentially bind to one or more EP receptors 
(Figure 2D). Stimulation with butaprost and misoprostol reduced CXCL10 and misoprostol 
also inhibited CCL5 secretion significantly, whereas sulprostone did not alter secretion of 
these chemokines. This indicates that mainly EP2 and EP4 signaling are responsible for the 
effect of PGE2 on the reduced secretion of CXCL10 and CCL5. In contrast, CCL19 
production was equally affected by mistoprostol and butaprost, demonstrating that EP2 is 
the most important EP receptor involved in the inhibition of CCL19 production. The 
addition of the intracellular cAMP analogue dibutyryl-cAMP mimicked the effect of PGE2 
for production of all three chemokines, suggesting that the effect of PGE2 was dependent 
on cAMP signaling.  
To evaluate whether the effect of PGE2 on chemokine production by DCs is imprinted 
during maturation or whether PGE2 can also exert its suppressive effect after initiation of 
maturation, chemokine production of DCs was analyzed when PGE2 was added during or 
after the first 6 h of DC maturation. After 24 h maturation in total, chemokine production 
was evaluated (Figure 2E). A decrease in CXCL10 and CCL5 secretion could only be 
detected when PGE2 was present during the first 6 h of maturation. CCL19 production was 
also affected by PGE2 after the 6 h maturation period, however the effect was less 
pronounced as compared to the effect of immediate addition of PGE2.  
These results indicate that the negative effect of PGE2 on production of DC-derived 
CXCL10, CCL5 and CCL19 is imprinted during maturation and depends on EP2/EP4-
mediated cAMP signaling. In addition, we show that the NK cell recruiting capacity of DCs 
is reduced due to the influence of PGE2. 
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Figure 2. PGE2 inhibits DC-derive CXCL10, CCL5 and CCL19 secretion (continued). 
(D) Quantitative comparison of CXCL10, CCL5 and CCL19 production after stimulation with different EP receptor 
agonists and cAMP as measured by ELISA. Results shown are the mean plus SEM of combined data of at least 4 
different donors. (E) Quantitative comparison of CXCL10, CCL5 and CCL19 production after stimulation with PGE2 
either during or after DC maturation as measured by ELISA. Results shown are the mean plus SEM of combined 
data of at least 4 different donors. * P<0.05; ** P<0.01; *** P<0.001. 
 
Effect of PGE2 on DC-derived IL-12/IL-18 production is imprinted during maturation and 
inhibits NK cell IFN-γ secretion  
We previously showed that production of IL-12 and IL-18 by IFN-γ/FMKp matured DCs is 
needed to induce NK cell activation (32). To evaluate the effect of PGE2 on NK cell 
activation, production of these cytokines by IFN-γ/FMKp DCs stimulated with PGE2 was 
determined in 24 h DC-supernatant. As described previously, TLR-triggered DCs produce 
less IL-12 when matured in the presence of PGE2 (17, 39). We show here that PGE2 also 
has this effect on IL-12 production by IFN-γ/FMKp matured DCs and, additionally, PGE2 
triggering results in less IL-18 secretion (Figure 3A). Moreover, PGE2 exerted its effect on 
the secretion of these cytokines only when it was present during DC maturation, as 
evidenced by lack of inhibition of IL-12 and IL-18 production when PGE2 was added after 
the 6 h DC-maturation period (Figure 3B). 
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Figure 3. PGE2 inhibits DC-derived NK cell activation.  
Monocyte-derived DCs were matured with IFN-γ/FMKp in the presence of different concentrations of PGE2. After 
6 h maturation, DCs were washed to remove the stimulation medium, and matured for an additional 18 h in  
AIM-V® medium only. (A) Quantitative comparison of IL-12 and IL-18 production as measured by ELISA. Results 
shown are the mean of combined data of at least 4 different donors plus SEM (IL-12, n=16; IL-18, n=4). (B) 
Quantitative comparison of IL-12 and IL-18 production after stimulation with PGE2 either during or after 6 h DC 
maturation as measured by ELISA. Results shown are the mean of combined data of at least 3 different donors 
plus SEM.  
 
NK cell activation, evaluated by IFN-γ production of NK cells cultured for 16 h in DC 
supernatant, was significantly reduced when DCs were matured in the presence of PGE2 
(Figure 3C). NK cell activation was completely restored after addition of IL-12 to the 
supernatant of IFN-γ/FMKp DCs matured in the presence of PGE2, indicating that the 
effect of PGE2 on DC-mediated NK cell activation mainly depends on the inhibition of IL-12 
secretion (Figure 3D). Although the decrease in DC-mediated NK cell activation is caused 
by the decrease in IL-12 secretion, these data do not exclude that other factors might 
contribute. One candidate cytokine produced by TLR-triggered DCs in the presence of 
PGE2 is IL-23, a cytokine implicated in the induction of TH17 responses (19). Also IFN-
γ/FMKp matured DCs produce IL-23, which is enhanced when DCs are matured in the 
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presence of PGE2 (Figure 3E), albeit with an apparent optimum at 50 ng/ml PGE2. 
Addition of IL-23 to DC supernatant during NK cell activation did not affect IFN-γ 
production by NK cells (data not shown). 
These data indicate that PGE2 added to the maturation of DCs is not only responsible for 
decreased production of the NK-activating cytokines IL-12 and IL-18, but also enhances IL-
23 secretion.  
 
  
Figure 3. PGE2 inhibits DC-derived NK cell activation (continued).  
(C) NK cell IFN-γ production, as measured by ELISA, after incubation for 16 h with DC supernatant. Results 
presented are the mean plus SEM of combined data of 11 different donors. (D) NK cell IFN-γ production, as 
measured by ELISA, after incubation for 16 h with DC supernatant, or DC supernatant supplemented with 2ng/ml 
IL-12, 100pg/ml IL-18 or both. Results presented are the mean plus SEM of combined data of 6 different donors. 
(E) Quantitative comparison of IL-23 production as measured by ELISA. Results shown are the mean plus SEM of 
combined data of 4 different donors. * P<0.05; ** P<0.01; *** P<0.001. 
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Presence of PGE2 during DC maturation stimulates IL-22 production by NKp44+ NK cells 
isolated from human tonsils  
Recent studies showed that in mucosa-associated lymphoid tissue, a NK cell subset with 
inflammation restraining properties resides. This NKp44+ subset produces IL-22, IL-26, and 
LIF in response to IL-23 or after co-culture with TLR-matured DCs and are not proficient at 
typical NK cell functions such as cytotoxicity and IFN-γ secretion (34). In contrast to 
conventional NK cells, that secrete cytokines in response to IL-12, this NK cell 
subpopulation produces IL-22 after IL-23 triggering and, to a lesser extent, after triggering 
with IL-6 and IL-15.(34) Furthermore, these NKp44+ NK cells express the transcription 
factor RORγT and therefore show functional and phenotypic similarity to TH17 cells (41, 
42). Given the positive effect of PGE2 matured DCs on the induction of TH17 cells,(15) we 
hypothesized that the addition of PGE2 to IFN-γ/FMKp DC maturation may enhance 
activation of NKp44+ cells.  
 
Figure 4. Effect of PGE2 matured DCs on IL-22 production by NK cells residing in the tonsil. 
Monocyte-derived DCs were matured with IFN-γ/FMKp in the presence or absence of 50 ng/ml PGE2. After 6 h 
maturation, DCs were washed to remove the stimulation medium, and matured for an additional 18 h in AIM-V® 
medium only. (A) Percentage of NKp44+ NK cells isolated from tonsils, accumulating IL-22 after 16 h of coculture 
as analyzed by flow cytometry, gated on CD56+CD3- cells. Representative data of one out of 6 independent 
experiments are shown. (B) NKp44+ NK cells accumulating intracellular IL-22 of 7 different donors. In 6 out of 7 
donors there is an increase in % of IL-22 positive NK cells. Wilcoxon signed-rank test significance * P<0.05. 
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To test this hypothesis, NK cells were isolated from human tonsils and cocultured for 16 h 
with DCs that were matured in the presence or absence of 50 ng/ml PGE2. Production of 
IL-22 by NKp44+ NK cells was evaluated by flow cytometry. There was a significant increase 
in percentage of NK cells accumulating IL-22 when NK cells were cocultured with PGE2-
stimulated DCs as compared to cocultures with DCs matured in the absence of PGE2 
(Figure 4A, B). Notably, the IL-22 producing NK cell subset expressed NKp44+ and did not 
accumulate IFN-γ.  
Taken together, these data indicate that PGE2 is responsible for the induction of DCs that 
activate inflammation restraining NK cells.  
 
Decreased activation of NK cells by PGE2-matured DC inhibits NK cell-dependent TH1 
polarization and augmentation of cytotoxicity 
NK-derived IFN-γ has been implicated in the induction of TH1 polarization (31, 43). 
Consequently, it can be anticipated that the decreased activation of NK cells by DCs 
matured in the presence of PGE2 results in decreased TH1 polarization. To evaluate 
whether this hypothesis is true, DCs (washed after 6 h maturation) were matured with or 
without PGE2 and after 24 h NK cells were added. In this experiment we were only 
interested in the effect of NK cell-derived cytokines on TH1 polarization and not in the 
previously reported negative effect of PGE2 matured DCs on TH1 skewing. Therefore, DCs 
without PGE2 stimulation were coated with SEB and used in a T cell stimulation assay. To 
study the effect of NK cell-secreted cytokines, T cell stimulation medium was exchanged 
every other day by the supernatant of the NK-DC cocultures (Figure 5A). TH1 polarization 
was detected by accumulation of the TH1 cytokine IFN-γ (Figure 5B). Only T cells 
stimulated with medium of NK-DC cocultures, in which the DCs were not triggered with 
PGE2 during maturation, benefited from the TH1 polarizing effect of NK cells, as more IFN-
γ producing T cells were detected (Figure 5C).  
Previously, we showed that IFN-γ/FMKp matured DCs are able to augment NK cell 
cytotoxicity, which is mediated by DC-derived IL-12 (32). These observations opened the 
possibility that PGE2 triggering of DCs could abrogate the beneficial effect on NK cell 
cytotoxicity. To evaluate this, killing assays against the NK-cell resistant Raji cells were 
performed. Raji cells are insensitive for lysis by naive NK cells, however if NK cells are pre-
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activated, they become able to kill Raji cells. When DCs were matured with increasing 
concentrations of PGE2, NK cell-mediated lysis of target cells decreased (Figure 5D). These 
data indicate that PGE2 does not only inhibit NK cell cytotoxicity via direct action on NK 
cells (Figure 1B), but also indirectly affects augmentation of NK cell cytotoxicity via its 
effect on DC maturation. Taken together, these data show that PGE2 inhibits NK cell-
mediated cytotoxicity via two independent mechanisms. 
 
Figure 5. Effect of PGE2 matured DC on NK cell function. 
(A) IFN-γ/FMKp matured DCs with or without 5 µg/ml PGE2 were cultured for 24 h in the presence or absence of 
freshly isolated NK cells. IFN-γ/FMKp matured DCs were coated with Staphylococcal Enterotoxin B and 
cocultured with freshly isolated CD45RA+/RO-CD4+ TH cells, every other day stimulation medium was exchanged 
with supernatant from IFN-γ/FMKp matured DCs (with or without 5 µg/ml PGE2) cultured with or without NK 
cells. (B) Percentage of naive CD4+ T cells accumulating IFN-γ after 10 days of coculture and stimulation with 
PMA/ionomycin for 4 h as analyzed by flow cytometry, gated on CD4+CD3+ T cells. Representative data of one out 
of 3 independent experiments are shown. 
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Figure 5. Effect of PGE2 matured DC on NK cell function (continued). 
 (C) CD45RA+/RO-CD4+ TH cells accumulating intracellular IFN-γ of 5 different donors. Results presented are the 
mean of combined data of 5 different donors plus SEM. (D) Freshly isolated human NK cells and undiluted, 
filtered supernatants of IFN-γ/FMKp DCs matured in the presence of different concentrations of PGE2 were used 
for induction of NK cell cytotoxicity. NK cell cytotoxicity toward Raji cells was assessed by a flow cytometry-based 
kill assay. Data represent means ± SEM of triplicate wells. Data shown are representative of 3 independent 
experiments. (E) Cytotoxicity toward Raji without, after preincubation and early incubation of NK cells with PGE2 
and activation in DC supernatant. Data represent means plus SEM of triplicate wells of E:T ratio of 10:1. Data are 
representative of 3 independent experiments. * P<0.05. 
 
To determine whether activation of NK cells by NK-DC crosstalk could overcome the 
negative effect of PGE2 on NK cell mediated cytotoxicity, killing of Raji cells was tested 
with either NK cells pre-incubated with PGE2 (pre-incubation) before stimulation with DC 
supernatant or NK cells triggered with PGE2 during stimulation with DC supernatant (early 
incubation). Flow cytometric analysis showed that NK cells pre-incubated with PGE2 are 
able to kill Raji cells when activated by DCs (Figure 5E). When PGE2 was present during the 
NK cell activation kill of Raji cells was decreased. However, when NK cells are pre-activated 
by DCs, PGE2 had a minor inhibitory effect on NK cell cytotoxicity, indicating that the 
negative effect of PGE2 on NK cells is partly overcome.  
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In summary, these results show that PGE2 matured DCs inhibit NK-cell mediated TH1 
polarization and also suppress augmentation of NK cell killing capacity.  
 
 
Discussion 
 
COX2-derived PGE2 is abundantly expressed in various malignancies and is one of many 
factors that directly promote tumor growth by regulation of cancer cell proliferation, 
apoptosis, migration and invasion (7-11). Moreover, PGE2 plays a pivotal role in 
immunosuppression creating a tumor supportive environment by inhibiting tumor 
immune-surveillance. Increasing the knowledge about the mechanisms by which PGE2 
mediates immunosuppression is crucial in understanding tumor formation and might lead 
to the development of new immunotherapeutic strategies for cancer.  
In this paper, we report on a novel mechanism by which PGE2 inhibits NK cell effector 
functions. In addition to its inhibition of NK cell activation by direct binding to NK cells, 
PGE also inhibits crosstalk with IFN-γ/FMKp matured DCs. This is mediated via modulation 
of chemokine and cytokine secretion of IFN-γ/FMKp matured DCs, which is responsible for 
inhibition of NK cell recruitment and activation. We show that PGE2 has an inhibitory 
effect on the secretion of CCL5, CXCL10 and CCL19, which are implicated in NK cell 
migration (31, 38). Decreased production of DC-derived CCL19 (implicated in naïve T cell 
recruitment) and CCL5 due to PGE2 triggering has recently been described (22, 44). 
Interestingly, the effect of PGE2 on chemokine secretion is imprinted during DC 
maturation as we show that PGE2 stimulation after maturation does not influence 
chemokine secretion. 
Additionally, our data evidence that NK cell activation is altered due to the effect of PGE2 
on IFN-γ/FMKp DC-derived cytokine secretion. PGE2-induced changes in the IL-12/IL-23 
balance of DCs have been described to account for skewing of TH1 responses toward 
TH2/TH17 responses (15, 16, 19). Here, we show that it is also responsible for decreased 
IFN-γ secretion by NK cells. In addition, PGE2 is responsible for decreased production of IL-
18, which is besides IL-12 an important cytokine for NK cell activation. This is in apparent 
paradox, to the reported IL-18 mediated induction of PGE2 secretion in the synovial fluid 
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of osteoarthritis patients (45). Possibly, this represents a feed-back loop by which PGE2 
constrains inflammation during a normal immune response. Mainly the decreased 
production of IL-12 by IFN-γ/FMKp matured DCs due to PGE2 accounts for the inhibition 
on IFN-γ secretion, since addition of IL-12 restores IFN-γ secretion by NK cells. However, 
our data do not preclude that other cytokines that have an inhibitory effect on NK cell 
activation are produced by DCs in response to PGE2 triggering. As a functional 
consequence of the DC-mediated effect of PGE2 on NK cell activation, NK cell-dependent 
TH1 polarization and tumor cell lysis is inhibited. Interestingly, the reported effect of PGE2 
on NK-DC interaction was not only demonstrated for monocyte-derived DCs, but also for 
blood-derived BDCA1+ DCs that were matured with IFN-γ/FMKp in the presence of PGE2 
(Supporting Information Figure 2). Additionally, the effect of PGE2 could also be induced 
by tumor cell-derived PGE2 (Supporting Information Figure 3 A,B). Under different cell 
culture conditions the same tumor cells did not produce PGE2, but were still able, though 
less efficiently, to inhibit NK-DC crosstalk (Supporting Information Figure 3A,B). A possible 
candidate for this inhibition is TGF-β, which is possibly one of many immunosuppressive 
factors produced by this cell line (Supporting Information Figure 3C). Thereby these data 
illustrate the redundancy of different tumor-derived factors on NK-DC crosstalk, during 
different culture conditions. We anticipate that among the many mechanisms tumors 
have to escape immune surveillance, PGE2 is very potent to prevent NK-DC interactions 
because the application of COX-inhibitors in tumor bearing mice completely restores the 
reduced CCL5 and IL-12 production of myeloid cells (14, 44).  
In relation to the enhanced production of IL-23 by PGE2 stimulated DCs, it is relevant to 
note that Cella et al. reported on an NK cell subset (NK-22 cells) that resides in mucosa-
associated lymphoid tissue, expresses NKp44 and produces IL-22 rather than IFN-γ upon 
IL-23, IL-6 and IL-15 stimulation (34). Additionally, they showed that these NK cells 
produce IL-22, IL-26 and LIF after contact with IL-23 producing monocytes that were 
stimulated with LPS. This NK cell subset was suggested to contribute to mucosal 
homeostasis, since IL-22 induces production of the anti-inflammatory cytokine IL-10 by 
epithelial cells (34, 41, 46, 47). We show here that PGE2 is responsible for the maturation 
of DCs that are capable of inducing mucosal NKp44+, IL-22 secreting NK cells and not IFN-γ 
secreting peripheral NK cells. Given the fact that NKp44+ NK cells produce IL-22 in 
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response to IL-23, the increased IL-23 secretion of PGE2 matured IFN-γ/FMKp DCs could 
represent one of several mechanisms by which DCs induce IL-22 secretion of these NK 
cells.(34) In this light, it is interesting to note that IL-22 as well as tumor-derived PGE2 
have the same immune-protective effects on epithelial cells, which is characterized by 
increased proliferation and decreased apoptosis (7). It can be hypothesized that the IL-22, 
secreted by NK cells, also has this effect on tumor cells (Supporting Information Figure 4). 
Future studies addressing this question are of significance to elucidate the function of 
these NKp44+ NK cells in cancer. 
As demonstrated by us and others, PGE2 induces expression of CCR7 on DCs and 
functionally increases their migratory responsiveness to lymph node-homing chemokines 
in vitro (22, 35, 39). Based on these observations, PGE2 is often incorporated in DC 
maturation cocktails used in clinical vaccination studies. Our data on the inhibitory effect 
of PGE2 on NK-DC interaction in combination with previous reports on enhanced TH17 and 
TH2 induction by PGE2 matured DCs and the decreased ability to induce antigen specific 
CTLs (35) argue against the use of PGE2-matured DCs in dendritic cell-based vaccines, as it 
does not contribute to in vivo DC-migration and has detrimental effects on immune 
effector mechanisms. In addition, Muthuswamy et al. showed that increased CCR7 
expression of PGE2 matured DCs, as compared to TLR-matured DCs, correlates with their 
lack of CCL19 production (48). If TLR-matured DCs, that express low levels of CCR7, are 
cultured in an environment with low concentrations of CCL19, CCR7 expression is 
increased. Additionally, they showed in a clinical trial that PGE2-matured DCs 
demonstrated no advantage over TLR-triggered DCs in lymph node homing. In the current 
study, we show that the effect of PGE2 is imprinted during IFN-γ/FMKp DC maturation 
since cytokine and chemokine secretion is only affected by PGE2 in the first 6 h of 
maturation and this effect is mainly mediated via EP2 and EP4 and depends on cAMP 
signaling. In terms of vaccination protocols, these data support the application of ex vivo 
matured DCs in patients with tumors secreting PGE2. Moreover, our data indicate that 
PGE2 does not induce permanent changes in NK cell cytotoxic capacity, since the 
suppressive effect of PGE2 on NK cells can be easily overcome by DC-induced NK cell 
activation. However, to effectively activate NK cells, NK-DC interaction should take place 
in an environment with low concentrations of PGE2, emphasizing the need of NK cell 
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recruitment by DCs. Our results also open the possibility to combine DC vaccination with 
COX2-inhibitory therapy, which has previously been shown in mouse models to enhance 
the efficacy of cancer vaccines (49, 50).  
In conclusion, we report on a novel immunosuppressive effect of PGE2, mediated by IFN-
γ/FMKp matured DCs, on NK cell function. These current data help to understand the 
complex role of PGE2 in the regulation of immune responses during inflammation. The 
extent of effect of PGE2 on the immune system in relation to other tumor-derived factors 
and thereby the redundancy of this mechanism is yet not completely elucidated and in 
vivo studies should be performed to answer this question. However, we show in vitro that 
the immunosuppressive effect of PGE2 on NK-DC interaction possibly represents one of 
many tumor-mediated mechanism to hamper acute immune responses.  
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Figure. 1. Effect of PGE2 on surface expression of maturation markers by DCs matured with IFN- γ/FMKp and 
migration toward CCL19. 
Monocyte-derived DCs were differentiated for 5 days by IL-4 and GM-CSF to immature DCs. Maturation was 
induced by IFN-γ/FMKp in the presence or absence of 5 μg/ml PGE2. After 6 h maturation, DCs were washed to 
remove the stimulation medium, DCs were matured for an additional 18 h in AIM-V® medium only. (A) Surface 
expression of HLA-DR, CCR7, CD80, CD83, CD86 and CD40 was evaluated by flow cytometric analysis.  Gray filled 
histograms represent immature DCs, solid black lines IFN- γ/FMKp matured DCs and red line represent 
IFN-γ/FMKp matured DCs in the presence of 5 μg/ml PGE2. Representative data of one out of four different 
donors. (B) Expression of CCR7 as evaluated by flow cytometry. Results are presented as mean MFI plus SEM and 
are obtained from 3 different donors. (C) Percentage of DCs specifically migrated toward a CCL19 gradient (250 
ng/ml). Results are presented as mean plus SEM and are obtained from 3 different donors that were analyzed in 
triplicate. ANOVA significance * P<0.05, ** P<0.01. 
Chapter 5 
 
152 
 
Figure 2. Phenotype, cytokine production and NK cell activating properties of blood-derived BDCA1+ DCs. 
BDCA1+ DCs were isolated from 500 ml of fresh blood using an immunomagnetic, negative isolation kit (Miltenyi 
Biotec). Cells were seeded at a density of 5x105 cells/ml in a 24-well plate and matured with IFN- γ/FMKp or with 
IFN-γ/FMKp in the presence of PGE2. 6 h after maturation induction, the maturation stimuli were removed by 
extensive washing and DCs were incubated in serum-free medium for 42 h. (A) Flow cytometric characterization 
of differently matured BDCA1+ DCs. Gray, filled histograms represent the surface expression observed in 
non-matured BDCA1+ DCs, black line histograms represent the IFN-γ/FMKp matured and red line histograms 
represent IFN- γ/FMKp BDCA1+ DCs matured in the presence of PGE2. Representative data of 2 independent 
experiments are shown. (B) CCL5 production by differently matured BDCA1+ DCs as measured by ELISA. Data 
show the mean + SD of 2 independent experiments. (C) IFN- γ secretion of NK cells cultured in the supernatant of 
the three differently matured BDCA1+ DCs. Fresh NK cells were cultured in the supernatant of differently 
matured BDCA1+ DCs. After 24 h the supernatant was harvested and IFN- γ was quantified with ELISA. NK cells 
from 2 different donors were cultured in supernatants of 2 different BDCA1+ DC donors. (ANOVA significance 
*P<0.05). 
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Figure 3. Effect of A549 cell-derived factors on NK-DC interaction. (A) IL-12 secretion of IFN-γ/FMKp matured 
DCs in serum-free or A549 tumor cell-conditioned medium with or without PGE2. The A549 cell line was cultured 
for 48 h in serum-free AIM-V medium in presence or absence of (250µM) arachidonic acid (AA). Immature DCs 
were matured either in tumor cell-conditioned medium (PGE2-producing or not) or in AIM-V supplemented 
with IFN-γ/FMKp in the presence or absence of Rh-PGE2 (recombinant). After 6 h, maturation stimuli were 
washed away and DCs were incubated for an additional 18 h in AIM-V. Supernatant was collected and IL-12 was 
determined by ELISA. Data show the mean plus SEM of 2 donors. (B) NK cell-derived IFN-γ production in 
supernatant of IFN-γ/FMKp DCs matured in AIM-V or tumor cell-conditioned medium in presence or absence of 
PGE2 (recombinant or tumor cell-derived). Freshly isolated NK cells were co-cultured for 16 h with differently 
matured DCs. IFN-γ was quantified using Cytometric Bead Array. Shown results represent the mean plus SEM of 
NK cells from 2 different donors added to the supernatants of 2 different DC donors (n=4). (C) The A549 cell line 
was cultured for 4 days in serum free medium with (250µM) or without arachidonic acid. TGF-β and PGE2 were 
quantified using ELISA. 
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Figure 4. Model of the inflammation restraining effects of PGE2 on NK-DC interaction on tumor development. 
Presence of tumor-derived PGE2 during DC maturation inhibits  the production of NK cell-recruiting chemokines 
(CCL5, CCL19, CXCL10) and thereby decreases NK cell recruitment. Additionally, PGE2 reduces IL-18 production 
by DCs and shifts the IL-12/IL-23 balance toward IL-23 production. This results in decreased IFN-γ production and 
cytotoxic capacity of peripheral blood NK cells and enhanced secretion of IL-22 by NK cells residing in 
mucosa-associated lymphoid tissue. Decreased IFN-γ production of NK cells together with the altered cytokine 
profile of PGE2 matured DCs is responsible for inhibition of TH1 polarization. Tumor development is possibly 
stimulated by three independent effects of PGE2: 1) Direct effect of PGE2 on tumor cell proliferation and 
apoptosis, 2) decreased killing of tumor cells by NK cells that were either directly stimulated with PGE2 or 
interacted with PGE2 triggered DCs and 3) effects of IL-22, produced by NK cells that interacted with PGE2 
stimulated DCs, on tumor cell proliferation and apoptosis. 
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Abstract 
 
Mucin-1 (MUC1) is a heavily O-glycosylated, transmembrane protein that is expressed on 
the apical surface of most secretory epithelia. In malignantly transformed epithelia, MUC1 
has lost its apical distribution, is underglycosylated and is secreted into the circulation. 
Due to the underglycosylation of MUC1, cancer-specific MUC1-Tn/STn antigens, which are 
highly immunogenic, become exposed. We aimed at developing a system that allows 
detection of antibodies directed to the native form of MUC1 and the underglycosylated 
MUC1-Tn epitopes. To this end, we made use of the Chinese Hamster Ovary (CHO) ldlD 
cell line stably transfected with MUC1. This cell line has a glycosylation defect, which can 
be reversed by addition of different monosaccharides to the cell culture and enables the 
production of cells expressing the MUC1-Tn glycoforms. After validation with glyco-
specific antibodies, the CHO-ldlD MUC1 system was used to detect serum MUC1 and 
MUC1-Tn antibodies. Using this system, we could confirm the presence of MUC1-Tn 
antibodies in the serum of a patient vaccinated with a truncated MUC1 peptide. This 
indicates that the CHO-ldlD MUC1 system represents a flow cytometry-based technique to 
detect antibodies binding to the underglycosylated MUC1 protein. This cellular system is 
complementary to previously published methods to detect MUC1 serum antibodies, since 
the antibodies to the native protein are evaluated and therefore it can be effectively used 
for MUC1 antibody monitoring in vaccination studies as well as for functional assays. 
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Introduction 
  
The transmembrane protein Mucin-1 (MUC1) is a heavily glycosylated protein, which is 
expressed on the apical surface of most secretory epithelia as well as on a variety of 
hematopoietic cells (1, 2). The extracellular domain of MUC1 consists of a variable number 
of 20 amino acid tandem repeats (HGVTSAPDTRPAPGSTAPPA). Within each tandem 
repeat, two serines and three threonines represent five potential O-glycosylation sites 
that are extensively glycosylated (Figure 1). The extent of glycosylation depends on the 
expression of tissue-specific glycosyltransferases (2).  
In most adenocarcinomas and some hematological malignancies, it has been 
demonstrated that MUC1 is overexpressed, lost its apical distribution and is secreted into 
the circulation (3-7). Moreover, the extracellular MUC1 domain is aberrantly glycosylated, 
which is caused by upregulation of sialyltransferases and downregulation of 
glycosyltransferases resulting in premature termination of glycosylation (8, 9). Altered 
MUC1 expression has been shown to increase tumorigenicity, by at least four different 
mechanisms. First, altered MUC1 expression has been coupled with enhanced metastasis 
formation due to direct binding of cancer-associated MUC1 to ligands augmenting cancer 
cell-endothelial cell adhesion (10). Second, signaling of the intracellular MUC1 domain is 
responsible for stabilization of growth factor receptors thereby enhancing cell 
proliferation (11). Third, MUC1 directly binds p53 inducing decreased production of 
apoptotic genes thereby supporting cell survival (12). Fourth, overexpression of MUC1 can 
reduce intercellular adhesion due to steric hindrance, allowing tumor cells to escape from 
immune recognition (13). 
Next to the tumor supporting capacity of MUC1, alteration of MUC1 can also increase the 
immunogenicity of tumor cells. Due to decreased MUC1 glycosylation, new tumor-
associated epitopes, which were normally masked by large sugar moieties, become 
exposed (14). MUC1-associated antigens frequently expressed in cancer are the 
immunogenic Tn (GalNAc-) and T (Galβ1-3GalNAc-) antigens along with their sialylated 
versions (ST and STn) (15, 16). Since it has been suggested that these antigens are not 
subjected to immune-tolerance, they represent attractive tumor associated antigens to 
target with immunotherapy (17, 18).  
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Figure 1. Schematic presentation of O-glycosylation of MUC1.  
O-linked glycosylation is initiated by (a) polypeptide N-acetylgalactosaminyltransferases (GalNAc-Ts), which links 
N-acetylgalactosamine (GalNAc) to a serine (Ser) or threonine (Thr) of the polypeptide backbone and results in 
the formation of the Tn antigen. This can be followed by sialic acid linkage to the GalNAc moiety, which is 
catalyzed by (b) sialyltransferase ST6GalNAc-I, and as a consequence the sialyl-Tn (STn) antigen is formed. If not 
sialylated, elongation of glycosylation can either form core 3 and 4 antigens or core 1 structures may be 
synthesized by (c) galactosyltransferase ß3GalT, which add galactose (Gal) to the GalNAc moiety, resulting in the 
T (core 1) antigen. Also the T antigen can become sialylated creating ST antigens by either linking syalic acid to 
the GalNAc moiety, catalyzed by (d) ST6GalNAc-I, II or to the Gal moiety, catalyzed by (e) ST3Gal-I. Additionally 
both Gal and GalNac can become sialylated. Linkage of more sugar moieties to the Tn antigen will result in the 
elongation of Core 1 structures or formation of core 2 antigens. 
 
 
The immunogenicity of MUC1 has been confirmed by the detection of anti-MUC1 
antibodies in the serum of healthy controls, as well as cancer patients (19). In many 
malignancies it has been demonstrated that MUC1 serum antibodies, which are able to 
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mediate antibody-dependent cellular cytotoxicity (ADCC) (20), are increased and correlate 
with a better prognosis (4, 21). However, in some cancer patients the presence of MUC1 
antibodies is decreased, due to immune complex formation with circulating MUC1 (4, 22). 
It can be anticipated that enhancement of anti-MUC1 immune responses by 
immunotherapy could induce strong antitumor responses. Studies using MUC1 antibody-, 
MUC1 peptide-, or DC-based vaccination strategies have been shown to be safe and 
feasible (17, 23-25). Additionally, these studies show promising results by boosting the 
immune response of cancer patients. 
Besides mounting clinical outcome, there is an urgent need for tools which monitor 
immune responses against tumor-associated, aberrant MUC1 glycosylation patterns. It can 
be anticipated, that monitoring of humoral immune responses with a system that detects 
responses to underglycosylated MUC1 might correlate better with clinical responses than 
evaluation with the current available techniques (26). Therefore, it is relevant to develop a 
system in which MUC1 glycosylation can be manipulated to detect immune responses 
against these underglycosylated MUC1 epitopes.  
In this study, we present a flow cytometry-based method to evaluate the presence of 
antibodies directed to MUC1-Tn epitopes in serum. To this end, we made use of the 
Chinese Hamster Ovary (CHO) ldlD cell line, which is deficient in its UDP-galactose/UDP-N-
acetylgalactosamine 4-epimerase enzyme (27, 28). This enzyme is crucial for the formation 
of UDP-Gal and UDP-GalNAc from UDP-Glc/GlcNAc and as a consequence both N-linked 
and O-linked glycosylation are affected by the defect. The glycosylation can be restored by 
providing the CHO-ldlD cell with exogenous sources of Gal and GalNAc (27).  
We used the CHO-ldlD cells stably transfected with a full coding sequence of the MUC1 
protein (32 tandem repeats), enabling the production of cells expressing specific MUC1 
glycoforms. After validation of this system by glycosylation-specific as well as MUC1-
specific antibodies, we used these cells to screen antibodies recognizing MUC1-Tn 
epitopes in sera from breast cancer patients, healthy controls and a breast cancer patient 
vaccinated with a keyhole limpet hemocyanin-conjugated truncated MUC1 peptide.  
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Materials and methods 
 
Cell culture 
CHO-ldlD and CHO-ldlD cells stably transfected with MUC1F were cultured in Iscove’s 
Modified Dulbecco Medium supplemented with 3% FBS, 1% penicilline/streptomycin and 
600 µg/ml G418. The UDP-Gal/UDP-GalNAc 4-epimerase deficient CHO-ldlD MUC1 cells 
and the CHO-ldlD cells, which served as a negative control, were cultured for 3 days with 
1mM GalNAc (Sigma-Aldrich, St. Louis, MO, USA), inducing them to express Tn-MUC1 or 
with 1mM GalNAc and 0.1 mM Gal (Sigma-Aldrich), inducing them to express T-MUC1 
(Figure 1). 
 
Serum  
Frozen serum (-20°C) of five healthy controls and seven breast cancer patients were 
obtained from the department of clinical chemistry (Maastricht University Medical 
Center+). A positive serum sample, from a breast cancer patient, vaccinated with a keyhole 
limpet hemocyanin-conjugated truncated MUC1 peptide, expressing anti-Tn-MUC1 
antibodies was used as a positive control (29, 30). 
 
Antibodies 
MUC1 antibody 214D4 (purified from the supernatant of the 214D4 cell line (31)) was 
kindly provided by Dr. J. Hilkens (the Netherlands Cancer Institute, Amsterdam, the 
Netherlands), MAb 5E5 (16) and MAb 5F4 (32) were used for flow cytometric evaluation of 
MUC1 eptitope expression by CHO-ldlD MUC1 cells. A detailed description of the 
specificities of the MUC1 antibodies used in this study has been published previously (6). 
Briefly, the MAb 214D4 recognizes human MUC1 irrespective of its glycosylation pattern, 
MAb 5E5 exclusively recognizes MUC1-Tn/STn and MAb 5F4 recognizes Tn epitopes 
irrespective of peptide backbone they are associated with. 
 
Flow cytometry  
CHO-ldlD and CHO-ldlD MUC1F cells supplemented with either Gal, GalNAc, or Gal and 
GalNAC were incubated with different antibodies (MAb 214D4, 5E5 or 5F4), washed and 
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incubated with the secondary antibody goat-anti-mouse R-phycoerithrin (PE) labelled (BD 
Biosciences, San Jose, CA, USA). For the detection of human serum antibodies, CHO-ldlD 
and CHO-ldlD MUC1 cells supplemented with either Gal, GalNAc, or Gal and GalNAC were 
preincubated with rat serum, washed and incubated with 20 and 40 times diluted serum. 
Cells were then incubated with a secondary Donkey-anti-Human R-phycoerithrin (PE) 
labelled antibody, which is preabsorbed for rat (Jackson ImmunoResearch, West Grove, 
PA, USA). 7-amino-actinomycin D (7AAD) was used to differentiate between viable and 
dead cells. All antibody incubations were performed at 4°C for 1h. Reactivity of antibodies 
with the CHO-ldlD and CHO-ldlD MUC1F cells was analysed by flow cytometry using a BD 
FACSSort (BD Biosciences) and data were analyzed with BD CellQuestTM Pro Software (BD 
Biosciences). 
 
 
Results 
 
Detection of O-glycosylation of MUC1 after GalNAc and/or Gal supplementation 
To confirm surface expression of MUC1 by the CHO-ldlD MUC1 cells, reactivity of the cells 
with MAb 214D4, recognizing MUC1 irrespective of its glycosylation was analysed. The 
results of flow cytometric analysis showed that the non-transfected CHO-ldlD cells do not 
bind with the 214D4 antibody, whereas the CHO-ldlD MUC1 cells do (MFI of 4,43 and 210, 
respectively) (Figure 2A).  
To evaluate whether the glycosylation defect of the CHO-ldlD cells can be reversed by 
supplementing the culture medium with GalNAc and/or Gal, we performed binding 
experiments with antibodies specific for different MUC1-assocated, O-glycan structures 
(or O-glycan haptens). O-glycosylation of MUC1 is initiated after binding of GalNAc to one 
of the glycosylation sites (threonine or serine), creating the MUC1-Tn epitope. Thereafter, 
glycosylation is continued by linking of Gal to the first GalNAc (Figure 1). To induce 
glycosylation, CHO-ldlD and CHO-ldlD MUC1 cells were cultured for 3 days in the presence 
of GalNAc, Gal or a combination of both GalNAc and Gal. The cells were then harvested 
and binding with MAb 5E5, which specifically recognizes the combined glycopeptide 
epitope MUC1-Tn/STn (16), was assessed with flow cytometry. When CHO-ldlD MUC1 cells 
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were cultured in medium supplemented with GalNAc, a shift in 5E5 binding signal was 
observed as compared to CHO-ldlD MUC1 cells cultured without sugar (MFI increased 
from 25 to 213) (Figure 2B). 
This shift in 5E5 binding signal was not observed in untransfected CHO-ldlD cells incubated 
with GalNAc. In addition to 5E5 MAb binding, MUC1 glycosylation was further analyzed by 
staining with MAb 5F4, which recognizes Tn epitopes irrespective of the peptide 
backbone. Also with this antibody, a shift in binding signal was observed when CHO-ldlD 
MUC1 cells were cultured in GalNAc-containing medium (MFI increased from 6,8 to 33) 
(Figure 2B). These shifts in 5E5 and 5F4 binding indicate that supplementation with 
GalNAc results in MUC1-Tn epitope formation.   
When in addition to GalNAc also Gal was added to the medium, decreased binding of MAb 
5E5 was detected (Figure 2B), indicating that glycosylation proceeds after Gal linking to 
the first GalNAc. In contrast, neither supplementation of Gal alone to the CHO-ldlD MUC1 
cells nor the addition of any monosaccharide to the CHO-ldlD cells resulted in the 
formation of MUC1-Tn epitopes (data not shown). These data reveal that it is possible to 
reconstitute MUC1 O-glycosylation in the CHO-ldlD MUC1 cells by GalNAc 
supplementation, which results in MUC1-Tn epitope formation and if Gal is also 
supplemented the surface expression of these epitopes decreases (MFI 6.9). 
 
       A 
 
 
 
 
 
 
 
 
Figure 2. Expression of MUC1 and MUC1-Tn epitopes by CHO-ldlD MUC1 cells as analyzed by flow cytometry. 
CHO-ldlD and CHO-ldlD MUC1 cells were cultured for 3 days in the presence or absence of GalNAc, Gal or the 
combination of GalNAc and Gal. Analysed cells were gated on 7AAD-. (A) Binding of MAb 214D4 (recognizing 
MUC1) by CHO-ldlD cells and CHO-ldlD cells transfected with MUC1.  
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Figure 2. Expression of MUC1 and MUC1-Tn epitopes by CHO-ldlD MUC1 cells as analyzed by flow cytometry 
(continued). (B) Binding of MAb 214D4, 5E5 (recognizing MUC1-Tn/STn) or MAb 5F4 (recognizing STn) by CHO-
ldlD and CHO-ldlD MUC1 cells cultured with or without GalNAc or GalNAc and Gal. ND, not determined. 
 
Optimization of CHO-ldlD MUC1 flow cytometric analysis 
The use of CHO-ldlD cells for flow cytometric analysis is complicated by the culture 
characteristics of the CHO-ldlD cells and therefore needed optimization. Since the CHO-
ldlD cells scavenge the medium for free Gal and GalNAc, they must be cultured at low 
serum concentrations, to preserve the glycosylation defect. Additionally, because CHO-
ldlD cells are adherent, the generation of a single cell suspension is accompanied by cell 
death. Dead cells are responsible for aspecific binding of antibodies and co-staining with 
7AAD showed that in the 7AAD positive population there is a subpopulation clearly 
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positive for the MUC1 antibodies (Figure 3A). Moreover, reactivity with isotype antibody 
control could be detected, confirming the aspecific staining of the 7AAD positive cells.  
To decrease the amount of dead cells and increase the yield, two different harvesting 
techniques were evaluated. Cell scraping was compared with trypsinization of the CHO-
ldlD MUC1 cells. In contrast to cell scraping, trypsinization reduced the number of dead 
cells by 30%, however flow cytometric analysis showed that trypsinization induced 
expression of new epitiopes reactive with the MUC1 specific antibodies, but not isotype 
control antibody (Figure 3B). Cleaving of the MUC1 peptide by trypsin could be 
responsible for this new epitope formation. Even though cell scraping induces a lot of cell 
death, it remains the preferred option in this system since death cells can be excluded 
using 7AAD staining.  
 
 
 
Figure 3. Optimization of CHO-ldlD culture for flow cytometric analysis. 
(A) CHO-ldlD cells were cultured in monolayer were scraped, incubated with isotype (IgG1) and anti-MUC1 
antibodies (MAb 214D4 and 5E5). Before analysis cells were stained with 7AAD. Without gating (left panel) a 
population of CHO-ldlD cells is positive for all antibodies, which is due to the two subpopulations of 7AAD+ cells 
(middle panel) and which not present after gating on 7AAD- cells (right panel). (B) Comparison antibody (isotype, 
214D4, 5E5) binding of CHO-ldlD MUC1 cells after being scraped or trypsinized.  
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Detection of serum antibodies directed to MUC1-Tn/STn epitopes in healthy controls 
and (vaccinated) breast cancer patients.  
As shown in figure 2, the CHO-ldlD MUC1 system is effective in generating MUC1-Tn 
epitopes. To analyse if MUC1-Tn antibodies are present in sera of breast cancer patients 
as well as in healthy controls, CHO-ldlD MUC1 cells were cultured in the presence or 
absence of GalNAc and prior to flow cytometric analysis cells were incubated with human 
serum. The CHO-ldlD cells were taken along as a negative control, to exclude aspecific or 
specific reactivity. Secondary antibody staining was performed for detection of serum 
antibodies to MUC1 and Tn-MUC1. Both anti-human IgM- and IgG-detecting secondary 
antibodies were used to discriminate between primary (IgM) and secondary humoral 
responses (IgG). Healthy controls as well as breast cancer patients did not show specific 
binding of serum antibodies with CHO-ldlD MUC1 cells cultured with or without GalNAc. 
Even though in the serum of breast cancer patients repetitively a marginal shift of the 
histogram could be observed when a secondary IgM-recognizing antibody was used 
(Figure 4A).  
In contrast, a post-vaccination serum sample of a breast cancer patient vaccinated with a 
keyhole limpet hemocyanin-conjugated truncated MUC1 peptide, which was tested 
positive for antibodies directed to aberrantly glycosylated MUC1 by O-glycopeptide 
microarray (33), showed an increased binding signal after incubation with CHO-ldlD MUC1 
cells (Increase in MFI of anti-IgG binding from 53.7 to 127 and of anti-IgM binding form 5.4 
to 9.4). Moreover, both IgG and IgM antibodies directed to MUC1-Tnepitopes were 
present in this serum (increase in MFI of anti-IgG binding from 91.7 to 143 and of anti-IgM 
binding form 8.4 to 12.9). To confirm that reactivity to CHO-ldlD MUC1 cells cultured with 
GalNAc was actually directed to MUC1 Tn epitopes and not to the MUC1 protein, antibody 
reactivity to CHO-ldlD MUC1 cells cultured with GalNAc and Gal, restoring glycosylation, 
was analyzed. No antibody reactivity was detected if serum was incubated with these 
CHO-ldlD MUC1 cells (Figure 4B), indicating that the antibodies were indeed MUC1 Tn 
specific.  
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Figure 4. Presence of MUC1-Tn antibodies in serum of breast cancer patients and healthy controls.  
CHO-ldlD and CHO-ldlD MUC1 cells were cultured for 3 days in the presence or absence of GalNAc, Gal or the 
combination of GalNAc and Gal. Cells were incubated with serum, analyzed by flow cytometry and gated on 
7AAD-. (A) Expression of MUC1 and MUC1-Tn IgG and IgM antibodies by breast cancer patients (representative 
data of one out of seven patients), healthy controls (representative data of one out of five patients) or a breast 
cancer patient, vaccinated with a keyhole limpet hemocyanin-conjugated truncated MUC1 peptide (this sample 
was tested in two independent experiments). Only the serum from the vaccinated patient contained MUC1-Tn 
IgG and IgM antibodies and thus reacted with the CHO-ldlD MUC1 cells cultured with GalNAc, however (B) when 
CHO-ldlD MUC1 cell were cultured in the presence of both Gal and GalNAc, reactivity with the anti-IgG antibody 
decreased. 
  
 
Discussion 
 
In the present study we describe a flow cytometric method to detect both MUC1 and 
MUC1-Tn antibodies in human serum. To this end, we used CHO-ldlD cells stably 
transfected with MUC1. Due to its UDP-Gal/UDP-GalNAc 4-epimerase enzyme deficiency, 
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the glycosylation of MUC1 can be effectively manipulated by addition of different 
monosaccharides. Supplementation of GalNAc to the cell culture results in the formation 
of the cancer-associated MUC1-Tn epitope that can be detected by flow cytometry using 
glycospecific MUC1 antibodies. Additionally, the detection of these MUC1-Tn epitopes is 
decreased after supplementation of both Gal and GalNAc, which presumably is caused by 
extension of glycosylation. The capacity of CHO-ldlD cells to express MUC1-Tn antigens, as 
detected by cytospin analysis, has been reported by Sørensen et al. (17). In this report, we 
extend these observations by showing that expression of MUC1 and MUC1-Tn epitopes 
can also be detected with flow cytometry, which is a more sensitive method that 
quantifies expression (34).   
With the CHO-ldlD MUC1-based flow cytometric assay, we do not detect serum antibodies 
against the unglycosylated MUC1 protein in non-vaccinated breast cancer patients. 
However, both IgG and IgM antibodies can be detected in the serum of a breast cancer 
patient vaccinated with a truncated MUC1 peptide, indicating that immune responses 
induced by immunotherapy can be detected with this flow cytometric system. Detection 
of antibodies against unglycosylated MUC1 seems to be in apparent contrast with 
previous reports by Altschuler et al, who showed that CHO-ldlD cells rapidly endocytose 
and degrade non-glycosylated surface MUC1 (35). Nevertheless, MUC1 expression can be 
detected by flow cytometry with MAb 214D4 when the CHO-ldlD culture is not 
supplemented with any carbohydrate, indicating that CHO-ldlD still express non-
glycosylated surface MUC1.  
Detection by ELISA and Western Blot of anti-MUC1 antibodies in serum of cancer patients 
as well as healthy controls has been described previously. However, the percentage of 
patients and controls expressing these antibodies show large variations between studies 
(4, 36-39). In some studies, MUC1 serum antibodies could not be detected in healthy 
controls (39), whereas other studies demonstrated that up to 16% of healthy controls 
show reactivity to MUC1 peptides (37). In cancer patients, the reported levels of anti-
MUC1 antibodies also differ, due to the presence of soluble serum MUC1. Depending on 
tumor type, these serum MUC1 antigens have been shown to complex with anti-MUC1 
antibodies (4). Standardization of the different methods, including the flow cytometric 
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assay we describe, seems to be necessary to answer the question on prevalence of anti-
MUC serum antibodies in healthy controls and cancer patients. The number of samples 
tested in this study do not justify a conclusion on prevalence of these antibodies, we 
merely show that with this technique we are able to detect human serum antibodies 
directed to MUC1 and underglycosylated MUC1.  
In addition to the detection of serum antibodies against unglycosylated MUC1, 
manipulation of MUC1 glycosylation in the CHO-ldlD MUC1 system allowed us to 
selectively test for the presence of IgG and IgM antibody responses to MUC1-Tn. These 
serum antibodies could only be detected in a breast cancer patient after vaccination and 
not in non-vaccinated cancer patients or healthy controls. Detection of antibodies directed 
to underglycosylated MUC1 has been recently described by Wandall et al. (29), who made 
use of an O-glycopeptide microarray to demonstrate that MUC1-Tn/STn associated IgG 
serum antibodies are present in low numbers of newly diagnosed breast, ovarian and 
prostate cancer patients and not in healthy controls. Additionally, in patients who had no 
pre-existing MUC1-Tn/STn IgG antibodies, it was shown that they did develop detectable 
serum IgG and IgM MUC1-Tn antibodies after vaccination. Similar findings were previously 
described by Sabbatini et al. (30), who demonstrated that MUC1-Tn antibodies could be 
detected by ELISA. 
Both, ELISA and O-glycopeptide microarrays make use of small MUC1 peptides that are 
differently glycosylated. The O-glycopeptide microarray allows rapid mapping of serum 
antibody specificity and has already been proven to be reliable in detection of MUC1 
serum antibodies in mice vaccination studies (40). Even though the glycosylation sites can 
be controlled in the small peptide-based methods, allowing specific antibody mapping, 
these methods are only able to detect antibodies binding to linear MUC1 structures. In 
contrast to this highly sensitive method, which can be efficiently used for detection of 
cancer biomarkers, the CHO-ldlD MUC1 system is able to detect antibodies to the native, 
three dimensional MUC1. Moreover, since it is a cellular system, it is possible to do in vitro 
functionality studies like ADCC and complement activation. This makes the CHO-ldlD 
MUC1 system complementary to the previously published methods to detect MUC1 
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serum antibodies, since the clinical significance of underglycosylated MUC1-antibodies in 
relation to cancer is largely unknown. 
In conclusion, we report on a cellular, flow cytometry-based technique to detect serum 
MUC1-Tn antibodies. We show that it is a unique system to detect antibodies binding to 
the native underglycosylated MUC1 protein and can be effectively used for antibody 
monitoring and functional assays. 
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Abstract 
 
Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is a treatment option 
for patients with hematopoietic malignancies that is hampered by treatment-related 
morbidity and mortality, in part the result of opportunistic infections, a direct 
consequence of delayed T cell recovery. Thymic output can be improved by facilitation of 
thymic immigration, known to require precommitment of CD34+ cells. We demonstrate 
that Deltalike ligand-mediated predifferentiation of mobilized CD34+ cells in vitro results in 
a population of thymocyte-like cells arrested at a T/natural killer (NK) cell progenitor 
stage. On intrahepatic transfer to Rag2-/-γc-/- mice, these cells selectively home to the 
thymus and differentiate toward surface T cell receptor-αβ+ mature T cells considerably 
faster than animals transplanted with noncultured CD34+ cells. This finding creates the 
opportunity to develop an early T-cell reconstitution therapy to combine with HSCT. 
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 Introduction 
 
Haploidentical hematopoietic stem cell transplantation (haplo- HSCT) has shown 
impressive results in the treatment of leukemia (1, 2). HSCT is hampered by treatment-
related mortality resulting from opportunistic infections (2-4). One obvious causative 
factor for enhanced susceptibility to pathogens is the slow recovery of T cells in the 
periphery (3, 5). In mice, it is established that T-lineage-directed progenitors generated in 
vitro have the capacity to migrate to the thymus and complete their development into 
host-tolerant T cells (6, 7). Because repopulation of the thymus after transplantation is 
considered a rate-limiting process, supplementation of in vitro pre-T-lineage-directed cells 
may be one approach with potential to improve T cell levels after HSCT. However, not 
much is known about the in vitro T-lineage commitment potential of granulocyte colony-
stimulating factor mobilized CD34+ (mCD34+) cells commonly used for haplo-HSCT. To 
stimulate development of T-lineage-directed cells, we use the TSt-4 murine thymic stromal 
cell line (8) transduced with human Delta-like ligand (hDLL), demonstrated to have the 
capacity to generate T-lineage-directed cells from cord blood (CB) CD34+ cells (9). 
Importantly, the T-lineage-directed cells were arrested at the CD5+CD7+ stage, considered 
to be the murine equivalent of double-negative 2 or 3 thymocytes, the designated stage of 
T-lineage development suitable for direct thymic reconstitution. The goal of this study is to 
examine the potential of mCD34+ cells to generate T-lineage-directed progenitors, 
determine whether this potential is influenced by a specific Notch ligand, and investigate 
whether mCD34+ cell-derived progenitors have the capacity to home to and mature in the 
thymus. 
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Materials and methods 
 
Cells 
Mobilized CD34+ stem cells were isolated from peripheral blood mononuclear cells (PBMC) 
obtained from healthy volunteers (V1–3) treated with G-CSF (Neupogen, Amgen Inc., 
Thousand Oaks, CA) at MUMC+ (Maastricht, The Netherlands). Isolation was performed 
with the Isolex 300i Magnetic cell selection system v2.5 (Baxter oncology, Brussels, 
Belgium) using the Isolex stem cell reagent kit (Miltenyi Biotec GmbH, Bergisch Gladbach, 
Germany) according to the manufacturer’s instructions. The positive fraction was frozen at 
a concentration of 5 × 106 cells per ml per vial. Purity of mobilized and CB cells, obtained 
after informed consent, was more than or equal to 95% CD34+ cells and less than or equal 
to 0.1% contaminating CD3/CD56+ cells. Informed consent was obtained from all CD34+ 
cell donors in accordance with the Declaration of Helsinki. TSt-4 cell lines (8-10) and K562 
were grown in standard media. 
Fresh human CB was obtained with parent written informed consent from healthy full-
term newborns (Department of Gynecology and Obstetrics, Ospedale San Giovanni, 
Bellinzona, Switzerland). After density gradient centrifugation, CD34+ CB cells were 
enriched using immunomagnetic beads according to the manufacturer’s instructions 
(CD34+ selection kit, Miltenyi). Samples were evaluated by FACS for CD34+ and CD3+ cell 
content. If CD34+ purity was < 95% and/or CD3+ cells were ≥ 0.1%, the sample was 
enriched again until these values were met, after which cells were frozen. 
Natural killer (NK) cells were enriched from peripheral blood of healthy donors using the 
NK isolation kit according to the manufacturer’s instructions (Miltenyi Biotec). 
Thymic stromal cell lines TSt-4 (8) and TSt-4 transduced with hDLL1 or hDLL4 (10) were 
maintained in RPMI 1640 (Sigma-Aldrich Co., St. Louis, MO) containing 5% fetal bovine 
serum (FBS, Greiner Bio-one, Solingen, Germany), 1% penicilline-streptomycine (PS), 1 
mM sodium pyruvate, 0.1 mM MEM non essential amino acids (NEAA), and 5 × 10−5 M 2-
mercaptoethanol (βME) (all from Invitrogen Ltd., Paisley, UK). The HLA Class I negative 
erythro-myeloid leukemia cell line K562 was grown in RPMI 1640 (Invitrogen) 
supplemented with 10% FBS and 1% PS. 
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Flow cytometry 
All antibodies, materials and equipment were obtained from BD Biosciences 
(Erembodegem, Belgium), unless stated otherwise. All materials were used according to 
the manufacturer’s instructions. At different time points, cells were analyzed using 
different combinations of fluorescein isothiocyanate (FITC), R-phycoerithrin (PE), PE-
Cyanine dye 7 (PE-Cy7), peridinin chlorophyll-a protein (PerCP)-, allophycocyanin (APC), 
and APC-H7 conjugated monoclonal antibodies (mAbs). The following antibodies (clones) 
were used: CD1a (HI149), CD2 (6G4- Sanguin, Amsterdam, The Netherlands), CD3 (UCHT1, 
SK7), CD4 (SK3, 13B8.2 – Beckman Coulter, Fullerton, CA), CD5 (UCHT2, L17F12, MEM32 – 
Immunotools, Friesoythe, Germany), CD7 (M-T701, 7F3- Sanquin, 124-1D1- eBioscience 
(San Diego, CA), 6B7- Caltag, Burlingham, CA), CD8a (HIT8a, RPA T8), CD14 (M5E2), CD19 
(HIB19), CD34 (8G12), CD38 (HB7), CD45 (2D1, HI30), CD45RA (HI100, MEM-56- Caltag), 
CD56 (B159, N901- Beckman Coulter), CD107a (H4A3), CD158a (HP-3E4), CD158b (CH-L), 
IFN-γ (25723.11), NKG2A (131411, R&D Systems, Minneapolis, MN), NKp46 (9E2), TCRαβ 
(IP26- eBioscience), TCRγδ (B1.1- eBioscience). 7-amino-actinomycin D (7AAD), 4′,6-
diamidino-2-phenylindole (DAPI), or propidium iodide (PI) was used to differentiate 
between viable and dead cells. For intracellular stainings, cells were permeabilized using 
perm/wash. Cells were analyzed on a FACSCalibur, FACScan, or FACSCanto II, with 
FACSDiva (BD), WinMDI (Joe Trotter, http://facs.scripps.edu/) or FlowJo (Treestar, 
Ashland, OR) software. 
Prior to differentiation, CD34+ cell preparations were depleted of CD38+ cells and 
contaminating T and NK cells by cell-sorting with a FACSAria using conjugated anti-CD3, -
CD4, -CD8, -CD38 and -CD56 antibodies. All mCD34+ cell preparations had ≤ 0.05% 
contaminating mature lymphoid cells. 
 
Co-culture of mCD34+ cells with stromal cells  
mCD34+ cells were seeded at a density of 2.6 × 103 cells/cm2 on monolayers of TSt-4 cells 
expressing Notch ligands DLL1 or DLL4. During the 1st week, cultures were maintained in 
RPMI 1640 containing 10% FBS, 1% PS, sodium pyruvate, NEAA, and bME that was 
supplemented with 100 ng/ml Stem Cell Factor (SCF), 100 ng/ml Fms-related tyrosine 
kinase 3 Ligand (Flt3-L), 50 ng/ml Thrombopoietin (TPO) (all from PeproTech, New York, 
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NY) and 10ng/ml Interleukin 7 (IL-7, R&D Systems). After 1 week, co-cultures were 
maintained in complete medium supplemented with IL-7 (20 ng/ml). Co-cultures were 
refreshed by halve medium change 3 times weekly. Differentiating cells were transferred 
to fresh monolayers every 2 weeks. For transfer, cells were separated from the 
monolayers by disruption of the monolayers using cell scrapers (BD), resuspension by 
pipetting, and filtration through a 100 µm mesh (Nedfilter, Almere, The Netherlands) 
directly onto the new monolayer. IL-15 (20 ng/ml, R&D) was added to enhance 
differentiation towards NK-lineage. 
For transfer to Rag2-/-γc-/- mice, differentiated hematopoietic cells were harvested as 
described above, after which dead cells, debris, and remaining TSt-4 cells were removed 
with a FACSAria. Purity of sorted cells was 80-90%. 
 
Polymerase chain reaction analysis 
Genomic DNA was extracted from cells using phenol-chloroform according to standard 
procedures. Primers and positive controls used for detection of TCR rearrangements are 
described in Dik et al.(11). PCR was carried out in 25 µl reaction volumes containing either 
50 ng DNA from differentiating cells or the negative control (breast cancer cell line ZR75-1, 
kindly provided by the Department of Pathology, MUMC+), or 1 ng positive control DNA. 
All PCR components were used according to the manufacturer’s instructions (iTaq, BioRad, 
Hercules, CA), supplemented with 1× bovine serum albumine (New England Biolabs, MA) 
and 540 nM of each primer (Eurogentec, Liege, Belgium). Optimal MgCl2 and anneal-
temperature for each primer-set proved to be 5mM/63.9°C and 3mM/60.5°C for Dδ2–δ1 
and Vδ1–Jδ1, respectively. All PCR products were validated by TA-cloning and sequencing 
according to standard procedures. 
 
Cytotoxicity assay 
Target cells (K562) were labeled with 3′-dioctadecyloxacarbocyanine (DiO) according to 
the manufacturer’s instructions (Sigma). 2 × 104 Target cells were incubated with effectors 
at various effector:target (E:T) ratios for 4 hours, each ratio in triplicate. Percentages of 
killed target cells (PI+ DiO positive) were determined by flowcytometry. Percentages 
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specific lysis were calculated as follows: ((% PI positive target cells − % spontaneous PI 
positive cells)/ % of vital cells) × 100. 
 
Rag2-/-γc-/- mice 
Rag2−∕−γc−∕− mice on a BALB/c background (kindly provided by Dr. M. Ito and the Central 
Institute for Experimental Animals, Kawasaki, Japan) were bred and maintained under 
specific pathogen-free conditions in accordance with the guidelines of the animal facility 
at the Institute for Research in Biomedicine. 
At day of birth, newborn Rag2−∕−γc−∕− mice were irradiated in a 4 hour interval with 2 times 
1.25 Gy (Rad Source Technologies, Inc., Alpharetta, GA) at 1 Gy/min, a dose that was 
titrated to be sublethal. At 4 hours post irradiation, mice were transplanted with either 1,5 
× 105 CB-CD34+ cells, 1,5 × 106 mCD34+ cells or 3 × 106 T/NK progenitors in 25 µl PBS into 
the liver (i.h.) using a 30-gauge needle (Hamilton Bonaduz AG, Bonaduz, Switzerland), as 
described previously (12). Mice were weaned at 3 weeks of age. 
 
 
Results and discussion 
 
mCD34+ cells develop into T/NK-lineage progenitors on hDLL1/4 interaction 
Sorted mCD34+ cells were cultured on monolayers of TSt-4 cells expressing either hDLL1 or 
hDLL4, and on TSt-4 control monolayers (Supporting Information Figure 1). First, we 
analyzed the time-dependent development of the phenotypic and genotypic markers 
associated with T-lineage development in human thymus (11, 13). Intracellular CD3+ (iCD3) 
cells became detectable after 1 week of coculture, expanded strongly during the following 
weeks, and costained with T-lineage–associated surface markers (Figure 1A; Supporting 
Information Figure 2). After 4 weeks, the overall phenotype and percentage distribution of 
the cells had stabilized, similar to the differentiation kinetics described for CB-CD34+ cells 
on TSt-4-hDLL1(9). Within this time period, cell numbers had increased 200 to 600 times 
(Figure 1B) with on average 50% of the cells coexpressing iCD3, CD45RA, CD7, and CD5 
(Figure 1A). Differences in overall phenotype of the cell populations were minimal 
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between different mCD34+ cell donors, or whether TSt-4-hDLL1 or 4 was used to induce 
differentiation (Figure 1A).  
To confirm T-lineage commitment, we analyzed early and late recombination events of 
TCR genes, Dδ-Jδ and Vδ-Jδ/Dβ-Jβ, respectively (11). After 4 weeks, T-lineage progenitors 
from all donors analyzed had either partially or completely rearranged the Dδ2-Jδ1 genes, 
whereas a smaller proportion had continued with rearrangement of the Vδ-Jδ genes 
(Figure 1C). There were no rearrangements of Dβ-Jβ genes detected (not shown).  
 
 
 
Figure 1. mCD34+ cells develop into T/NK progenitors on DLL1/4 interaction. mCD34+ cells were obtained from 
3 donors, V1 to V3. (A) Expression of indicated T-lineage–associated markers has stabilized after 4 weeks of 
culture on TSt-4-hDLL1/4 monolayers. For V2 and V3, the population percentage distribution of each marker 
combination falls within the following ranges: 88% to 92% for CD45RA+iCD3+ and 45% to 55% CD7+CD5+. For V1, 
these percentages are 63% to 68% and 37% to 58%, respectively. (B) Numbers/donor represent minimum and 
maximum of fold increases observed in 2 or 3 independent experiments/donor. (C) DNA was isolated from cells 
cultured on TSt-4 and TSt-4-hDLL1/4 for polymerase chain reaction analysis of gene rearrangements at the TCR 
locus. At the δ-locus, all donors show clear Dδ-Jδ rearrangement products, whereas Vδ-Jδ rearrangement 
products are faint and therefore must have occurred less frequently. In contrast to positive controls, 2 products 
are amplified from DNA of mCD34+ cell–derived progenitors. Sequence analysis demonstrated that the large 
products (> 1000 bp) are partial rearrangements of the δ-locus. (D) When differentiated cells were cultured for 
another 4 weeks on TSt-4 without DLL, the population lost surface expression of the T-lineage–associated marker 
CD5. 
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Figure 1. mCD34+ cells develop into T/NK progenitors on DLL1/4 interaction (continued). 
(E) Instead, cells gained expression of the NK lineage-associated markers NKp46 and NKG2A but did not express 
the killer cell immunoglobulin-like receptor proteins CD158a-c. Again, there are no differences between hDLL1- 
or hDLL4-derived cells. Similar results were obtained with another donor. (F) TSt-4–derived cells have killing 
capacity when coincubated at indicated effector (e) target (t) ratios with the HLA class I–negative leukemia cell 
line K562. Each point represents the average of a triplicate analysis. Similar results were obtained with another 
donor. Purified peripheral blood (PB) NK cells from healthy controls always served as positive control. 
 
Both phenotype and genotype of the T-lineage directed cells indicated that they were 
arrested at the T/NK pre-T-cell stages of T-lineage development (11, 13-15). Indeed, on 
transfer to TSt-4 control monolayers, cells gradually lost the T-lineage–associated marker 
CD5 (Figure 1D) and gained expression of the NK lineage-associated markers NKp46 and 
NKG2A (Figure 1E). Furthermore, the fact that the cells were able to kill the leukemia cell 
line K562 (Figure 1F) and did not express killer cell immunoglobulin-like receptor ligands 
(Figure 1E) established that they had developed into immature NK cells (16). 
 
T/NK progenitors fully mature on transfer to Rag2-/-γc-/- mice 
To determine whether these T/NK progenitors were able to complete their maturation in 
vivo, adoptive transfer experiments were performed using Rag2-/-γc-/- mice. Figure 2A 
shows that human T/NK progenitors home to the thymus of these mice and become 
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CD4+CD8+ double-positive (DP) thymocytes within 5 weeks after transfer. Furthermore, a 
clear population of surface CD3 and TCR-αβ–expressing thymocytes was observed within 
7 weeks (Figure 2A). Along with the appearance of TCR-αβ+ cells, there was a concomitant 
decrease in total number of huCD45+ cells in these thymuses (Figure 2A). This 
demonstrates that the T/NK progenitors are able to complete their TCR gene 
rearrangements and implicates that a single shot of T/NK progenitors provides one 
spatiotemporal wave of developing thymocytes. No CD56 expression was detected in the 
thymus (Supporting Information Figure 3), nor could huCD45+ cells be found outside of the 
thymus in mice given T/NK progenitors (Figure 2C), indicating that the lineage 
development was restricted to T cells in Rag2-/-γc-/- mice.  
As mentioned, in T/NK progenitor–injected mice, all huCD45+ cells were CD4+CD8+ DP by 
week 5, in contrast to animals that had received either CB- or mCD34+ cells. In these latter 
groups, T-lineage development was delayed by approximately 2 weeks, as percentage DP 
along with total number of huCD45+ cells at week 7 corresponded with week 5 data of 
mice supplied with T/NK progenitors (Figure 2B; Supporting information Figure 4), 
confirming the advantage provided by in vitro DLL-mediated predifferentiation.  
When compared, there were not many huCD45+ cells left in bone marrow at week 7 in 
mCD34+ cell–transplanted mice (Figure 2C). Apparently, the long-term engraftment 
potential of CB is favorable over mCD34+ cells in Rag2-/-γc-/- mice.  
At 7 weeks, one mouse given hDLL4 T/NK progenitors had very few huCD45 cells left in the 
thymus (Figure 2B-C), and none had mature T cells in the periphery. This is not unexpected 
because more than 95% of the thymocytes do not survive the positive/negative selection 
process, and the underdeveloped thymuses of Rag2-/-γc-/- mice have considerably reduced 
capacity. Even in CB-CD34+ cell–transplanted mice it requires continuous immigration of 
pro-thymocytes for 8 to 10 weeks before mature T cells can be found outside the thymus 
(12). 
The most important finding of this study is that mCD34+ cell–derived, in vitro–generated 
T/NK progenitors are able to migrate to the thymus and continue their development 
toward mature T cells. Conceptual similar findings were recently described for CB-derived 
progenitors (17). Prospectively, cotransplantation or sequential transplantation of CD34+ 
cells and T/NK progenitors will narrow the immunocompromised window of HSCT patients 
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considerably. Furthermore, the donor-derived thymus-matured T cells will also contain a 
patient-tolerant regulatory T-cell repertoire that may reduce graft-versus-host disease–
related complications. 
 
 
 
Figure 2. T/NK progenitors fully mature on transfer to Rag2–/–γc–/– mice. 
mCD34+ were differentiated on monolayers of TSt-4 expressing hDLL for 4 weeks, after which they were purified 
by cell sorting and injected intrahepatically into newborn Rag2–/–γc–/– mice. (A) Both hDLL1- and hDLL4-derived 
T/NK progenitors are found exclusively in the thymus at both time points analyzed and have progressed toward 
the CD4+CD8+ DP stage at 4.5 weeks. A limited number of DP and few CD8 single-positive (SP) cells already have 
CD3 surface expression (Supporting information Figures 3-4). The CD4+ cells at this time point are immature 
single-positive cells (ISP); sCD3– and CD5+CD7+. At 6.5 weeks, the percentages of huCD45+ have dropped sharply, 
but there is clear surface expression of sCD3 and TCR-αβ on T/NK progenitor-derived cells, on both DP and 
CD4/CD8 SP cells (Supporting information Figure 4).  
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Figure 2. T/NK progenitors fully mature on transfer to Rag2–/–γc–/– mice (continued). 
(B-C) Next to T/NK progenitors, mice were given mCD34+ or CB-CD34+ cells. (B) Thymus compartment was 
analyzed at indicated time points. Thymocyte subsetting is based on coexpression of CD5 and CD7 only (double-
negative), CD4+sCD3– (ISP), CD4+CD8+ (DP), and CD4+sCD3+ or CD8+sCD3+ (SP). The left 2 bars of each graph 
represent the data from mice displayed in panel A. Compared with mCD34+ and CB-CD34+ cells, 
predifferentiation of mCD34+ cells results in a higher percentage of cells at the DP stage at 4.5 weeks, but few 
cells are left at 6.5 weeks. (C) The total number of huCD45+ cells/tissue shows that T/NK progenitors are present 
temporarily and exclusively in the thymus. 
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Supporting information  
 
 
 
 
Figure 1. Set-up of mCD34+ cell differentiation on TSt-4 and TSt4-hDLL monolayers. 
mCD34+ cells were seeded at a density of 2.6 × 103 cells/cm2 on monolayers of TSt-4 cells expressing Notch 
ligands DLL1 or DLL4. During the 1st week, cultures were maintained in medium containing 10% FBS, 
upplemented with 100 ng/ml SCF, 100 ng/ml Flt3-L, 50 ng/ml TPO and 10ng/ml IL-7. After 1 week, co-cultures 
were maintained in complete medium supplemented with IL-7 (20 ng/ml). Co-cultures were refreshed by halve 
medium change 3× weekly. Differentiating HCs were transferred to fresh monolayers every 2 weeks. 
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Figure 2. Time-dependent development of DLL-induced T-lineage associated markers on mCD34+ cells. 
CD7 and iCD3 are differentiation-markers associated with T/NK cell lineage commitment that are upregulated 
during the first 4 weeks of culture. Results for mCD34+ cell donor V1 on TSt-4 and TSt-4-hDLL1 are shown. 
Quadrants are based on iCD3 background-staining of mCD34+ cells expanded on TSt-4. 
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Figure 3. CD56 expression on huCD45+ cells in thymuses of Rag2−∕−γc−∕− mice.  
Human CD45+ cells were stained for CD56 (and CD3). There may be insufficient production of growth factors (like 
IL- 15) that are required for normal development of NK cells in mice reconstituted with T/NK progenitors. 
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Figure 4. Expression of sCD3 on thymocyte subsets in Rag2−∕−γc−∕− mice. 
Human CD45+ cells were stained for CD4 and CD8, and quadrants were set for thymocyte-subsets indicated in the 
legend. Histograms display relative levels of surface CD3 expression of the subsets in each quadrant. CD3+CD4+ 
and CD3+CD8+ cells derived from T/NK progenitors were detected at both time-points. At week 6½, the results of 
the second DLL4 T/NK progenitor-injected mouse are difficult to interpret. Because of the low %CD45 left in the 
thymus (0.4%), it was not possible to do an additional staining for CD5 and CD7. Therefore we do not know if the 
CD4+ cells displayed are bona fide ISP. The fact that all other T/NK progenitor injected mice already had DP 
thymocytes at week 4½, it is likely that negative selection deleted most thymocytes and one is left with ISP-stage 
arrested cells. 
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Introduction 
 
In the early 1900s, the concept of involvement of the immune system in cancer 
development was first postulated by Ehrlich (1) and later transformed into the hypothesis 
of tumor immunosurveillance by Burnet and Thomas (2, 3). However, it took until the 
1990s before it was shown in mouse models that the hypothesis indeed was true (4). 
Immune competent mice were namely able to reject transplantable tumors. Eventually, 
due to increasing evidence, tumor immunosurveillance was acknowledged by many 
clinicians and translated into therapeutic concepts (5). Cancer patients were treated with 
either cancer cell vaccination, inoculation of serum prepared against a tumor or bacterial 
vaccines. Successes were reported, however, due to poor experimental execution clinical 
effects were unclear. Later, also donor bone marrow stem cell transplantation was 
explored making use of a donor’s immune system to fight cancer. Thus far, this is the most 
effective immunotherapeutic method used in patient care, though also here success is still 
limited. 
Increasing knowledge about the key players of the immune system involved in cancer like 
B cells, natural killer (NK) cells, antigen presenting cells (APC), T helper (TH) cells, cytotoxic 
T cells (CTL) and regulatory T cells (Tregs) combined with the knowledge of  interactions 
between these cells, have led to the development of improved immunotherapeutic 
strategies to fight cancer (6). While understanding more and more about the immune 
system also its complexity became cognizant. This led to a very broad field where 
immunologists tried to focus on only one cell type or one mechanistic system to cure 
cancer, without studying the complete immune response. This focus on single immune 
cells is probably why we became very efficient in eliminating cancer in genetically 
engineered mice in which only a very specific part of the immune system is studied, but 
experience many difficulties when conducting human trials (7, 8). When the body has such 
a sophisticated and well designed immune system that harnesses it especially against 
infections, it seems logical that inducing activation of the whole system in the fight against 
cancer would be more effective than focusing on single elements. 
Evidence for the strength of cooperation in anticancer therapy is illustrated by 
conventional therapeutic options, which are mainly based on the combination of surgery, 
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chemotherapy, hormonotherapy and radiation. Over the past decades several different 
combinations of chemotherapy have been utilized, combining alkylising cytostatics, 
antimetabolites, antimitotic agents, antitumor antibiotics, topo-isomerase inhibitors and 
others (9). These facts on anticancer therapy underline the need for combination therapy 
to attack tumors by different mechanisms.  
This has now been acknowledged by many researchers who are convinced that the 
immune system is such a strong defense mechanism due to the cooperation of different 
immune players (10). Therefore, efforts have been made in combining either different 
immunotherapeutic strategies, or combining immunotherapy with conventional 
anticancer therapy.  
In this thesis, we have investigated and optimized different immunotherapeutic strategies 
in vitro, including tumor-specific antibody transfer, induction of T and NK cell responses by 
DC vaccination and adoptive transfer of pre-T cells. The rationale behind this is that we are 
convinced that the complete immune system should be activated to induce effective 
anticancer responses.  
This discussion will explain the rationale behind combination therapy, which will be 
illustrated by the effect of DC vaccination on NK cell activation. Additionally, other 
therapeutic approaches that have been reported effective in combination with DC 
vaccination, will be reviewed.  
  
 
Clinical DC vaccination strategies 
 
Clinical DC vaccination trials illustrate nicely the downside of focusing on only one immune 
reaction, rather than studying the effects on the whole immune system. The initial 
vaccination strategies focused on inducing anticancer CTLs (11). However, after unraveling 
the function of MHC class II and the identification of TH cells, the induction of CTLs was 
analyzed in the context of TH cell polarization (12, 13). This eventually led to the 
development of DC differentiation and maturation cocktails that enhance the induction of 
TH1 polarization and the use of readout systems to evaluate the induction of these 
responses in vitro and in vivo (14). Even though the focus was not only on CTL induction 
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but also on TH cells, activation of other cell types was not acknowledged. In clinical DC 
vaccination strategies, about 10-20% of patients respond to therapy by tumor regression 
or stable disease, sometimes even complete remission is reported (15). However, these 
clinical outcomes often very poorly correspond to the induction of TH1 cells or tumor-
specific CTLs (Table I). This means either that T cell responses are analyzed at the wrong 
anatomical site or that other non-T cell responses are induced, which are also successful in 
anticancer reactivity. 
Next to T cell responses, sometimes also B cell responses were evaluated, by detection of 
tumor-specific antibodies. Though, results from clinical vaccination studies show that 
these tumor-specific antibodies are often produced after vaccination, they correspond 
very poorly with clinical responses (16). It took until 2000, before also other effector cells 
were analyzed in the context of DC vaccination. Martin-Fontecha et al. showed in mice 
that NK cells become activated after injection of matured DCs (17). They even showed that 
NK cells are an absolute requirement for the induction of TH1 polarization. But what about 
human studies? As nicely reviewed by Moretta, human in vitro data demonstrate that NK 
cells and DCs cooperate in pathologic conditions (18). Triggered by these human data, NK 
cell responses were evaluated in clinical DC vaccination studies. In a trial in AML patients, 
Van Tendeloo et al. showed that there was a significant correlation between clinical 
responses and the presence of high numbers of activated (HLA-DR+) NK cells post-
vaccination (19). Additionally, other studies in patients with solid tumors showed 
comparable correlations (Table II). In these studies, NK cell activation was often analyzed 
phenotypically, by increased expression of activation markers, or functionally by an 
enhanced cytotoxic or cytokine-producing capacity (20).  
The immunostimulatory effect of NK-DC interaction is based on a bidirectional crosstalk by 
which both cell types can become activated by either contact-dependent or independent 
factors. For DC vaccination techniques, activation of both cell types in vitro has been 
described and their effect on other immune cells and tumor cells has been suggested 
beneficial for the induction of antitumor responses (21, 22).  
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Table II. NK cell activation in clinical DC vaccination trials.  
 
Disease 
 
NK cell responses 
 
P-value 
 
Reference 
 
Acute myeloid leukemia 
 
4/5 clinical responders 
0/5 nonresponders 
 
0.01 
 
(19) 
 
CEA positive tumors 
(colorectal, lung and urachal cancer) 
 
4/5 clinical responders 
0/4 nonresponders 
 
0.016 
 
(30) 
 
Non-Hodgkin lymphoma 
 
 
5/6 clinical responders 
1/4 nonresponders 
 
0.009 
 
(31) 
 
 
NK cell-dependent DC responses 
NK cells hold the capacity to control and enhance DC-mediated antitumor immune 
responses. They do this by inducing maturation op TH1-polarizing  DCs and killing of 
inappropriately matured DCs. Additionally the NK cell’s intrinsic capacity to kill malignantly 
transformed cells, provides DCs with antigenic material for presentation. 
 
NK cell-induced DC maturation  
NK cells have been shown to mediate immunoregulatory “helper” functions. These helper 
NK cells were defined by Mailliard et al. as CD83+CCR7+CD56dim NK cells that possess a DC-
activating capacity (22). This DC activation is mediated by both soluble factors produced 
by NK cells as well as ligation of DC-surface receptors with activating ligands expressed on 
the NK cell surface (Figure 1A). Important soluble NK cell-derived factors implicated in NK-
DC crosstalk are INF-γ and TNF-α (32-34). The production of these cytokines by NK cells 
depends on reciprocal DC-induced NK cell activation by engagement of the NKp30 
receptor (35, 36). NK-DC interaction results in the development of stable, type-1 polarized 
DCs that produce high amounts of proinflammatory cytokines and thereby hold the 
capacity to enhance TH1 and CTL-mediated immunity against intracellular pathogens and 
cancer (Figure 1A) (32, 37, 38). Additionally, human in vitro and mouse in vivo models 
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have shown that the production of IFN-γ and TNF-α by NK cells is also directly associated 
with induction of enhanced antitumor TH1 cell responses (17, 35, 39, 40), whereas in the 
absence of NK cells, TH polarization is biased toward TH2 polarization, without induction of 
CTLs (41). NK cell-derived IFN-γ induces upregulation of the major TH1 transcription factor 
T-bet and inhibition of the TH2 transcription factor GATA-3 (17, 22). These IFN-γ-secreting 
cells were named “helper” NK cells, which gained their function after activation by a 
combination of IL-18 and IL-12 (22). Next to IL-12 and IL-18, also other pro-infammatory 
cytokines (IL-2, IL-15, Type-I interferons: IFN-α/β), NK-cell sensitive tumor cell lines and 
opsonizing tumor-specific antibodies can induce NK cell activation and IFN-γ production 
(42, 43). However, NK cell activation depends on a two-signal mechanism where two 
activating signals have to synergize (38, 44). Recently, it was shown that NK cells from 
melanoma patients can efficiently fulfill their “helper” function in vitro after induction 
with IL-18 and IFN-α (42). These NK cells are high IFN-γ producers and induce a DC subset 
which is superior at inducing antigen specific T cells as compared to non-polarized 
standard DCs. Whether these “helper” NK cells also naturally occur in vivo and whether 
they indeed represent a distinct NK cell subpopulation is still unknown. Reports on the 
IFN-γ secreting NK cell subset are controversial. The CD56bright NK cell subset was 
historically described as the cytokine-secreting subpopulation (45), however, others 
including us, showed that the CD56dim population can also produce large amounts of IFN-γ 
after NK-DC interaction (21, 22). Our studies on NK cell phenotype, show that NK cells 
display a high plasticity and upon stimulation can easily up- and downregulate surface 
receptor expression (unpublished data). Therefore, we propose that NK cell function and 
phenotype depend on the direct micro-environment and NK-induced DC maturation is not 
confined to a certain subtype of NK cells.  
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Figure 1. NK cell-dependent DC activation.  
NK cells can enhance DC function by three 
different mechanisms. (A) NK cells can become 
activated to produce IFN-γ and TFN-α by a two-
signal mechanism, including activation by 
cytokines (IL-12, IL-18, IL-15, IL-2 and IFN-α/β), by 
induction of ADCC via antibodies or by ligation of 
activating receptors (NKp30, DNAM-1). Both NK 
cell-derived cytokines enhance maturation of IL-
12-producing DCs, which effectively induce TH1 
polarization. Additionally, NK cell-derived IFN-γ 
directly enhance TH1 polarization. (B) Due to NK 
cell-mediated tumor cell lysis, tumor antigens 
become available for DCs to engulf and present. 
Activated NK cell also upregulate the expression 
of MHC class II and become weak antigen 
presenters themselves. (C) NK cells kill immature 
DCs (iDCs), because of low HLA-E expression. The 
ligation NKp30 enhances this NK cell function. By 
elimination of iDCs, NK cells prevent T cells to 
become tolerogenic due to contact with 
inadequately matured DCs.  
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Facilitation of antigen presentation  
Next to their “helper” effect on DC activation, NK cells have the natural capacity to kill 
virally infected or malignantly transformed cells (46). This function is not only of direct use 
for tumor elimination, but also facilitates uptake and cross-presentation of tumor-related 
antigenic material by DCs (47, 48). Thereby, NK cells contribute to DC-mediated induction 
of tumor-specific T cells (Figure 1B). Additionally, activated NK cells are induced to express 
MHC class II and costimulatory molecules (CD80, CD83 and CD86) and are therefore also 
able to present antigen to T cells themselves (Figure 1B) (49-51). These NK cells with DC-
like qualities have been described in humans and mice and have been reported as a new 
immune cell subpopulation referred to as NKDCs as well as IKDCs (IFN-producing killer 
dendritic cells) (52-57). Though their etiology is not yet completely elucidated, IKDCs are 
functionally and developmentally more similar to NK cells than to DCs (58-60). MHC class II 
expressing-NK cells are able to present antigen and induce T cell responses, however, 
conventional DCs are much more efficient antigen presenters. Target cell lysis and 
cytokine secretion of IKDCs is comparable to conventional NK cell function. 
Developmentally, mouse IKDCs resemble activated, human, MHC class II expressing NK 
cells, and are absent from recombinase activating gene-2-null, common γ-chain-null 
(RAG2-/-IL2rg-/-) mice, which lack NK cells but not DCs. Additionally, these cells efficiently 
proliferate by IL-15 activation (58, 61). Although nomenclature might be contradictive and 
confusing, these different subsets are most likely to resemble activated NK cells (52).  
In summary, by their natural cytotoxic capacity NK cells provide DCs with antigenic 
material. These antigens can be presented by DCs as well as by NK cells to induce effective 
adaptive antitumor responses.   
 
NK cell-dependent lysis of immature DCs 
NK cells are not only able to kill tumor cells, but also have the capacity to eliminate both 
autologous and allogeneic immature DCs (iDC). NKp30, which is involved in NK cell-
mediated DC maturation, has been shown to play a major role in iDC lysis (32) and 
cooperates with DNAM-1, a triggering receptor expressed by virtually all NK cells (62) 
(Figure 1C). Since both, mature as well as immature DCs express ligands for NKp30 and 
DNAM-1 (62, 63) an additional mechanism must be involved in the recognition of iDCs by 
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NK cells. Analysis of NK cell clones has revealed that killing of iDCs was confined to NK cells 
that lack expression of inhibitory KIRs specific for self-HLA class I alleles, but do express 
the HLA-E-specific CD94/NKG2A inhibitory receptor (64). The iDC becomes susceptible to 
NK cell-mediated cytotixicity, not because of low expression of all HLA molecules, but only 
because of low expression of HLA-E. In contrast, mature DCs express higher amounts of 
HLA-E and are therefore kept untouched (64, 65). Upregulation of MHC and costimulatory 
molecules is needed for DCs to induce efficient T cell responses. Whereas mature DCs are 
thought to be the most effective antigen presenters and inducers of adaptive immunity, 
iDCs have been implicated in tolerance and induction of regulatory T cells (66). Thus, it can 
be hypothesized that by elimination of iDCs, NK cells ensure the activation of adaptive 
immune responses by preventing inadequately matured DCs to interact with T cells (67). 
Interestingly, in an immunosuppressive environment with high production of IL-10, it has 
been demonstrated that iDCs become less susceptible to NK cell-mediated lysis, whereas 
mature DCs exhibited increased susceptibility to NK cell-dependent elimination (68). 
Though in apparent paradox, NK cells can induce DC maturation as well lysis of iDCs. This 
paradox can be explained by work from Piccioli et al., who showed that the result of NK 
cell activation depends on the relative numbers of each cell type and NK cell-mediated 
lysis of iDCs is only induce if NK cells outnumber iDCs (32).  
In conclusion, NK cells induce effective antitumor immune responses, by inducing DC 
maturation and antigen presentation, but inhibiting tolerogenic responses mediated by 
inappropriately matured DCs.   
 
 
DC-induced NK cell responses 
The bidirectional crosstalk between NK cells and DCs, is also characterized by DC-mediated 
NK cell activation. DCs are capable of providing NK cells with soluble as well as contact-
dependent activators, thereby enhancing their cytokine production, proliferation, survival 
and cytotoxicity. NK cells make use of all these four mechanisms in to eliminate cancer 
cells.  
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Induction of cytokine production and proliferation 
Reciprocally, DCs activate NK cells to produce cytokines. Also this activation is mediated by 
a two signal mechanism of which both signals are DC-derived The major cytokines 
produced by NK cells after NK-DC crosstalk are TNF-α and IFN-γ. NK cell activation by DCs 
is mediated by both soluble as well as contact-dependent factors (Figure 2). Depending on 
their maturation stimuli DCs upregulate the expression of NK cell- activating surface 
molecules and start producing NK cell–stimulating cytokines (59, 60). 
 
 
Figure 2. DC-induced NK cell activation. 
DCs can affect NK cell function by augmentation of cytotoxicity, cytokine secretion (IFN-γ and TNF-α) and 
proliferation. This depends on contact-dependent (ligation of NKp46, NKp30, NKG2D, 2B4 and CD27 and 
presentation of IL-15 in trans) as well as soluble factors (IL-2, IL-12, IL-15, IL-18, IFN-α and IFN-β). IFN-γ secretion 
by NK cells is in turn responsible for DC maturation and TH1 polarization, whereas augmentation of NK cell 
cytotoxicity contributes to tumor cell lysis. Which cytokines or contact-dependent factors are involved depends 
on the triggers involved in DC activation (most likely TLR ligands). 
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Among the soluble factors IL-12 and IL-18 have shown highly efficient in NK cell activation.    
We and others have shown that this capacity is confined to DCs trigged by PRR (pattern 
recognition receptor)-signaling, which produce high amounts of IL-12 and IL-18 (11, 61). 
Both cytokines synergize in the induction of NK cell activation, which requires the 
formation of an immunological synapse with cytokine secretion polarized at the NK-DC 
interface (62, 63). Additionally, it has been demonstrated in humans and mice that DC-
derived IL-2 also contributes to NK cell activation (64, 65). IL-15 is another DC-derived 
factor, which works both as a soluble factor as well as a contact-dependent factor (10, 66, 
67), since DCs as well as DC exosomes can bind IL-15 to their IL-15Rα thereby presenting 
IL-15 in trans. The effect of IL-15 on NK cell proliferation, survival and cytokine secretion is 
much stronger, when presented in trans than in its soluble form (66). 
In addition to these soluble factors, it was shown that NK-DC crosstalk was enhanced 
when both cell types were in contact with each other, suggesting that also contact-
dependent factors must be involved in this crosstalk (22). These factors include surface 
molecules expressed on DCs that ligate with activating NK cell receptors. One of these NK 
cell receptors is NKG2D, which is an C-type lectin coactivation receptor expressed on all 
NK cells (68). NKG2D binds to stress-inducible members of the polymorphic MHC class I-
related Chain A/B (MICA/MICB) family, which are upregulated on mature DCs (69, 70). The 
NK cell activating receptors NKp30 and NKp46 are involved in NK-DC crosstalk as well as in 
NK-mediated tumor cell lysis (25, 71, 72). In mice also CD27, expressed by NK cells, has 
shown to be implicated in NK-DC crosstalk. It binds to the co-stimulatory  molecule CD70, 
which is exclusively expressed by DCs and therefore the CD27high expressing mouse NK cell 
subset is superior in cytokine production after DC interaction. Since this subset resides in 
the lymph nodes, it has been proposed that these cells might resemble the human 
CD56bright NK cell subset (73, 74). Moreover, 2B4, which ligates with CD48, has been 
implicated in NK-DC crosstalk however, its function is still promiscuous. The 2B4 pathway 
can be both activating as well as inhibitory (75, 76). Which pathway is induced depends on 
the NK cell maturation status and on NK cell localization (77). It has been demonstrated by 
Morandi et al., that lymphoid NK cells express 2B4 that functions as an inhibitory receptor. 
However, they also show that lymphoid DCs show very low expression of CD48, thereby 
preventing NK cell inhibition (78). All the previously mentioned surface molecules are 
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stress-dependent factors that can be upregulated during DC maturation, thereby 
mediating danger signals to the surrounding tissue.  
Taken together these studies indicate that NK cell activation results from a combination of 
DC-derived factors. These factors include soluble as well as contact-dependent stimuli. 
Which mechanism is utilized depends on the DC maturation status. NK cell activation 
involves cytokine production, cytotoxicity, proliferation and increase of their lifespan. 
Production of IFN-γ by NK cells in response to DC activation is again involved in TH1 
polarization and thereby induction of CTLs (7).  
 
Induction of NK-mediated cytotoxicity  
NK cells can lyse virally infected or malignantly transformed cells. This cytotoxic activity is 
based on a delicate balance of inhibitory and activating signals and depends on the 
expression of MHC class I and activating ligands on the target cell as well as on expression 
of the respective receptors by NK cells (89, 90). NK cell cytotoxicity can be enhanced by 
DC-dependent mechanisms (Figure 2) (33, 91). These mechanisms include DC-derived IL-
12 (21), IL-2 and IL-15 (92) as well as contact-dependent factors like NKG2D, NKp46 and 
NKp30 (81). Which cytokines or NK cell receptor ligands are responsible for the enhanced 
tumor cell lysis depends on different DC subsets or maturation stimuli (92, 93). 
 
 
Common playground for NK cells and DCs? 
 
For reciprocal NK-DC activation it is obligatory for the two cell types to meet. It has been 
proposed that NK-DC interaction takes place at the site of inflammation as well as in the 
lymph nodes (18). During an inflammatory response, a burst of immunoactive molecules is 
secreted including chemokines. These chemokines are responsible for the recruitment of 
immune cells, which produce even more chemokines and cytokines in response to the 
inflammatory reaction. For NK-DC crosstalk specifically, it is necessary that one cell type 
produces chemokines, important for recruitment of the other cell type. We have shown 
that upon maturation TLR-triggered DCs produce high quantities of many different 
chemokines (94). Among these, there are  NK cell recruiting chemokines produced like 
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CCL5, CXCL10 and CCL19. We have shown that in human TLR2/4 matured DCs, the most 
important chemokine receptor for NK cell recruitment is CCR5 (21). However, other 
groups have also reported on the involvement of CXCR3 and its subsequent chemokines 
CXCL10 in recruitment of blood-derived NK cell by LPS and poly I:C triggered DCs (17, 71). 
Therefore, it seems that there are multiple, non-redundant mechanisms to recruit NK 
cells. Which of these mechanism is utilized depends on the DC maturation-triggers and 
eventually on the invading microorganism.   
 
Figure 3. Where do NK cells and DCs interact? 
Tissue-resident DCs matured upon inflammatory stimuli produced by the tumor and its surrounding tissue. Upon 
maturation, these DCs upregulate MHC, costimulatory molecules and CCR7. Additionally, these DCs start to 
produce cytokines and chemokines. These chemokines are responsible for NK cell recruitment (either CCR5 or 
CXCR3-dependent). (A) Blood-derived NK cells are then recruited into the tumor environment and interact with 
DCs resulting in reciprocal activation of both cell types. Upon maturation, DCs upregulate their CCR7 expression 
and migrate into the draining lymph nodes. (B) While migrating, DCs still produce chemokines and thereby 
recruit NK cells into the lymph nodes. (C) Additionally, NK-DC interaction induces the upregulation of CCR7 
expression by NK cells, which constitutes a secondary mechanism by which NK cells migrate into the draining 
lymp node. (D) Due to migration of both cell types into the lymph node and also the presence of lymph node-
residing NK cells, NK-DC crosstalk can take place in the lymph node. 
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Since maturing DCs migrate into the draining lymph nodes, chemokine production by 
mature DCs is possibly also responsible for the recruitment of NK. It has been shown in 
CXCR3-/- mice that TH1 polarization was inhibited, due to impaired recruitment of NK cells 
into the lymph nodes (17). In humans, however, additional NK cell-migrating mechanisms 
have been proposed. NK cells are able to upregulate their CCR7 expression and 
subsequently their responsiveness to the lymph node-associated chemokine CCL19 upon 
activation with IL-18 and upon NK-DC crosstalk (21, 22). This would represent a secondary 
mechanism by which DCs induce NK cell migration into the draining lymph nodes. These 
already activated NK cells could effectively induce TH1 cell polarization (Figure 3).  
In summary, DCs induce NK cell migration either due to recruitment by DC-derived 
chemokines and/or due to upregulation of CCR7 after NK-DC crosstalk, thereby facilitating 
interaction of the two cell types in the lymph node or at the site of inflammation.  
 
 
NK-DC crosstalk in immunotherapy  
 
The reciprocal effects of NK-DC interaction provide a strong rationale for the combined 
use of NK cells and DCs in immunotherapy. Autologous as well as allogeneic NK cells have 
been used in cancer immunotherapy and have been proven effective in defined tumors 
(95). However, in these therapies, NK cells were always used as lonely killers. With our 
recent knowledge about NK-DC interaction, one could argue that DCs used in DC 
vaccination strategies should be matured by NK cells, since these DCs produce high 
concentrations of IL-12 and are therefore excellent TH1 polarizing DCs (42). When looking 
from another point of view, there is also a rationale to use DCs that are able to optimally 
activate and recruit NK cells (21, 71). The NK cell-activating capacity of these DCs depends 
on the maturation triggers used for ex vivo DC maturation. Additionally, an absolute 
prerequisite for these DCs is that they actively recruit NK cells (17, 21). We and others 
have shown that for this purpose DC maturation protocols should contain TLR-triggering 
agents whereas PGE2, another DC activating molecule produced during inflammation, has 
a negative effect on the production of NK cell-activating cytokines and NK cell-recruiting 
chemokines (71). These results are in line with data showing that PGE2 matured DCs 
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induce more TH2 than TH1 polarization and induce a lower number of tumor-specific CTLs 
(14, 94, 96). Even though these reports on the negative effects of PGE2-mediated DC 
maturation, most clinical trials use PGE2-matured DCs. The rationale behind this is the in 
vitro capacity of these DCs to migrate towards a CCL19 gradient (97, 98). Therefore, PGE2-
matured DCs are also thought to migrate into the lymph nodes after injection in vivo. 
However, in vivo studies do not support this hypothesis. TLR-matured DCs are not only 
superior in the induction of TH1 polarization but are also much better NK cell activators by 
inducing both NK cell-mediated cytotoxicity and IFN-γ production, resulting in strong 
antitumor responses. The lack of migratory capacity of TLR-matured DCs opens the 
possibility for the combination of NK-DC therapy, where both cell types are injected into 
the tumor. Thereby, both cell types will be directly present at the battlefield and are able 
to interact. NK cells lyse tumor cells, thereby making antigenic material available for DCs 
to take up and present. Additionally, NK cells induce maturation of bystander DCs and lyse 
inappropriately matured iDCs. Reciprocally, mature DCs can activate NK cells to 
proliferate, secrete cytokines and augment NK cell cytotoxicity.  
All three options for the combined use of NK cells and DCs in vaccination strategies for 
cancer are based on theoretical solid grounds. However, only the activation of NK cells by 
DC vaccination strategies has been utilized and shows promising results (19).   
 
Tertiary lymph node  
As mentioned before, ex vivo matured DCs show a bad migratory capacity in vitro. The 
positive effect of PGE2 on in vitro DC migration is promising (97, 98), in vivo migration of 
these DCs, however, is comparable to non-PGE2 matured DCs (99). This means that until 
now, no DC maturation strategy has been described to manipulate in vivo DC-migration. 
The percentage of DCs that reach the draining lymph node in clinical DC vaccination 
protocols is about 4% (100). To increase the number of DCs entering the draining lymph 
node, different DC injection techniques have been used. Next to the subcutaneous 
injection, DCs have been injected intranodally (101, 102), intratumoral (103), intravenous 
and intralymphatically (104). Only few studies with low patient numbers compared the 
effect of different injection methods on clinical responses (104). Additionally, these 
techniques appear difficult to perform and success rates completely depend on the 
Chapter 8 
 
208 
experience of the injecting radiologist (105). Therefore, we would like to propose a new 
option to compensate for the poor DC-migratory capacity, the tertiary lymphoid structure. 
This technique makes use of the capacity of TLR-matured DCs to produce large amounts of 
different chemokines (94). By manipulating chemokine production, DCs are able to 
selectively recruit effector cells for interaction. This is illustrated by the capacity of TLR-
matured DCs to produce NK cell-recruiting chemokines (106) and thereby recruit NK cells 
(17, 21, 71). DC-mediated chemokine production is also attractive for recruitment of other 
immune effector cells (107). For CTL recruitment both CXCL10 and CCL5 have been shown 
important (108-110). Interestingly, by manipulating the chemokine profile of DCs different 
TH cells can be recruited, thereby controlling T cell responses. Like CTLs and NK cells, TH1 
cell migration also depends on CXCL10 and CCL5 secretion (111). We hypothesize that by 
recruitment of all these effector cells by DCs the same interactions that take place in 
lymph nodes can be induced extranodally, thereby compensating for the lack of migration 
by ex vivo matured DCs. Another possibility is intratumoral injection of DCs, recruiting 
effector cells directly into the tumor. One should however take into account that the 
immunosupressive effect of the tumor micro-environment could have detrimental effects 
on effector cell induction by DCs.  
 
 
Combination therapy 
 
After reviewing the possibility of combination therapies for cancer by using NK-DC 
crosstalk, DC vaccination could also be combined with other therapies that target 
additional immune cells, induce tumor cell lysis or modulate the tumor micro-
environment. A short overview of these strategies is presented here.  
 
Adoptive T cell transfer 
In terms of combining different immunotherapeutic strategies, one could argue that DC- 
vaccination should be accompanied by adoptive T cell transfer. The capacity of DCs to 
induce tumor-specific T cell responses depends on the presence and activation status of 
these T cells. In cancer patients, tumor-specific T cells are often anergic or subjected to 
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silencing. Additionally, it is possible that the tumor-specific T cell is not present in the 
patient’s natural T cell repertoire. Therefore, the transfer of specific T cells or de novo pre-
T cells could do both, increase the prevalence of specific T cells thereby expanding the 
natural repertoire and providing T cells that are not subjected to silencing. It has been 
shown in mice that the combination of DC vaccination and adoptive T cell transfer led to a 
more robust antitumor response than the use of each treatment individually (112, 113). 
De novo development of tumor-specific T cells would be the ultimate goal for DC 
vaccination strategies. To date, however, it is still impossible to produce these cells ex vivo 
(114). Though, with the use of pre-T cells the T cell repertoire can be expanded and 
hopefully supplemented with the missing tumor-specific T cells (115). It can be envisioned 
that with the latter strategy the prevalence of tumor-specific T cells will be much lower. 
The positive effect of the use of pre-T cells, however, is strengthening of the immune 
system with new specific T cells that can not only fight tumors, but also infectious agents. 
Moreover, with pre-T cells the risk of auto-reactivity is very low, because both negative 
and positive selection of these autologous T cells take place in vivo. This makes the use of 
pre-T cells also attractive for immune reconstitution after the immunosuppressive effect 
of chemotherapy or stem cell transplantation (116). Additionally, in auto-immune patients 
that receive high dose immune suppressive drugs, T cell reconstitution could prevent 
development of opportunistic infections. Results on the use of pre-T cells are still 
preliminary, however our mouse studies indicate that these cells have the capacity to 
migrate into the thymus of humanized mice (115).   
 
Antibody therapy 
To enhance immune responses, not only cellular responses can be enhanced but also 
humoral responses. DC vaccination induces both immune responses and often tumor-
specific antibodies can be detected after DC vaccination (16). Therefore, antigen 
presentation in MHC class I and II by DCs is obligatory and this depends on the 
characteristics of the antigen used by ex vivo antigen loading. Not all antigens used in DC 
vaccination studies possess these characteristics and are therefore only expressed in MHC 
class II. However, humoral responses can be enhanced by simultaneous injection of 
tumor-specific antibodies thereby improving tumor cell elimination due to complement 
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activation and ADCC (117). Furthermore, antibodies can target antigens expressed by 
tumor surrounding tissue, thereby manipulating the immune suppressive environment, 
they can bind tolerogenic ligands on immune cells and they can prevent induction of 
tolerance (117). Clinical trials in which DC vaccination is combined with antibodies 
inhibiting development of Tregs show an increase in antitumor responses (118). Also the 
use of tumor-specific antigens enhances DCs to opsonize tumor cells and present tumor 
antigens (119). Next to these effects, antibodies can activate NK cells due to their ADCC 
function, thereby not only enhancing their cytotoxicity, but also their cytokine secretion, 
which promotes NK-DC crosstalk (42). One could hypothesize that DC vaccination, 
combined with adaptive NK cell transfer and antibody vaccination, would be superior at 
inducing antitumor responses.  
 
Immunotherapy and conventional anti-cancer therapy 
Current antitumor therapy is mainly based on surgery, chemotherapy and radiotherapy. 
All these strategies have been shown to have immunomodulatory effects. Many of these 
therapies curtail the immune response against tumor cells. These immunosuppressive side 
effects are induced either directly, by inhibiting or killing effector cells, or indirectly, by 
provoking anergy or immune paralysis (120). This is well illustrated with the combined 
resection of the primary tumor as well as the tumor draining lymph nodes. Though cancer 
cells could have metastasized into these lymph nodes, this is also the location where 
antitumor immune cells become activated and start proliferating. Therefore radical 
resection of these lymph nodes does not always improve overall survival in cancer 
patients (121). Additionally, chemotherapy and radiotherapy have direct negative effects 
on immune cells due to their direct cytotoxicity, thereby inducing lymphopenia (122, 123). 
Moreover, many chemotherapeutics are used as immunosuppressants for the treatment 
of severe autoimmune disease. This applies to steroids, methotrexate and 
cyclophosphamide, which have been demonstrated to bias T cell polarization toward a TH2 
response (124), inhibit DC maturation (125) and inhibit NK cell proliferation and 
cytotoxicity (126).  
However, accumulating evidence indicates that innate and adaptive immune responses 
make a crucial contribution to the antitumor effects of conventional chemotherapy- and 
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radiotherapy-based cancer treatment (120, 127). Surgical resection of most of the tumor 
mass prevents the production of immunosuppressive factors by tumor cells, thereby 
reducing the suppressive effect on the immune system. Radiotherapy and chemotherapy 
have the same effect since they also induce apoptosis of tumor cells, thereby decreasing 
tumor burden. Additionally, they induce other immunomodulating mechanisms. One of 
these mechanisms is induced by the direct apoptotic effect of both therapies. By the 
induced cell death, antigenic material becomes available for DCs to take up and efficiently 
present to T cells (128, 129). Additionally, the toxic effect enhances expression of stress 
factors by tumor cells due to DNA-damage, which enhances expression of NKG2D ligands 
on tumor cells that ligate with the NKG2D (130). Also upregulation of other stress factors 
enhances NK cell-mediated tumor cell death. Unpublished work by Frings et al., indicates 
that murine breast cancer cells upregulate specific NK cell stimulating molecules after 
chemo- and radiotherapy, thereby enhancing the effect of haploidentical stem cell and NK 
cell transplantation (Frings et al. manuscript in preparation and (131)). Upregulation of 
stress factors has also been shown to amplify  DC-mediated responses due to secretion of 
HMGB1 by apoptotic cells, which triggers TLR4 and thereby enhances DC activation and 
cross-presentation of tumor antigens (132). Low dose radiation is known to upregulate the 
expression of MHC class I molecules, tumor-associated antigens (including Mucin 1), the 
FAS death receptor and adhesion molecules (133, 134). Due to these immunostimulatory 
effects, radiation of a single tumor site can induce tumor regression of non-irradiated 
metastasis (134). Lymphoablation induced by low dose total body irradiation combined 
with chemotherapeutics does not only have detrimental effects on the immune system, 
but also opens opportunities for adoptive cell transfer. Due to the induction of transient 
lymphopenia, Tregs are eliminated as well and lymphoid reconstitution could overcome 
immune cell anergy (135, 136). Additionally, low dose cyclophosphamide has direct T and 
NK cell stimulatory effects, augmenting their proliferative and cytotoxic capacity (137).  
Both in mice and humans, several anti-cancer chemotherapeutic agents have been used in 
combination with immunotherapy and results are promising. The effect on NK cell 
cytotoxicity by DC vaccination strategies can be improved by pretreatment with 5-
fluorouracil (34). Also the use of adjuvant oxaliplatin and capecitabine enhances the effect 
of DC vaccination (127, 138). Moreover, DC vaccination was able to increase 
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chemosensitivity of previously chemoresistant tumors (139). A combination of doxorubicin 
with IL-12 therapy prolonged survival of mice with leukemia (140). In extension with these 
findings, it can be anticipated that other immunomodulating drugs could boost anticancer 
immune responses. These drugs are not classified as chemotherapeutics, but have an 
effect on the tumor micro-environment. They include agents that inhibit tumor 
microvasculature like VEGF (141) and also cyclooxigenase (COX) inhibitors, which have 
been shown to inhibit tumor cell proliferation and migration but enhance apoptosis and 
immune cell invasion (142). Since COX2 inhibition prevents the formation of PGE2, it also 
prevents the inhibitory effect of PGE2 on immune cells (143). Previously, it has been 
shown that the combined use of DC vaccination and COX2 inhibitors is superior at inducing 
antitumor responses than DC vaccination alone (144, 145).  
In conclusion, though conventional therapy, as well as immunotherapeutic strategies have 
been shown to induce antitumor responses, relapses are still frequent. To win the fight 
against cancer it is not only necessary to kill all cancer cells, but also chemoresistant 
cancer stem cells and induce protective immune responses. Therefore, combination 
strategies including both conventional and immunotherapy could enhance antitumor 
responses, break anergy and protect the patient from tumor recurrence (146).  
 
 
Monitoring immune responses 
 
New insights in interactions of different immune cells can be provided by closely 
monitoring immune responses. It has been demonstrated extremely difficult to identify a 
readout methods, that correlates best with clinical outcome. Different immunomonitoring 
strategies have been developed (Table III), they are, however, not applied in all 
immunotherapeutic trials.  
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Table III monitoring systems for cancer therapy 
Responses Methods Reference  
Clinical responses Tumor size and metastasis (Radiology) 
Tumor markers (PSA, CEA) 
(147, 148) 
DCs Migratory capacity (cell tracking)  
Cytokine production 
(149) 
NK cell  Phenotype (expression of NCRs and activating molecules ) 
Cytokine production (IFN-γ, TNF-α) 
Cytotoxic capacity  
(30) 
Antibodies Tumor-specific antibodies (monoclonal/polyclonal) (150) 
T helper induction  Signature cytokine production  
Signature gene expression 
(151-153) 
CTL cell responses Presence of tumor-specific CTLs (or KLH/DTH responses) 
Cytotoxic capacity of tumor-specific CTLs  
(154) 
 
 
 
Future perspectives  
 
For immunotherapy to be an effective therapeutic option, clinical trials should be 
performed. A major drawback of immunotherapy, compared to conventional anticancer 
therapy, is that it is a patient-specific therapy. This makes it very expensive and 
unattractive for most companies to invest in. Though over the past few years many cell 
therapy companies have been founded, only few major clinical trials have been 
performed. To reduce the costs of immunotherapy, many investigators have been 
studying the possibility of an off-the-shelf product. Examples are the use of immune cells 
developed from autologous or allogeneic stem cells that are genetically altered to 
specifically target antigens expressed by the majority of tumors. Also cell lines can be used 
for this purpose. However, I am convinced that the development of these products can 
only be effective if we have elucidated the different responses induced by regular 
immunotherapy. With these new therapies we have to overcome many more hurdles, 
including transplantation over HLA-borders. Therefore, I would suggest to perform clinical 
immunotherapeutic trials, where not only clinical responses are investigated, but also 
immune responses. Additionally, these responses should be analyzed in patients treated 
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with conventional anticancer therapy. We should learn more about the nature of immune 
responses induced to determine the possible additive effects.  
Over the past years, vaccination strategies have been extensively studied in vitro. 
Different maturation cocktails have been used, different immune interactions have been 
studied and different tumor targets have been investigated. With increasing knowledge it 
is now possible to produce DCs with better in vitro capacities than previous DCs that were 
only scarcely used in clinical trials. Next to these developments, also genetically altered 
DCs that can be used as an off-the-shelf product are being developed. But where we seem 
to get stuck is the translation into clinical practice. This is nicely illustrated by the quest of 
developing DCs that are able to migrate in vitro. Many different groups have investigated 
the behavior of DCs matured by different factors that either enhance or inhibit DC 
migration. However, in vivo all DCs seem to migrate just as poor and development of in 
vitro migrating DCs seems of no in vivo or clinical use. Therefore, immunotherapy screams 
for clinical trials to be used in regular anticancer, since in vitro optimization is only useful if 
we know what the in vivo problems are. 
In nearly every review on immunotherapy, one of the biggest problems in effectiveness of 
immunotherapy is the patient population used in trials. In nearly every trial, end-stage 
cancer patients are included. One could reason that the immune system in these patients 
suffers from the enormous suppressive effect of the tumor. Additionally, these patients 
were previously treated with different regimens of radio- and chemotherapy, thereby 
already selecting the most aggressive tumor cells. The use of immunotherapy as an 
adjuvant in current therapeutic strategies might be very appealing, since these adjuvants 
could possibly induce protective immune responses. Tumor immune surveillance would be 
enhanced, prohibiting tumor cells to grow. Hopefully, this will translate into increased 
tumor-free survival en decreased recurrence rates.  
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Figure 4. The Holy Grail of anticancer therapy. 
With our present knowledge it is an euphemism the think that there is a single anticancer agent that serves as 
the Holy Grail in antitumor responses. Until we have found this strategy, we have to combine different 
therapeutic options that either activate the immune system, manipulate the tumor microenvironment and 
efficiently use the tumor characteristics to induce stable antitumor responses. 
 
In my opinion, the key to development of effective antitumor protocols lies in performing 
clinical studies and acknowledging the fact that anticancer therapy is not a one man show. 
It depends on the tumor characteristics, the tumor microenvironment, activation and 
suppression of the immune system and of course on the patient’s condition. History has 
proven that there is not one therapy that ticks all the boxes (Holy Grail) and therefore 
different antitumor strategies have to cooperate (Figure 4): cooperation of different 
immune cells and cooperation of conventional therapy with immunotherapy. Of course 
these combinations will not only augment anticancer responses, also inhibition is possible, 
therefore clinical effectiveness should be very closely monitored, with a special regard to 
immune responses.  
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Summary  
 
In this thesis we studied various aspects of different immunotherapeutic therapies for 
cancer in vitro. The aim was to improve clinical outcome by combining different 
immunotherapeutic approaches. We thereby present methods for combination therapy 
and provide tools to evaluate immunologic responses.  
In chapter 2 we investigated the possibility to utilize passive antibody transfer for ovarian 
cancer. We show that most ovarian tumors and their metastasis express 
underglycosylated MUC1 (MUC1-Tn/STn), whereas healthy ovarian cells don’t. Therefore, 
we reason that MUC1-Tn/STn epitopes could serve as tumor-specific antigens, which can 
be targeted with adoptive transfer of humanized antibodies or DC vaccination in 
immunotherapy for ovarian cancer.  
To optimize DC-based vaccination strategies, we show in chapter 3 that TLR2/4-matured 
DCs are superior in inducing TH1 polarization and additionally induce more MUC1-specific 
CTLs as compared to PGE2-matured DCs. Additionally, in chapter 4 we show that these 
TRL2/4-matured DCs are also superior in interaction with NK cells. This interaction does 
not only enhance NK cell-mediated cytotoxicity, but also IFN-γ-dependent TH1 
polarization.  The use of PGE2 in DC maturation protocols is based on the positive effect of 
PGE2 on the DC’s migratory capacity. Indeed, though TLR2/4-matured DCs are superior in 
activating immune effector cells, they display a very poor migratory capacity in vitro. By 
analyzing the chemokine profile of these TLR2/4-matured DCs, which produce high 
amounts of TH1, CTL and NK cell-recruiting chemokines we have formed the basis of a new 
approach for DC vaccination strategies. As opposed to previous reports on enhancement 
of DC migration, we reason that if ex vivo developed DCs are such poor migrators, they 
should be stimulated to recruit effector cells. For NK cells we show that TLR2/4-matured 
DCs do this very efficiently in a CCR5-dependent mechanism.  
In terms of combination therapy, we investigated possible additional factors produced by 
tumors, which inhibit antitumor immune responses. One important factor is PGE2, a 
potent immune suppressor, which is secreted by many solid as well as hematological 
malignancies. Paradoxically, this is the same factor often used in DC maturation protocols. 
PGE2 has previously been shown to inhibit both innate as well as adaptive immune 
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responses. Interestingly, in chapter 5 we show that PGE2 has also detrimental effects on 
NK-DC interaction. PGE2 directly affects NK cell function by inhibiting cytotoxicity and 
cytokine production and also indirectly via DCs it inhibits NK-DC crosstalk. PGE2-matured 
DCs are less capable of recruiting and activating NK cells, which we have shown in chapter 
4 to be essential for TH1 polarization.  
To evaluate the effect of DC vaccination, we state that different immune responses should 
be monitored. Next to the conventional T cell monitoring techniques, including DTH-
reactions, tetramer staining and cytokine profiles also NK cell activation should be 
monitored. Additionally, we developed the tools to evaluate humoral immune responses. 
In chapter 6 we describe a flow cytometry-based assay to detect human serum antibodies 
to MUC1 and MUC1-Tn/STn epitopes. 
To enhance the effectiveness of cellular immune responses by DC vaccination, we 
investigated the possibility to develop ex vivo generated T cells that are not subjected to 
tolerance during development. In chapter 7 we show that we are able to develop these 
cells that hold the capacity to develop into mature T cells in humanized mice models. 
Though our data are still preliminary, one could envision that these pre-T cells can be 
developed into tumor-specific T cells in vivo or ex vivo to be adoptively transferred.   
In conclusion, in this thesis we present an anti-MUC1 strategy for anti-cancer therapy, 
which could be used in many different patients with either solid tumors or hematological 
malignancies that express MUC1 (Figure 1). Since we do not expect immunotherapy to be 
effective by targeting individual immune cells, we propose to combine adoptive antibody 
therapy with TLR2/4 matured DC vaccination, adoptive pre-T cell transfer and possibly 
COX2 inhibition to reduce the effect of tumor-derived PGE2 on immune responses. To 
evaluate immune responses innate as well as adaptive and humoral as well as cellular 
responses should be monitored. 
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Figure 1. Summary of this thesis: combination therapy 
In terms of combination therapy, different immunotherapeutic strategies can be combined. (2) tumors 
expressing tumor-specific antigens can be targeted by adoptive antibody transfer. (3) DC vaccination can be 
utilized to induce tumor-specific T cells and (4) activation of NK cells, by recruiting these cells creating a tertiary 
lymphoid structure, and enhancing their cytotoxic as well as their cytokine secreting capacity.  (5) Tumor-derived 
PGE2, which has immunosuppressive characteristics should be inhibited by COX2- inhibitors. (7) Additionally, to 
replenish the immune effector population effector cells, like T cells, can be adoptively transferred. (6) Finally, to 
evaluate immune responses innate as well as adaptive and humoral as well as cellular responses should be 
monitored. The different numbers also correspond to the different chapters in which the issues were addressed.  
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Nederlandse samenvatting 
 
In dit proefschrift hebben we verschillende in vitro aspecten van immunotherapie voor 
kanker bestudeerd met als doel de klinische resultaten te verbeteren door verschillende 
immunotherapeutische strategieën te combineren. We beschrijven nieuwe methodes die 
als combinatietherapie gebruikt kunnen worden voor kanker patiënten. Daarnaast 
presenteren we een innovatieve manier om immuunresponsen te analyseren.  
In hoofdstuk 2 hebben we onderzocht of antilichaam therapie effectief kan zijn voor 
patienten met ovarium tumoren. Eén van de vereisten hiervoor is de expressie van 
tumorgeassocieerde antilichamen door de tumorcellen. In deze context hebben we 
aangetoond dat de meerderheid van de ovariumtumorcellen ondergeglycosyleerd MUC1 
(MUC1-Tn/STn) tot expressie brengen. Niet alleen de primaire tumoren zijn hiermee 
mogelijk gevoelig voor antilichaamtherapie, maar ook de metastasen brengen dit 
ondergeglycosyleerde MUC1 tot expressie, terwijl gezonde ovarium cellen dit niet doen. 
Hieruit concluderen we dat de MUC1-Tn/STn epitopen gebruikt kunnen worden als 
tumorspecifieke antigenen in ovarium kanker en dat deze antigenen getarget kunnen 
worden met antilichamen of middels DC vaccinatie strategieën.  
Ter optimalisatie van DC vaccinatie strategieën laten we in hoofdstuk 3 zien dat TLR2/4 
gematureerde DCs superieur zijn aan PGE2 gematureerde DCs. TLR2/4 gematureerde DCs 
induceren voornamelijk TH1 polarisatie en induceren meer antigeenspecifieke CTLs. 
Daarnaast laten we in hoofdstuk 4 zien dat deze TLR2/4 gematureerde DCs ook veel beter 
zijn in de communicatie met NK cellen. Hierbij ontstaat er een bidirectionele activatie van 
DCs en NK cellen, waarbij NK cellen gestimuleerd worden tot het induceren van 
celgemedieerde cytotoxiciteit en inductie van IFN-γ afhankelijke TH1 polarisatie. PGE2 
wordt frequent gebruikt in DC maturatie protocollen, gezien het positieve effect op de in 
vitro migratie van DCs. In vergelijking met PGE2 gematureerde DCs vertonen TLR2/4 
gematureerde DCs inderdaad een vele slechtere capaciteit tot migreren. Echter, bij 
analyse van het chemokine profiel van deze TLR2/4 gematureerde DCs blijkt dat deze 
grote hoeveelheden aan TH1, CTL en NK celrekruterende chemokines produceren. Deze 
data leggen de basis voor een nieuwe strategie voor DC vaccinatie, waarbij het migrerend 
vermogen van de DC niet meer centraal staat, maar juist het rekruterend vermogen veel 
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belangrijker is. Voor TLR2/4 gematureerde DCs laten we zien dat ze NK cellen rekruteren 
middels eens CCR5 gemedieerd mechanisme.  
In relatie tot combinatie therapie hebben we additionele factoren onderzocht die 
geproduceerd worden door tumoren en die een negatieve invloed hebben op de 
immuunrespons. Gezien de negatieve effecten van PGE2 op DC maturatie en gezien veel 
solide tumoren evenals hematologische maligniteiten hoge concentraties PGE2 
produceren hebben we het effect van PGE2 op NK-DC interactie verder bestudeerd. Van 
PGE2 is bewezen dat het zowel de aangeboren als de verworven immuniteit negatief kan 
beïnvloeden. In hoofdstuk 5 laten we zien dat PGE2 een negatief effect heeft op NK-DC 
interactie. PGE2 heeft een direct effect op NK cellen, waarbij de cytokine secretie en 
cytotoxiciteit van NK cellen geinhibeerd wordt en daarnaast inhibeert PGE2 ook NK-DC 
interactie door de negatieve invloed van PGE2 op DC maturatie. 
Om te evalueren of DC vaccinatie succesvol is, is het van belang dat naast de klinische 
responsen ook de immunologische responsen geëvalueerd worden. Naast de 
conventionele methoden waarbij T cel activatie geanalyseerd wordt, middels DTH-
reacties, tetrameer analyse en cytokine profiel, moeten ook NK cell responsen worden 
geëvalueerd. Daarnaast hebben we een nieuwe methode ontwikkeld om humorale 
immuunresponsen te analyseren. In hoofdstuk 6 beschrijven we deze op flow cytometerie 
gebaseerd methode, waarbij humane serum antilichamen tegen MUC1 en MUC1-Tn/STn 
epitopen gedetecteerd kunnen worden.  
Om de effectiviteit van de cellulaire immuunresponsen die door DC vaccinatie 
geïnduceerd worden te verbeteren hebben we gepoogd om T cellen ex vivo te genereren 
uit stamcellen. Hiermee kunnen T cellen gemaakt kunnen worden die tijdens hun 
ontwikkeling niet onder druk van immuunsuppressie staan. In hoofdstuk 7 laten we zien 
dat we ex vivo pre-T cellen kunnen ontwikkelen die in staat zijn uit te groeien tot mature T 
cellen in een gehumaniseerd muis model. Onze data zijn nog steeds preliminair, maar 
mogelijk kan met deze methode uit ex vivo gegenereerde pre-T cellen in vivo 
tumorspecifieke T cellen ontwikkeld worden. Dit zou een potentiële therapieoptie zijn, die 
in combinatie met een DC vaccine toegediend kan worden.    
In dit promotieonderzoek presenteren we een anti-MUC1 strategie die toegepast kan 
worden in patiënten met solide tumoren evenals in patiënten met hematologische 
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maligniteiten (Figuur 2). Gezien we ervan overtuigd zijn dat immunotherapie alleen 
succesvol zal zijn indien meerdere strategieën gecombineerd worden en daarmee ook 
verschillende immuuncellen getarget worden, stellen we voor om antilichaam therapie te 
combineren met DC vaccinatie, pre-T cell toediening en COX2-inhibitie om het effect van 
PGE2 te onderdrukken. Om het effect van deze therapie te evalueren dienen naast 
klinische responsen ook de immunologische responsen geëvalueerd te worden.  
 
 
Figuur 2. Samenvatting van dit proefschrift: combinatie therapie 
Voor combinatietherapie kunnen verschillende immunotherapeutische strategieën gecombineerd worden. (2) 
Tumoren brengen tumorspecifieke antigenen tot expressie, die getarget kunnen worden middels antilichaam 
therapie. (3) DC vaccinatie kan gebruikt worden om tumorspecifieke T cellen te induceren en om (4) activatie van 
NK cellen te bewerkstelligen. Hiervoor zullen beide cellen door de DC gerekruteerd moeten worden, waarbij een 
tertiaire lymfoïde structuur gevormd wordt. (5) PGE2 dat geproduceerd wordt door veel tumoren, heeft een 
immuunsuppressieve invloed, hetgeen middels COX2-inhibitoren opgeheven kan worden. (7) Om het T cel 
repertoire aan te vullen, kunnen deze effectorcellen ex vivo worden gegenereerd om samen met een DC vaccine 
toegediend te worden. (6) Als laatste dienen cellulaire evenals humorale immuunresponsen geëvalueerd te 
worden. De verschillende nummers corresponderen met de hoofdstukken waarin de onderwerpen besproken 
worden.  
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“We bedanken de tegenstander, de scheidsrechter en het publiek voor een fantastische 
wedstrijd”. Dit schreeuwde ik ooit aan het einde van een softbal wedstrijd over het veld 
en hiermee wil ik ook mijn dankwoord beginnen. 
Promoveren lijkt in veel opzichten op een softbalwedstrijd. De belangrijkste overeenkomst 
is dat beide teamsporten zijn, waarbij je  een trainer nodig hebt. Dr. Bos, Gerard, ik weet 
niet waarom maar ergens had je er voldoende  vertrouwen in dat ik mijn promotietraject 
tot een goed einde zou brengen.  Als trainer ben je er altijd geweest met goede adviezen 
en had je al snel door dat ik me daar niets van aantrok. Zo leken voortgangsgesprekken 
ook meer op gezellige bijeenkomsten waarbij je me probeerde te overtuigen dat ik 
bepaalde experimenten niet uit moest voeren. Heel schappelijk vertelde je er echter bij 
dat je me niet tegen ging houden wanneer ik het toch zou gaan doen. Hetgeen vaak ook 
maar goed was ook, want meestal waren deze experimenten  al uitgevoerd. Daarnaast 
ben je niet alleen een goede trainer, maar ook een uitstekende skileraar gebleken. 
 Prof. Dr. H.C.  Schouten, ook U wil ik bedanken voor Uw vertrouwen en steun mijn 
promotie. Zoals dat vaak gaat is de baas niet altijd op het veld, maar heeft hij ter degen de 
touwtjes in handen bij het bepalen van de strategie.  
Laat ik hierbij ook de assistent trainers niet vergeten. Dr. Germeraard, beste Wilfred, als 
begeleider van mijn wetenschapsstage ben jij degene geweest die het balletje heeft 
opgegooid en heeft laten rollen voor een  aanstelling als promovendus. Daarnaast heb je 
me kennis laten maken met Japan, jouw tweede thuis en voor mij het land waarbij ze 
vergeten om de aardappels en groente te serveren bij de vis (die ze dan overigens ook nog 
vergeten te bakken). Jouw liefde voor dit land heeft zeer aanstekelijk gewerkt en ik heb 
ook tijdens mijn tweede bezoek, veel van het land kunnen zien en veel van de hoge 
standaard van wetenschap kunnen leren. Joris, ook jou wil ik bedanken, dat je geheel 
vrijwillig mijn assistent trainer bent geweest.  We hebben veel, heel veel met elkaar 
kunnen lachen. In het bedenken van nieuwe of het verfijnen van oude strategieën heb ik 
me altijd als gelijke gevoeld hetgeen ik altijd als zeer prettig ervaren heb. Helaas heeft 
tijdgebrek en wederzijdse koppigheid (of moet ik zeggen onze sterke karakters) ook geleid 
tot interessante  maar minder effectieve discussies. Ik hoop dat je in je nieuwe baan een 
nieuwe uitdaging hebt  gevonden en bewonder je inzet bij het begeleiden van mij en 
ander promovendi. Ik had gehoopt je beter te kunnen bedanken voor je inzet, maar helaas 
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is er anders besloten. Dr. Van Gelder, Michel(e) ook jij bedankt voor je onuitputtelijke 
inzet om mij ervan te overtuigen dat DCs niet van belang zijn bij immunotherapie voor 
kanker en dat we NK cellen nodig hebben. Tegenwoordig mag jij je, als mijn mentor, er 
volledig op storten om mij hiervan alsnog te overtuigen. 
Softbal is een teamsport en daarbij zijn je teamgenoten erg belangrijk.  Goede 
teamgenoten heb ik dan ook gevonden in collegae promovendi, postdocs en analisten. Bij 
softbal heb je mensen nodig die goed kunnen slaan, zodat de mensen die goed kunnen 
rennen de punten kunnen maken. Ook in het veld heb je altijd een man achter je die de 
bal kan vangen, indien hij uit de handen glipt. Zo is het ook tijdens mijn promotie geweest, 
waarbij iedereen zijn eigen speciale plaats heeft gehad. Birgit, jij was de beste pitcher van 
ze allemaal. Niet alleen op het lab, maar ook tijdens een echt spelletje softbal heb ik 
gemerkt met hoeveel fanatisme jij je erop stort (zelfs kleine meisjes moeten het ontgelden 
als jij de overwinning ruikt).  Je was er altijd met zowel praktische als met persoonlijke 
adviezen. Als ik het tegenwoordig erg druk heb en te veel dingen tegelijk moet doen, dan 
mis ik ons Balisto-momentje nog steeds.  
Het  eerste honk is een hele belangrijke plaats, het is het eerste punt waar de 
tegenstander tegengehouden kan worden.  Bob, je hebben op deze plaats als eerste 
verdediging prima gefunctioneerd. Door vaak in een vroeg stadium al met jou te 
overleggen, hoefde ik het wiel niet opnieuw uit te vinden en is me veel extra werk 
bespaard gebleven. Bob, helaas hadden we niet voldoende sponsoring om je in het team 
te houden en ben je door een groter en professioneler team weggekaapt. Alle discussies 
met jou waren van zeer hoge wetenschappelijke kwaliteit, jij zorgde ervoor dat ik 
uitgedaagd werd en liet me zien dat wetenschap een fantastische hobby is.  Ook al 
moesten we eerst aan elkaars karakter wennen, uiteindelijk is er een fantastische 
vriendschap uit ontstaan en heb ik nog nooit zo veel chocolade taarten voor iemand 
gebakken.  
Peter,  het was geweldig om met jou samen op het tweede honk te staan (ook al zijn we 
persoonlijk nooit tot second base of zelfs first base gekomen). Je kwam er als eerste  
achter hoe geschift ik eigenlijk was. Zo heb je je meermaals moeten schamen met mij in 
de file en kan ik me voorstellen dat je nooit meer iemand in de auto hebt horen roepen: 
smiley, smiley, smiley! Congressen waren een feestje. Gelukkig waren we samen, anders 
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hadden we vast wel ergens een keer een vlucht gemist op weg naar Australië. Ook heb ik 
nog nooit iemand zo blauw met z’n snorkel uit de zee zien komen. Kortom we hebben veel 
lol met elkaar kunnen delen en als roommates hebben we veel onzin uitgehaald, zeker 
tijdens het EK van 2008 toen er een geur van rubberen ballonnen uit onze kamer kwam, 
aangevuld met een oranje gloed.   
Dan het derde honk, waar meerdere spelers hebben gestaan, die uiteindelijk ook door 
andere clubs zijn weggekaapt. Silvie, in het Pacrima project was je altijd duidelijk bezig 
met de klinische implicatie. Daarnaast heb je ons door Tongeren geleid en zal ik nooit 
meer vergeten wat een vidéke is. Ariane, zelfs vlak voor mijn promotie heb je me nog 
geholpen met informatie. Jullie twee zijn al die jaren mijn voorbeeld geweest en tijdens 
jullie promotie was in zenuwachtiger dan jullie. En natuurlijk Mariska, met jou op het NVVI 
op een kamer staat garand voor een nacht zonder veel slaap. Ik ben blij dat jullie alle drie 
op jullie eigen manier het geluk hebben gevonden in jullie leven.  
Natuurlijk moeten de we catcher niet vergeten. Lotte, gelukkig kwam jij via een transfer 
vanuit Utrecht naar het zuiden. Niet alleen de mannelijke teamgenoten waren blij met de 
aanschaf van deze blonde sterspeelster, maar ook ik was blij dat je bij het team kwam. 
Eindelijk was er een vrouwelijk iemand die net zo veel lol in wetenschap had als ik. Iemand 
die ook alles voor haar onderzoek over heeft en daarnaast heb ik nog nooit zo in een deuk 
gelegen tijdens experimenten dan met jou op het muizenlab in Utrecht.  
Dan  is natuurlijk ook het buitenveld van belang, Ans, Catharina, Melanie en ook de 
nieuwe lichting promovendi Subash, Tammie en Mirelle hebben wetenschappelijk hulp 
geboden en voor veel vermaak gezorgd. Velen van jullie zijn vanuit het buitenveld al in het 
binnenveld gekomen.  Vooral jou Tammie wil ik bedanken voor je hulp en ik wens je veel 
succes met het vervolg van het NK-DC-T cel werk.  
Natuurlijk heeft  elk team ook een sponsor nodig. Hierbij heb ik het geluk gehad een hele 
speciale sponsor te hebben, die gewoon mijn werkgever was “PharmaCell”. Dank je wel 
Rene om mij aan te nemen als junior scientist en bedankt  Maurice Horsten en Alexander 
Vos, dat jullie ook in moeilijkere tijden mijn sponsor zijn gebleven. Ook al lagen de 
prioriteiten vaak ergens anders, jullie hebben altijd je best gedaan om mij bij het bedrijf te 
betrekken, zelfs bij elk bedrijfsfeestje werd ik uitgenodigd. Een speciaal bedankje hierbij 
ook voor Marianne. Als er een prijs was voor beste secretaresse ooit, zou jij hem winnen. 
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Daarnaast wil ik ook wijlen Jan Thio niet vergeten als initiatiefnemer van het 
Pacrimaproject. Het project dat de succesvolle samenwerking tussen de Universiteit en 
Pharmacell tot stand heeft gebracht.  
Dan een grote dank aan het publiek. Vicky, je was niet alleen een collega, maar je bent ook 
een vriendin geworden en ik ben heel blij dat jouw grootste droom afgelopen jaar uit is 
gekomen. Marcel en Nordin, jullie zijn alle twee op jullie eigen manier compleet geschift 
en ook al willen jullie vaak een beetje dood, ik weet zeker dat jullie boekje fantastisch gaat 
worden.  Ook dank je wel aan de mede commissie leden van ProvUM, speciaal Cynthia, 
Floris, Mirjam en Jennifer met de belangen van de promovendus op de eerste plaats 
hebben toch ook heel veel lol gemaakt.  
Tja en bij het publiek horen natuurlijk ook de mensen die al die jaren op de eerste rij zitten 
en me aanmoedigen. Pap, Mam met veel trots, maar vaak ook gemengde gevoelens 
hebben jullie toegekeken hoe ik soms punten scoorde en soms ook flink getackeld werd. 
Jullie waren er altijd voor me, ook als ik heel laat op de avond of nacht nog op een 
incubatie moest wachten, werd bij jullie altijd de telefoon opgenomen. Als ik laat het ’s 
avonds naar huis  ging en langs jullie huis reed, brandde er altijd nog wel een lampje. Nog 
steeds staan jullie altijd voor ons klaar. Dank je wel, is eigenlijk te weinig, maar ik geloof 
dat jullie dat wel begrijpen.  
En ook al wil je het zelf niet, ook jou Daniël wil ik bedanken. Ik denk dat geen enkele 
vriend mijn gedrag van de afgelopen jaren zou hebben geaccepteerd. Ik was meer op mijn 
werk dan thuis, maar dat deed jou helemaal niets. Mijn werk, mijn promotie ging voor 
alles en daar zette jij je ook volledig voor in. Als ik in het weekeinde weer moest werken, 
ging je gewoon mee (misschien had de snoepautomaat daar ook iets mee te maken). Als ik 
thuis zat te werken kwam je me drinken brengen en als ik de studeerkamer weer eens 
ging verbouwen uit frustratie, dan liet je me rustig mijn gang gaan totdat ik weer bedaard 
was. Jou heeft het letterlijk bloed (veel bloed), zweet en tranen gekost.  
Tja en dan heb je nog de tegenstander. Daar zijn de reviewers, de beoordelaars van 
projecten en misschien  wel de grootste tegenstander mijn eigen ambitie. Vooral het 
laatste is een ziekte gebleken, die helaas besmettelijk is (hè Daniël?). Toch wil ik al deze 
tegenstanders bedanken, want zonder jullie commentaar was ik nooit zo ver gekomen.  
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Uiteindelijk kan ik zeggen dat ik in de afgelopen jaren een interessante wedstrijd gespeeld 
heb, waarbij we innings hebben gewonnen en verloren. Ik heb  de stand niet bijgehouden 
en ben ik er ook nog niet zo zeker wie gewonnen heeft,  maar uiteindelijk kan ik zeggen: 
It was one hell of a game. 
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